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Abstract 
Neutrophils constitute the main immune defence against microbial invasion. When activated, 
they migrate towards the site of infection where they eliminate any foreign material in an 
effort to prevent wide-spread tissue damage and ultimately resolve infection. Previous work 
on neutrophil function in the elderly has highlighted a number of neutrophil effector functions, 
including phagocytosis, superoxide production and migration that exhibit decreased 
efficiency suggesting the potential for reduced pathogen clearance in older adults.  
This thesis reveals a migratory phenotype distinctive of neutrophils isolated from healthy 
elderly donors (> 60 years) and characterised by a maintained speed of migration 
(chemokinesis) but with significantly reduced directional migration (chemotaxis) and overall 
migratory accuracy in response to a range of chemoattractants. This migratory phenotype 
was shown to be associated with a constitutive basal activation of PI3Kinase in neutrophils 
isolated from older donors and appears to be a causative factor as treatment of neutrophils 
with inhibitors selective for PI3Kinase-γ and –δ, was able to restore migratory dynamics. The 
‘old-migratory’ phenotype was amenable to correction by pre-incubation with 1nM 
Simvastatin in vitro and a two-week prescription of 80mg/day Simvastatin in vivo in healthy 
older adults.  
The ability of simvastatin to modulate migratory dynamics potentially provides a safe, cost 
effective intervention to reduce morbidity and mortality from infections in the elderly 
population. 
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INTRODUCTION 
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1.0 Introduction 
The demographics of our population are changing; since 2001 the number of males aged 75 
and over has increased by 26% [1]. Current projections estimate the proportion of our 
population aged > 60 years will reach 21% by 2050, a forecast based on past proportions in 
which older adults constituted 8% of the population in 1950 increasing to 10% in 2000 [2]. By 
2034 it is anticipated that 23% of the UK population will be over 65 years of age with 5% over 
85 years [3], proportions that will exceed those aged ≤ 16 years by 5% [4]. Driving these 
changes is the continual increase in life expectancy seen in the Western world, currently at a 
rate of approximately 2 years per decade [5]. Importantly, increments in lifespan are not 
matched by improvements in healthspan, defined as the number of years the average person 
can expect to remain in good health [5] thereby reducing quality of life in our later years and 
increasing healthcare utilisation which is associated with significant economic costs. For 
example, in-patient care for the treatment of community acquired pneumonia totalled £383.7 
million of which 65% of admissions were in the 64 years and over age group [6]. 
Furthermore, in 2007 – 2008, heath care costs associated with a retired household totalled 
approximately £5,200 per annum; this is compared to £2,800 for a non-retired household [7] 
while department of health estimates suggest the average cost for provision of both hospital 
and community healthcare for a single adult aged ≥85 years is approximately 3 times that of 
an adult aged 65 - 74 years [7]. 
The link between mortality and ageing was first described by Benjamin Gompertz in 1889 
when trying to model mortality rates mathematically. He wrote “…the power to oppose 
destruction loses equal proportions in equal times” [8], meaning that the older we get the less 
likely we are to survive. 123 years later we can now partly attribute the increased morbidity 
observed in old age to a progressive age-related decline in immune function. This is 
evidenced in part by:  
3 
 
 (1) An increased incidence of infectious diseases in the elderly population of both 
bacterial and viral origin. This includes influenza [9], community acquired [10,11] and 
nosocomial pneumonia [12], urinary tract infections [13,14], tuberculosis [15,16], periodontitis 
[17] and shingles [18], the latter arising from re-activation of the varicella zoster virus (VZV) 
in older adults. 
 
 (2) Poorer outcomes of the elderly from infectious diseases including Streptococcus 
pneumoniae and staphylococcal infections [19], influenza [20] and community acquired 
pneumonia [21] among others.  
 
 (3) Increased incidence of chronic inflammatory and autoimmune conditions including 
diabetes [22,23], cardiovascular disease [24,25] and rheumatoid arthritis [26,27] in the 
elderly population. 
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1.1 The Immune System 
The immune system has evolved to protect the host from infection, disease and injury and 
must therefore have the ability to immediately respond to both new and returning pathogenic 
threats. To achieve this, the immune system operates in two component parts: the adaptive 
and the innate (see Figure 1.1), though it is now clear that there is continual communication 
between the two and this divide is artificial in reality. 
The adaptive immune response refers to antigen-specific lymphocyte populations that 
respond to a large array of antigen epitopes and encompasses the subsequent development 
of immunological memory providing long-term protection against pathogens. It is also known 
as the acquired immune response and is mediated by clonal selection and expansion of T 
and B lymphocytes upon contact with antigen, with a fraction of cells retained after each 
infection to provide immune memory. However, as this arm of the immune response can take 
a number of days to reach an effective level of protection, initial immediate protection against 
invading pathogens is provided by the innate immune system, which is capable of 
responding in a matter of hours. This branch of the immune response is present in all 
individuals at all times, is not antigen specific and does not increase with repeated exposure 
to a given pathogen as the adaptive side does. The main cellular mediators of the innate 
response are: the granulocytes, which respond effectively to rapidly dividing bacteria, fungi 
and yeast; monocytes/macrophages, which play a role in antigen presentation to T cells and 
also in immunity to intracellular pathogens; Dendritic cells (DCs) which are the major antigen 
presenting cells; and natural killer (NK) cells which provide immunity to virally infected cells 
and cancer cells. 
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Figure 1.1 Mediators of the Innate and Adaptive Immune Response. 
The innate immune compartment mediates the first response to infection providing 
immediate, non-specific protection. Components if the innate immune response include 
macrophages, natural killer cells, granulocytes (basophils, eosinophils and neutrophils), 
dendritic cells, mast cells and complement factors. Although, technically part of the innate 
compartment, dendritic cells also constitute a significant link between the innate and adaptive 
compartments in addition to cytotoxic lymphocytes such as γδ T cells and Natural Killer T 
cells. The adaptive immune compartment responds much slower, generating protection 
hours of days after activation however, this compartment is highly specific and generates 
immunological memory. The adaptive response is mediated by antibodies, B cells and CD4+ 
and CD8+ T cells. 
Figure taken directly from [28] 
  
Innate 
Immunity 
 Adaptive 
Immunity 
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1.2 Ageing and the Immune System 
Ageing has been defined as a progressive, universal and intrinsic process that results in an 
increasing probability of death secondary to pathology [29], while Rossi et al [30] propose 
that ageing is characterized by a failure to maintain tissue homeostasis or return to normal 
homeostatic condition after exposure to stress or injury. The age-related decline or 
remodelling of the immune system was first described as immune-senescence by 
Makinodam and Kay [31] and manifests as an impairment of both cell-mediated and humoral 
immunity. 
 
1.2.1 Adaptive Immune-senescence  
Alterations in the adaptive immune compartment as a consequence of increasing age have 
been encompassed within the immune risk phenotype (IRP). This describes a set of immune 
parameters associated with poor immune function and increased mortality. The proportion of 
individuals within the population that satisfy the criteria of the IRP increases with advancing 
age [32]. 
The IRP was initially characterised by an altered ratio of CD4+:CD8+ cells (i.e. <1.0) with 
reduced proliferation to the T cell mitogen, Concanavalin A, [33]. An inverted CD4+:CD8+ 
ratio appears to be the result of both a reduction in the number of CD4+ and an increase in 
CD8+ cells. Immune senescence is also marked by atrophy of the thymus, which begins from 
puberty, and a decrease in the naive: memory ratio for T cells. The latter may be due to an 
attempt to maintain T cell homeostasis after thymic atrophy by expansion of the peripheral T 
cell pool [34,35]. Over subsequent years, the IRP has been expanded by various groups and 
now includes additional parameters including decreased telomerase activity and shortened 
telomeres in lymphocytes, cytomegalovirus (CMV) seropositivity, thymic atrophy and reduced 
CD19+ B cells among others, forming what we now recognise as a more comprehensive IRP 
(see Table 1.1). 
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Cytomegalovirus (CMV) is a latent β-herpes virus present within 60-85% of the western 
population and approximately 80-90% of adults aged over 65 years [36]. CMV infection is 
thought to be a contributing factor to the development of the IRP and associated immune-
senescence, and the driving force behind the accumulation of CD3+CD8+CD28- T cells [34]. 
CD28 is a co-stimulatory molecule required for full activation of T cells, of which reduced 
expression results in development of cellular anergy leading to limited activation and cytokine 
secretion. These cells have also been shown to be terminally differentiated [37] and exhibit 
an increased resistance to apoptosis [38]. In addition the terminally differentiated cells begin 
to express receptors normally associated with NK cells, such as NKG2D and killer cell lectin-
like receptor subfamily G member-1 (KLRG1) [39], they also express cytotoxic granules [40]. 
As a result these senescent T cells are able to react more easily to the self-antigens 
recognised by the NK cell receptors, thus making older adults more prone to autoimmune 
disease. Taken together these alterations result in the accumulation of dysfunctional, 
autoimmune-prone, senescent T-cells that remain in the circulation, taking up immunological 
space, thus preventing formation of new immunological memory to novel pathogens and 
vaccines [41]. Older adults are thus more at risk from outbreaks of novel pathogens. 
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Table 1.1 Parameters of the Immune Risk Phenotype (IRP) 
IL2, Interleukin-2; CMV, Cytomegalovirus 
Parameter
CD4+:CD8+ Ratio ≤ 1
Thymic Atrophy
Decrease in the number of naïve (CD8+ CD45RA CCR7+) cell in the periphery
Reduced T cell proliferation (related to reduced IL2 secretion and sensitivity)
Accumulation of memory T cells
Reduced numbers of B cells (CD19+)
CMV Seropositivity
Accumulation of CMV specific CD3+ CD8+ CD28- cells
Reduced Telomerase activity and subsequent telomere length
9 
 
Natural ageing is also associated with the development of a chronic, systemic, sub-clinical 
inflammatory state termed inflamm-ageing [42]. This term, describes the increased levels of 
serum pro-inflammatory cytokines including Interleukin-6 (IL6), Tumour Necrosis Factor-α 
(TNFα) and acute phase proteins such as C-reactive Protein (CRP) [42-45]. It is also now 
recognised that ageing is accompanied by reduced levels of anti-inflammatory cytokines, 
notably interleukin-10 (IL10) [43] which contribute to inflamm-ageing. CMV was initially 
thought to be causally associated with the development of inflamm-ageing; however, recent 
studies have called this into question by demonstrating the development of inflamm-ageing in 
the absence of CMV infection [43]. Nevertheless, a number of candidates remain as potential 
drivers of inflamm-ageing including the presence of other latent viruses such as Epstein Barr 
Virus (EBV), increased adiposity (and the concomitant increase in adipokine production) 
[46,47] and a sedentary lifestyle [48]. It has also been proposed that chronic antigen 
exposure and subsequent immune exhaustion over the lifetime may contribute to inflamm-
ageing [49]. 
Anti-inflamm-ageing is a term used to describe the activation of the hypothalamic-pituitary-
adrenal (HPA) axis to produce a number of immune-modulatory hormones in response to 
pro-inflammatory cytokines [50,51] including IL6 and TNFα [52]. Most notably, hormones 
produced include cortisol, a well-characterised corticosteroid produced by the adrenal glands 
with powerful immunosuppressive effects [53] and dehydroepiandrosterone (DHEA), an 
immune enhancing hormone [54] which is found in the serum in its sulphated form 
dehydroepiandrosterone sulphate (DHEAs) [55]. An elegant balance exists between cortisol 
and DHEAs in regulating immune function however, in the elderly, this ratio shifts resulting in 
an increased cortisol:DHEAs ratio and a propensity for immune suppression [56]. This shift is 
driven by a gradual decline in the production of DHEAs and maintenance of cortisol levels 
across the life span, termed adrenopause [57]. Serum DHEAs concentrations peak around 
24-30 years in males and 19-24years in females and decline thereafter to approximately 14% 
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of that maximal peak in males and 20% of maximum in females by the seventh decade 
[58,59]. 
Whether HPA activation is the result of chronic stress or an attempt to re-establish 
homeostasis as a result of the heightened pro-inflammatory state observed in the elderly 
remains to be determined. It is however, safe to conclude that the synergistic action of 
inflamm-ageing and anti-inflamm-ageing has consequences for immune function and may 
contribute to the senescent state observed in the elderly due to chronic low level stimulation 
of the immune system. Ultimately this renders these elderly individuals susceptible to 
infection, autoimmunity and disease. In addition low level systemic inflammation is now 
known to be a significant pathogenic factor in the major age-related conditions such as 
atherosclerosis [60], dementia [61] and sarcopenia [62]. 
Together, inflamm-ageing, the IRP and anti-inflamm-ageing document wide spread 
senescence within the adaptive and humoral compartments indicating significant immune re-
modelling as we age. A major clinical consequence of this is the reduced ability of the elderly 
population to produce a protective antibody titre and maintain that titre over time following 
vaccination against a number of pathogens including diphtheria, tetanus, polio [63], 
pneumococcal pneumonia [64] and influenza [65]. After initial vaccination, booster injections 
are recommended every 10 years in the UK irrespective of the age of the recipient. 
Unfortunately, protective titres are rarely maintained over this time period, particularly adults 
aged over 60 years: 10 years post-vaccination, of 734 donors tested, 20% of recipients aged 
over 60 years no longer retained a protective titre. In fact, a significant proportion of 
recipients aged over 60 years (16%) were unable to maintain a protective titre just 5 years 
following vaccination [66]. In persons under the age of 60 years, antibody titres below the 
level that confers protection only occurred in <3% of subjects tested [66]. This study 
suggests that current vaccination strategies leave too many people over 60 years 
unprotected resulting in increased morbidity and mortality from many vaccine-preventable 
diseases. New strategies are needed to combat this phenomenon including an increased 
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frequency of vaccination and the development of new vaccines utilizing antigens and 
adjuvants specifically tailored toward the ageing immune system. 
 
1.2.2 Innate Immune-senescence 
The innate immune compartment consists of a number of cell types working synergistically to 
provide near-immediate, non-specific protection from infection (see Figure 1.1). Monocytes 
fulfil this requirement two fold by possessing their own anti-microbial arsenal but also through 
differentiation into tissue resident macrophages, which patrol the tissues and alert the 
immune system to potential pathogenic threats, through secretion of cytokines and 
presentation of antigen-derived peptides. Macrophages are also professional phagocytes 
capable of phagocytosis and production of toxic metabolites. Neutrophils are the first cell 
type to be recruited to the site of infection where they mediate host protection in much the 
same was as macrophages as they are professional phagocytes themselves. NK cells exist 
to protect against viral infection, whilst DCs constitute the major link to initiation of the 
adaptive arm of the immune response through antigen presentation and cytokine secretion. 
Table 1.2 details the age-related changes observed in this compartment with the notable 
exception of neutrophils of which their development and function will be discussed in detail in 
later sections as these cells are the focus of this thesis. 
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Table 1.2 Innate Immune-senescence 
Cell Type  Effect of Ageing Reference 
Monocytes Number ↔ Unchanged [67,68] 
 Composition ↓ Classical (CD14+ CD16-) [69] 
  ↑ Non-Classical (CD14+ CD16+) [67,69] 
 Function ↓ Chemotaxis [70] 
     
Macrophages Number ↓ Frequency (alveolar 
macrophages) 
[71] 
 Function ↓ Chemotaxis [70] 
  ↔ Phagocytosis  
        Increased [72,73] 
        Unchanged [74] 
        Decreased [75,76] 
  ↓ ROS Production [77-79] 
  ↓ Cytokine Production [80-83] 
 Signalling ↓ MHC II, CD80 and CD86 
Expression 
[84,85] 
  ↓ TLR Signalling Impaired [81,82] 
     
pDCs Number ↔ Unclear  
        Reduced [86-89] 
        Unchanged [86-91] 
 Function ↓ Cytokine Secretion [86,87,89,92,93] 
 Signalling ↓ TLR-7 and -9 Expression [86,87] 
  ↓ TLR Signalling Impaired [93] 
mDCs Function ↓ Stimulatory Capacity [93-96] 
  ↓ IFNγ Production [96,97] 
     
NK Cells Number ↑ Increased [98-101] 
 Composition ↑ Mature CD57+ NK Cells [99,100,102] 
 Function ↓ NKCC [101,103,104] 
  ↓ ADCC [100,105,106] 
  ↓ Cytokine Production [107-110] 
 Signalling ↓ KLRG1 & NKG2A Expression [98,100,111] 
     
iNKT Cells Number ↓ Reduced [112] 
 Function ↓ IFNγ Production [112,113] 
     
Immune-senescence of the cell-mediated arm of the innate immune response. 
MHC II, Major Histocompatibility Complex class II; TLR Toll-like Receptor; pDCs, 
plasmacytoid Dendritic Cell; mDCs myeloid Dendritic Cell; IFNγ, Interferon-γ; iNKT Cell, 
Invariant Natural Killer T Cell; NK Cell, Natural Killer Cell, NKCC; Natural Killer Cell 
Cytotoxicity, ADCC, Antibody Dependent Cell Cytotoxicity, KLRG1, Killer Cell Lectin-like 
Receptor subfamily G member-1. 
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1.3 Neutrophil Immune-senescence 
Neutrophils form our first line of defence against bacterial infection and are the first 
cells to be recruited to the site of infection. In times of inflammation and infection, neutrophils 
leave the circulation and migrate into the tissues where they act in concert with tissue 
resident macrophages to neutralize and eliminate potentially pathogenic material utilising a 
diverse range of anti-microbial machinery. The absolute requirement of neutrophils in host 
defence is demonstrated in patients with chronic granulomatous disease (CGD) (reviewed in 
[114]) or leukocyte adhesion deficiency (LAD) syndrome (reviewed in [115]) who are 
extremely susceptible to bacterial and fungal infections which are often fatal. Underlying 
these pathologies are mutations in genes encoding key components of a neutrophils anti-
microbial arsenal resulting in loss of function and ultimately compromising host defences.  
 
1.3.1 Neutrophil Development 
Cells of the immune system are derived from, and are subsequently replenished throughout 
life by haematopoietic stem cells (HSCs) which reside within the bone marrow. During 
development, HSCs commit to either the myeloid (granulocytes, monocytes, megakaryocytes 
and erythrocytes) or lymphoid (T and B cells, NK cells) lineage and populate the immune 
system. Cells of the myeloid lineage leave the bone marrow as fully mature cells whereas T 
and B cells leave the bone marrow as immature cells, with maturation occurring in the 
thymus and lymphoid organs respectively. Neutrophil maturation occurs in six stages, each 
characterised by the presence or absence of cell surface markers, granule subsets and 
nuclear morphology (see Figure 1.2). 
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Figure 1.2 Neutrophil Bone Marrow Development. 
Neutrophil development occurs in the bone marrow in 6 stages. (i) Myeloblast: an 
undifferentiated cell with a large nucleus and nucleolus, free from cytoplasmic 
granules; (ii) Promyelocyte: characterized by its large size, rounded nucleus and 
the first appearance of the azurophil granules in the cytoplasm; (iii) Myelocyte: 
large rounded nucleus with the first appearance of specific granules (iv) 
Metamyelocyte: exhibiting a kidney bean shaped nucleus with a mixed 
cytoplasmic granule population, at this stage in development, subsets lose their 
ability to proliferate becoming post-mitotic; (v) Band Cell: contains a condensed 
band shaped nucleus, and the first appearance of cytoplasmic gelatinase granules 
(vi) Mature Neutrophil: Nuclear constituents further condense forming the 
characteristic multi-lobed nucleus of peripheral blood neutrophils with the first 
appearance of cytoplasmic secretory vesicles (vii) Release into the blood stream. 
 
 
i. Myeloblast 
  
ii. Promyelocyte 
 
 
iii. Myelocyte 
 
 
iv. Metamyelocyte 
  
v. Band Cell 
  
vi. Mature 
Neutrophil 
  
vii. Release into 
the Circulation 
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Under steady-state conditions, fully mature neutrophils are released into the circulation at a 
rate of approximately 5x1010 - 1x1011 cells/day [116] with numbers differing depending on 
age, gender, ethnicity and smoking status [117]. Adult caucasian females have 
approximately 7.4x109 neutrophils/litre and caucasian adult males 7.2x109 neutrophils/litre at 
any one time throughout the day [117]. Once in the circulation, neutrophils were widely 
thought to have a half-life of approximately 6-10 hours [116,118-122] due to the constitutive 
expression of the anti-apoptotic protein induced myeloid leukaemia cell differentiation 
protein-1 (Mcl-1), levels of which decline rapidly when cells are isolated from the blood and 
show a positive association with neutrophil survival [123]. However, neutrophil half-life has 
recently come under scrutiny with a new estimate, established using in vivo isotope labelling 
techniques, putting the half-life at 5.4 days [124]. During an infectious insult and in response 
to exposure to pro-inflammatory cytokines and bacterial products such as 
granulocyte/macrophage-colony stimulating factor (GM-CSF), Interleukin-1β (IL1β), 
Interferon-γ (IFNγ) and Lipopolysaccharide (LPS) [123,125], neutrophil output from the bone 
marrow increases approximately 10-fold [126] and the typical half-life of a neutrophil 
increases to 115 hours [125]. 
A number of factors are involved in the development of HSCs into mature neutrophils 
including differential expression of transcription factors, including CCAAT/enhancer binding 
protein (C/EBPs) and PU.1 [127], proteins including the small GTPase Ras-related C3 
botulinum toxin substrate (Rac2) [128] and soluble factors such as granulocyte-colony 
stimulating factor (G-CSF), GM-CSF and interleukin-3 (IL3) [129,130]. Of these three factors, 
G-CSF seems to be the dominant factor in generating mature neutrophils as mice lacking the 
G-CSF gene (G-CSF-/-) exhibit a 73% significant reduction in the number of mature 
neutrophils in the circulation compared to their wild type (G-CSF+/+) counterparts [129]. 
Regulation of G-CSF levels within the bone marrow is also involved in the resolution of 
inflammation utilizing a feedback mechanism which also includes Interleukin-23 (IL23), and 
Interleukin-17 (IL17). Uptake of apoptotic neutrophils by tissue resident macrophages, a 
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process known as efferocytosis, induces a reduction in the secretion of IL23 by macrophages 
and DCs and IL17 by γδ T cells with an ensuing reduction in bone marrow G-CSF levels 
[131]. This results in reduced neutrophil release into the circulation and therefore restores 
homeostasis.  
Within the hematopoietic stem cell compartment, a number of age-related changes have 
been observed. CD34, an adhesion molecule whose expression is gradually lost during 
development, is used to identify hematopoietic stem and progenitor cells present within the 
bone marrow and circulation. Numbers of CD34+ cells in the bone marrow remain unchanged 
with age [130], however, increasing age negatively correlates with the number of circulating 
CD34+ cells [132]. Within the circulation, CD34+ cells contribute to vascular health due to 
their endothelial progenitor cell capacity, hence the reduced frequency of these cells 
associates with increased risk of cardiovascular disease [133]. 
With increasing age there is also a shift in the homeostatic control of HSC differentiation 
favouring progenitors of the myeloid lineage at the expense of common lymphoid progenitor 
cells (CLP) [30,134,135]. This imbalance can be traced back to the genomic level with 70% 
of lymphoid genes differentially expressed in aged HSCs were found to be down-regulated 
while 76% of differentially expressed myeloid genes were up-regulated [30]. Modulation in 
this manner appears not to result from modification of the genes themselves but instead from 
epigenetic dysregulation [136]. This phenomenon seems to have a greater impact on the 
adaptive immune response and although it is worth noting, it does not appear to have an 
effect on the number of late myeloid progenitors in the bone marrow [130,137] or mature 
neutrophils in the circulation [130,138].  
Fully mature neutrophils can be found within the bone marrow, circulation and liver/spleen, 
with each compartment comprising 15%, 40% and 45% of the total marginated granulocyte 
pool [139]. If, and when, exposed to an inflammatory signal, neutrophils leave these sites 
and migrate through tissue to the site of infection where they mediate host defence by 
phagocytosing, eliminating and preventing further dissemination of pathogenic material.  
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1.3.2 Neutrophil Anti-microbial Functions 
Neutrophils have three main mechanisms for killing microbial targets: phagocytosis followed 
by generation of reactive oxygen and nitrogen species; release of degradative granule 
contents; and extracellular killing via neutrophil extracellular traps. Intracellular mediators of 
neutrophil anti-microbial functions are fully developed upon release from the bone marrow 
and are stored throughout the life of a neutrophil ready to be employed as soon as the 
appropriate stimulus is received thus mediating host defence.  
 
1.3.2.1 Neutrophil Degranulation 
Upon egression from the bone marrow, neutrophils contain anti-microbial proteins and pro-
inflammatory mediators utilized during an immune response in addition to a number of 
surface receptors and membrane proteins all of which are stored in four distinct granule and 
secretory vesicle subsets: the azurophil (primary), specific (secondary) and gelatinase 
(tertiary) granules and finally secretory vesicles, named according to their order of 
appearance during neutrophil development [140]. When the appropriate stimulus is received, 
granule release, known as degranulation, occurs in a hierarchical manner [141]. Neutrophils 
isolated from the inflammatory exudate obtained from a blister model of skin inflammation 
demonstrate 38.1% release of gelatinase, 21.9% of specific and 7% azurophil granule 
release with complete release of secretory vesicles [142]. Azurophil granules are thought to 
play a major role in the degradation of phagosomal contents [143] owing to the nature of anti-
microbial and cytotoxic proteins such as neutrophil elastase, myeloperoxidase (MPO) and 
cathepsin G which may account for their limited extracellular release upon stimulation. 
Granule contents are determined by their presence or absence during the developmental 
process, which is known as the targeting by timing hypothesis [144]. Azurophil granules are 
identified by the presence of MPO [145] whereas the presence of gelatinase but absence of 
lactoferrin denotes gelatinase granules [146] (see Table 1.3). There are also a number of 
protein markers specific for different granule subsets, for example CD63, CD67 and annexin 
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I which identify the azurophil, specific and gelatinase granules respectively [147-149] while 
alkaline phosphatase and CD35 (CR1) have been used as markers of secretory vesicles 
[142].  
Neutrophil functionality is mediated by synergistic granule release. For instance, proteins 
contained within all three granule subtypes are required for efficient production of reactive 
oxygen species [146]. In addition, mobilisation of secretory vesicles to the plasma membrane 
is thought to be the source of the adhesion complex CD11b/CD18 (Macrophage -1-antigen, 
Mac-1) which mediates firm adhesion upon the endothelium and allows extravasation from 
the circulation. CD11b (stored within the specific and gelatinase granules and the secretory 
vesicles) is also involved in recognition of complement protein C3bi and therefore mediates 
phagocytosis of opsonised material. 
Acting in unison, granules and their contents are thus able to modify both the neutrophil 
surface phenotype, and the extracellular environment as well as being critical mediators of 
anti-microbial functions.   
To date, there are few reports regarding the effect of ageing on neutrophil degranulation and 
the release of proteases. In 1990, MacGregor et al [150] found that the proportions of both β-
glucuronidase in primary granules or vitamin B-12 binding protein in secondary granules was 
not affected by increased chronological age; nor did they find any change in the extent to 
which granules were released either spontaneously i.e. in the resting state, or following 
stimulation with fMLP [150]. This is supported by Dalboni et al [151] who demonstrated 
maintenance of elastase activity in neutrophils from old donors when compared with those 
from young donors in response to 10ng/ml IL8 [151]. 
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  Adapted from [152] 
  
Table 1.3 Neutrophil Granule Constituents 
BPI, Bacterial Permeability Protein; MPO, Myeloperoxidase; fMLP-R, fMLP 
Receptor; TNF-R, TNF Receptor;  
Azurophil Specific Gelatinase Secretory
Granules Granules Granules Vesicles
Membrane CD63 CD11b/CD18 CD11b/CD18 CD11b/CD18
Cytochrome b558 Cytochrome b558 Cytochrome b558
fMLP-R fMLP-R fMLP-R
G-protein α-subunit CD16
Leukolysin Leukolysin Leukolysin
TNF-R CD45
Cytosol α1-antitrypsin Collagenase Acetyltransferase Plasma Proteins
BPI Gelatinase Gelatinase
Cathepsins Lactoferrin
Defensins
Elastase
MPO
Proteinase-3
Lysozyme Lysozyme Lysozyme
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1.3.2.2 Phagocytosis 
Phagocytosis is the process by which foreign or altered-self material is recognised and 
internalised into a membrane bound vesicle via cytoskeletal re-modelling in a receptor-
mediated manner. Following ingestion a complex network of intracellular signalling pathways 
are activated resulting in the degradation of ingested material [153]. These events include 
phagosome fusion with lytic granules, assembly of the enzyme nicotinamide adenine 
dinucleotide phosphate (NADPH oxidase; see the following section for more detail) and 
production of pro- or anti-inflammatory cytokines. Depending on the type of material 
ingested, the secretory cytokine profile of these cells can be altered i.e. ingestion of 
pathogenic material initiates production of pro-inflammatory cytokines such as TNFα and IL8 
[154] whereas ingestion of apoptotic cells induces secretion of anti-inflammatory cytokines 
such as transforming growth factor-β1 (TGFβ1), Prostaglandin E2 [155] commencing the 
resolution of inflammation.  
A diverse repertoire of receptors expressed on the neutrophil surface are capable of 
stimulating phagocytosis, these include but are not limited to, Fcγ Receptors (FCγRII [CD32] 
and FcγRIII [CD16]), which recognise antibody opsonised material and complement 
receptors (CR1 [CD35] and CR3 [CD11b]) which recognise complement opsonised material 
[156,157]. 
With ageing, a number of groups have observed a reduction in the phagocytic ability of 
neutrophils to a variety of stimuli including opsonised yeast [158-160]; Staphylococcus 
aureus (S.aureus) [161] and Escherichia coli (E.coli) [138,161]. 
Potential underlying mechanisms for reduced phagocytic ability in the elderly have been 
studied with a number of likely candidates put forward. Opsonisation marks material for 
destruction making phagocytosis more efficient. Major opsonins within the immune system 
are serum immunoglobulins and complement proteins. Serum concentrations of 
immunoglobulin-M (IgM) are significantly lowered with age whilst immunoglobulin-G (IgG) 
and immunoglobulin-A (IgA) concentrations remain unaltered [150]. Serum complement 
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proteins C3 and C4, show a 19% and 57% increase respectively in the elderly, however, 
values for both immunoglobulins and complement proteins remain within the normal clinical 
range [150] and are therefore unlikely to be driving reduced phagocytic function. In addition, 
surface expression of a number of phagocytic receptors remains unchanged with age 
including TLR2 and 4 [162], the fMLP receptor [163] and CR3 (CD11b) [138]. However, 
surface expression of FcγRIII (CD16) is significantly reduced on neutrophils from elderly 
donors and positively correlates with the observed reduction in phagocytic index [138]. At 
present, no studies have considered the effects of age on surface expression of other 
receptors involved in the phagocytosis of phagocytic material such as CD14 (an essential co-
receptor for TLR4 in recognising lipopolysaccharide (LPS)), CD32 or CD35 and therefore 
defects in phagocytic ability cannot yet be fully attributed to reduced CD16 expression alone. 
However, phagocytosis of gram-positive bacteria such as S.aureus, is highly dependent on 
Fc receptors [164] and therefore may contribute to the increased incidence of S.aureus 
infection evident in the elderly population [165]. 
 
1.3.2.3 ROS Production 
Reactive oxygen species (ROS) is an umbrella term that refers to a number of free radical 
oxidising species such as superoxide (O2-) and hydroxyl species (OH-) as well as non-radical 
oxidising species such as  hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) [166]. 
ROS are produced primarily through the action of the enzyme NADPH oxidase [167], which 
is assembled on the phagosome membrane during maturation [168]. NADPH oxidase 
transfers electrons from NADPH onto molecular oxygen to produce the radical O2- in a 
process known as the respiratory burst. This free radical is then metabolised by superoxide 
dismutase (SOD) to produce H2O2, which in itself is cytotoxic but can also be further 
metabolised by MPO, delivered to the phagosome through fusion with primary granules, to 
produce HOCl. In the basal state, the 5 subunits of NADPH oxidase reside independently, 
either membrane bound (p22phox and cytochrome b558, also known as gp91phox), or in the 
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cytosol (p40phox, p47phox and p67phox) and are assembled on the phagosome or plasma 
membrane along with the small GTPase Rac2 in response to stimulation [169]. In addition, 
other GTPases such as Arf protein family members, particularly Arf6 have been shown to be 
required for activation of NADPH oxidase in a phospholipase-D (PLD) dependent manner 
[170]. 
Production of ROS are vital for maintaining the anti-microbial defences of neutrophils and 
macrophages, but also have a role in maintaining homeostasis in the absence of 
inflammation, acting as second messengers in a number of signalling pathways (such as 
tyrosine kinase activation [171], NF-κB [172] and Protein Kinase C (PKC) [173] activation) 
and as electron carriers in the electron transport chain.  
The literature on the effect of age on the production of ROS is contradictory. A number of 
groups have reported a reduction in the levels of O2- produced in response to GM-CSF and 
fMLP stimulation [174-177] while other groups have reported enhanced ROS production 
(particularly H2O2) by neutrophils from elderly donors [178,179]. This discrepancy has been 
clarified recently with ROS production varying across stimuli, including the response to gram-
positive or gram-negative bacteria. Neutrophils from elderly donors exhibit a significant 
reduction in ROS production in response to stimulation with S.aureus (gram-positive) 
compared to neutrophils from young donors, however, when stimulated with E.coli (gram-
negative), neutrophils from old donors demonstrated a maintained ability to produce ROS 
when compared to young donors [161]. Wenisch et al [161] postulated this discrepancy is 
due to the differential effects of ageing on receptor surface expression and the related signal 
transduction pathways e.g. the CD14-dependent, calcium-independent pathways involved in 
ROS production in response to E.coli but not S.aureus [161]. 
 
1.3.2.4 Neutrophil Extracellular Traps (NETs) 
In 2004 Brinkmann et al [180] described a novel neutrophil function that was believed to have 
extracellular anti-microbial properties persisting beyond the typical neutrophil lifespan. This 
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function was termed Neutrophil Extracellular Traps (NETs) and refers to the presence of 
neutrophil granule and nuclear constituents in an extracellular web-like structure made up of 
a chromatin backbone studded with cytoplasmic and granule proteins including histones 
(specifically H2A and H2B), MPO, serine proteases (neutrophil elastase, proteinase 3 and 
Cathepsin G), bacterial permeability increasing protein (BPI), lactoferrin and calprotectin 
[180-182]. Not only does the chromatin backbone provide the structural support for these 
anti-microbial proteins maintaining a high, localised concentration and potentially preventing 
collateral damage from these proteins, it also is hypothesised to limit microbial spread by 
physically trapping the bacteria and bringing them into direct contact with the anti-microbial 
proteins. A number of organisms that have been shown to bind to NETs include S.aureus 
[180], Streptococcus pneumoniae [183], Salmonella typhimurium [180] and the yeast 
Candida albicans [184]. NETs have also been shown to have both anti-fungal, mediating 
protection against fungal hyphae too large to be phagocytosed [184] and anti-viral activity 
against human immunodeficiency virus-1 (HIV1) mediating viral capture and subsequent 
elimination [185]. However, it is possible that the anti-viral activity of NETs is virus specific as 
NET formation is not required for protection against influenza infection [186]. 
Owing to their recent discovery, there is limited knowledge on the effect of increasing 
chronological age on NET production. Using a mouse model of severe skin infection, Tseng 
et al [187] demonstrated a reduced ability of neutrophils from aged mice to produce NETs in 
response to infectious stimuli with a concomitant increase in bacterial dissemination 
throughout the host [187]. As the production of reactive oxygen species has been shown to 
be essential in the formation of NETs [167], and since old age results in a stimuli-dependent 
reduction in ROS production [161] it is conceivable that NET production would decline with 
increasing age and may also be stimuli specific.  
Of course the efficiency of these anti-microbial functions would be irrelevant should 
neutrophils be unable to migrate from the blood stream to the site of aggression be that of 
infection or injury. The ability to migrate, mechanisms controlling directional migration and 
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the effects of age on this process form the focus of this thesis and shall therefore be 
discussed in much greater detail than other neutrophil functions 
 
1.4 Neutrophil Chemotaxis 
Chemotaxis is the process of directed movement along a chemotactic gradient observed in 
many areas of cell biology and development including egress of immune cells from the bone 
marrow, neuronal development in the brain [188], leukocyte homing to the thymus [189], 
angiogenesis [190], re-epithelialisation mediating wound healing [191], metastasis [192] and 
immune defence against disease, injury and infection [193]. 
Chemotaxis begins with extravasation, the process whereby neutrophils leave the blood 
stream by adhering to and then transmigrating through the vascular endothelium. In order to 
begin extravasating from the blood stream, the endothelium itself must first become 
activated. This occurs following exposure to pro-inflammatory cytokines such as TNFα and 
IL8 produced by tissue resident macrophages in response to infection [194-196]. This 
induces the expression of a number of adhesion markers on the endothelial surface e.g. P- 
and E- Selectin, which bind P-selectin glycoprotein ligand-1 (PSGL-1) and E-selectin ligand-1 
(ESL-1) respectively on the neutrophil surface inducing transient tethering allowing the 
neutrophils to roll along the vasculature [197,198]. This allows neutrophil recognition of 
chemotactic signals inducing neutrophil activation and delivery of β1 and β2 integrins, 
particularly Mac1 (αMβ2; a heterodimer consisting of CD11b and CD18) and leukocyte 
function associated antigen-1 (LFA1, αLβ2; a heterodimer of CD11a and CD18) stored within 
the cytoplasmic granules to the cell surface [199,200]. Cellular activation results in a 
conformational change within β2 integrins [201] allowing recognition of intercellular adhesion 
molecule-1 (ICAM-1) expressed on the endothelium. Ligation of integrins with endothelial 
ligands induces firm adhesion and arrest of rolling neutrophils onto the vasculature [199]. 
Platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31), CD99 and junctional 
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adhesion molecule-A (JAM-A) then facilitate homing to cell junctions allowing migration 
through the endothelium in a process known as diapedesis [202]. 
Two modes of diapedesis through the endothelium have been demonstrated: paracellular 
and transcellular [203]. Paracellular migration describes migration through the tight junctions 
between adjacent endothelial cells while transcellular migration describes migration through 
a pore an individual endothelial cell [204]. These modes of migration are thought to arise 
following the formation of ‘invadosome-like protrusions’, actin-dependent protrusive 
structures that ‘probe’ the endothelium finding sites at which diapedesis can occur [204]. 
Interestingly, vascular permeability does not appear to be affected by either mode of 
diapedesis due to formation of dome-like structures by endothelial cells encapsulating the 
migrating neutrophil and therefore preventing increases in vascular permeability [205]. 
Overall, the mechanisms driving diapedesis remain elusive however, blocking of PECAM-1 
using monoclonal antibodies results in neutrophils that are capable of locating endothelial 
junctions but are unable to initiate diapedesis and are therefore unable to migrate out of the 
vasculature [206] whilst ICAM-1 has been shown to facilitate diapedesis by forming ‘cup-like’ 
structures around migrating cells guiding diapedesis [207,208]. 
Once through the endothelium neutrophils begin the process of tissue migration also referred 
to as interstitial migration. Initiation of this process begins with the interaction between a 
chemoattractant and their receptors on neutrophils. Neutrophils are exquisitely sensitive to 
gradients of chemotactic molecules demonstrating accurate movement in very shallow 
gradients – a 2% change in chemoattractant concentration across the length of the cell is 
capable of inducing robust migration [209]. Various lipid mediators such as Leukotriene-B4 
(LTB4) and platelet activating factor (PAF), complement proteins such as C5a and C3bi, 
inflammatory cytokines including IL8 and stromal cell-derived factor-1 (SDF1) and bacterial-
derived proteins such as fMLP and LPS are all neutrophil chemoattractants.  
Chemotactic cytokines, known as chemokines, are classified into 4 groups based in the 
position of the first two, highly conserved cysteine (C) residues within the chemokine 
26 
 
structure: CXC, CX3C, CC and C where X denotes an amino acid residue other than cysteine 
[210]. The CXC chemokine IL8 (CXCL8) is a particularly potent chemokine produced in 
response to inflammation mediating neutrophil extravasation from the blood stream and the 
initial stages of interstitial migration. Given the complex nature of the immune system, it is 
entirely plausible that a migrating neutrophil may be surrounded by multiple chemoattractants 
at any given time and must therefore navigate towards the most appropriate signal. To do 
this, neutrophils respond to chemoattractants in a hierarchical manner taking preference for 
‘end-target’ chemoattractants over ‘intermediary’ chemoattractants. Heit et al [211] 
categorised intermediary chemoattractants e.g. IL8 and LTB4, as those that induce 
extravasation and bring neutrophils into the general vicinity of infection whereas ‘end-target’ 
chemoattractants are those produced directly by bacteria or through direct contact of immune 
components with bacteria e.g. fMLP and C5a and therefore hone directional migration to the 
site of infection. Therefore, not only do neutrophils respond to chemoattractants in a 
hierarchical manner [212] but chemoattractants themselves exist in distinct zones throughout 
the tissue guiding neutrophils directly and accurately to the site of infection or injury [213]. 
Production in this manner then requires neutrophils to ignore a particular chemoattractant 
once its source has been reached in order to continue toward the site of infection. This 
process is known as desensitisation and is achieved through internalisation of the 
chemoattractant receptor [211] a process involving G-protein-coupled receptor kinases 
(GRKs) and β-arrestin (reviewed in [214]).  
Most chemoattractants, and all thus far identified chemokine receptors, are G-protein 
coupled receptors (GPCR) composed of 7-transmembrane domains (3 extracellular and 3 
intracellular loops) coupled to heterotrimeric guanine nucleotide binding proteins (G-proteins) 
at the inner leaflet of the plasma membrane [210]. GPCRs constitute the largest superfamily 
of membrane receptors containing receptors for hormones, inflammatory mediators (both 
pro- and anti- inflammatory), lipids and calcium ions [215]. Known G-protein coupled 
chemoattractant receptors include CXCR1 (IL8-Ra) and CXCR2 (IL8-Rb) [210], FPR1 and 2 
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which recognise formylated peptides such as fMLP, C5a-receptor and BLT1 and 2 (LTB4 
receptors) allowing neutrophils to respond to both intermediary and end-point 
chemoattractants. 
G-proteins consist of 3 subunits – α, β and γ that, in the quiescent state, exist as a single 
heterotrimeric protein with guanosine di-phosphate (GDP) associated to the α subunit [216]. 
Interaction of the GPCR with its ligand causes a conformational change allowing the 
exchange of GDP for GTP (guanosine-tri-phosphate) by the Gα-subunit and dissociation 
from the Gβγ-subunit [216,217]. This allows independent activation of a diverse and complex 
range of intracellular signalling pathways including PI3Kinase, PLC and small GTPases such 
as Ras- and Rac- GTPase (reviewed in [218]). Pathways activated by G-protein subunits are 
shown in Table 1.4. Heterogeneity between GPCR and the responses they elicit have been 
attributed to the combination of G-protein isoforms making up the complete protein. 4 classes 
of the α subunit have been identified – Gαi/o, Gαq, Gαs and Gα12/13 which share 45-80% 
homogeneity whilst 5 β- and 12 γ- isoforms have been identified exhibiting 27-75% 
homegenity and a high rate of post-translational modification [219]. GPCR mediated 
signalling is antagonised through the intrinsic GTPase activating protein (GAP) activity of the 
Gα subunit hydrolysing GTP, restoring GDP to the nucleotide binding pocket. This causes 
the Gα subunit to re-associate with the βγ subunit once again rendering the complex inactive 
(reviewed in [218,219]). 
Through coupling of membrane receptors to G-proteins, neutrophils are thus able to respond 
to a number of stimuli co-ordinating the relevant cellular response that provides both host 
protection against infections and mediates tissue repair upon injury or damage. 
However, in order for effective migration to occur through tissues, we hypothesise that the 
release of granule-specific proteases during migration remodels the extracellular matrix 
(ECM) and facilitates recruitment to the site of infection. The major proteases involved in this 
process are elastase (EC 3.4.21.37), cathepsin G (EC 3.4.21.20) and proteinase 3 (EC 
3.4.21.76). These serine proteases are stored within the azurophil granules of neutrophils 
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and possess both anti-microbial and fungistatic ability [220]. Small amounts of neutrophil 
elastase have also been observed within mast cells, basophils [221] and tissue resident 
macrophages [222]. 
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ERK, Extracellular Related Kinase; GTP, Guanine-tri-phosphate; PLC, Phospholipase C; 
PLD, Phospholipase D; iNOS inducible Nitric Oxide Synthase; GEF, Guanine Exchange 
Factor; HSP, Heat Shock Protein; PI3Kinase, Phosphatidylinositol-3-kinase; GRK, G-protein 
coupled Receptor Kinase.  
Adapted from [218]  
Table 1.4 Function of Heterotrimeric G-protein Subunits  
G-protein 
Subunit
Effect on 
Activity
Effectors
Gαs Enhances Adenylyl cyclases
Src Tyrosine Kinases
GTPase of Tubulin
Gαi Reduces Adenylyl cyclase
Ca2+ Channels
Enhances Erk Activation
K+ Channels
GTPase of Tubulin
Src Tyrosine Kinases
Gαq Enhances PLCβ
K+ Channels
Bruton's Tyrosine Kinase
Gα12/13 Enhances PLD
PLCε
iNOS
p115 Rho-GEF
E-cadherin-mediated cell adhesion
HSP90
Gβγ Enhances PLCβ
PI3Kinase
K+ Channels
P-Rex-1
SRC Kinases
GRK membrane recruitment
Reduces Adenylyl Cyclase I
Ca2+ Channels
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1.4.1 Serine Proteases as an aid to Migratory Processes 
Upon neutrophil activation, serine proteases are released from the azurophil granules into 
either the extracellular space, although a proportion of this is retained within the plasma 
membrane [223-225], or released into the newly formed phagosome [226]. Importantly, 
serine proteases are also important mediators of non-oxidative host defence and act by 
facilitating transendothelial migration [223,227,228] and neutrophil detachment during 
migration [229]. Release of neutrophil elastase at the neutrophil leading edge mediates 
tissue digestion, allowing cells to move through dense tissue. The action of these proteases 
has also been associated with the progression of a number of chronic inflammatory 
diseases. For example, proteinase-3 (PR3) has been implicated in rheumatoid arthritis (RA) 
and anti-neutrophil associated autoantibody (ANCA) associated vasculitis [230] with an 
increased risk of relapse associated with increased surface expression of PR3 [231]. 
Elastase has also been implicated in disease pathogenesis, with an active role for this 
protease (usually acting in conjunction with other proteases) in the progression of chronic 
obstructive pulmonary disease (COPD) [232-235] and RA [236,237]. Mutations in the gene 
encoding neutrophil elastase, ELA2, have also been identified in 50% of patients diagnosed 
with severe congenital neutropenia (SCN), an inborn disorder of granulopoiesis due to arrest 
in the differentiation of granulocyte precursors, and in all cases of cyclic neutropenia (CN), a 
less severe form of granulopoiesis. Both SCN and CN leave individuals particularly 
susceptible to infection and have an increased propensity to develop acute myeloid 
leukaemia and myelodysplasia [238]. 
Although release of azurophil granules is relatively limited when compared to secretory 
vesicles or gelatinase granules, sequential release of single azurophil granules into the 
extracellular space has been shown to occur during neutrophil migration, each with 
concomitant protease activity [223,239]. Neutrophil elastase is released from granules at a 
concentration of 5.33mM [240], a concentration 150-1500 times greater than that of its 
endogenous inhibitors - α1-antitrypsin (α1-AT, 32.8μM) [239], secretory leukocyte peptidase 
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inhibitor (SLPI, 11μM) [241] and α2-macroglobulin (α2M, 3.5μM) [242] resulting in an area of 
obligate tissue damage at the point of release. Away from the point of release, the 
concentration of elastase decreases exponentially thus allowing inactivation of the protease 
once the elastase:inhibitor ratio has reached 1:1. At this point, protease activity is abolished 
by the action of local inhibitors, α1AT inhibiting free elastase in an irreversible manner and 
SLPI reversibly inhibiting membrane bound elastase [225], however this does not arise until 
a localised area of protease mediated tissue destruction has occurred, a phenomenon 
termed ‘quantum proteolysis’.  
Endogenous substrates for these proteases encompasses a number of extracellular matrix 
components including elastin [243], fibronectin [244] and collagen [245] however out of the 
three serine proteases, neutrophil elastase is the most potent due its ability to degrade the 
vast majority of extracellular matrix components (reviewed in [246]). This makes neutrophil 
elastase a particularly powerful protease at mediating large-scale tissue damage, particularly 
during interstitial migration. Consequences of matrix degradation are undoubtedly negative 
when prolonged, for example in the context chronic inflammatory diseases or in the absence 
of protease inhibitors e.g. α1-AT deficiency. However, matrix degradation when adequately 
regulated, may also facilitate interstitial migration by exposing extracellular matrix 
components and strengthening host defences. Interstitial migration can occur in the absence 
of the β2 integrins [247], with adhesion instead mediated through the action of β1 integins 
such as very late antigen-6 (VLA-6, α6β2) and -9 (VAL-9, α9β2), expression of which is up-
regulated following neutrophil activation e.g. in response to fMLP and transmigration 
following interaction with PECAM-1 [247,248]. β1 integrin ligands include a variety of 
extracellular matrix proteins including laminin [249], collagen [250] and fibronectin [251]. 
 
1.4.2 Signalling pathways involved in the regulation of migration 
In order for migration to occur, neutrophils adopt a polarized phenotype involving the 
formation of a leading edge and uropod tail as a function of general motility [252]. Within this 
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morphology, the leading edge demonstrates enhanced sensitivity allowing directional 
sensing of the chemotactic gradient [253]. There are a significant number of signalling 
pathways involved in the generation of directional migration however it is important to 
remember they do not act in isolation and instead exist as a complex signalling network 
involving both positive and negative regulation, see Figure 1.3.  
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Figure 1.3 A Diagrammatic Representation of the Complex Network of Signalling Pathways 
Thought to be involved in the Regulation of Migration to Date 
 
 
 
 
 
 
 
 
 
 
Taken directly from [254] 
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1.4.2.1 PI3Kinase 
The phosphotidylinositol-3-kinase (PI3Kinase) family consists of conserved enzymes present 
in mammalian cells that phosphorylate the D3-position of the inositol ring of phosphoinositide 
lipids. This produces a number of inositol lipid second messengers in response to a number 
of extracellular signals including cytokines, integrin engagement and FcγR ligation. The 
PI3Kinase family, through association with pleckstrin homology (PH) domains present in 
target proteins, recruits a number of signalling molecules to the plasma membrane thus 
amplifying the signal. 
The PI3Kinase family is divided into 3 classes based on their lipid products and the identity of 
the subunits present in each protein complex. Class I PI3Kinases, the most studied of the 
PI3Kinase subfamilies, are heterodimeric proteins consisting of both a regulatory and a 
catalytic subunit which phosphorylates phosphatidylinositol - 4,5 - bisphosphate (PI(4,5)P2) 
to produce phosphatidylinositol - 3,4,5 - triphosphate (PIP3), the only triphosphate inositol 
lipid present in mammalian species; Class II PI3Kinases exist as monomers and Class III as 
heterodimers both of which phosphorylate phosphatidylinositol (PI) to form 
phosphatidylinositol-3-phosphate (PI(3)P) (see Table 1.5).  
 Production of multiple lipid products places PI3Kinase at the centre of multiple signalling 
networks eliciting a role for this enzyme family in a multitude of cellular functions including 
migration, proliferation, cell survival and endocytosis. Human neutrophils are known to 
express all of the above mentioned isoforms [255], however, it is members of the class I 
family that are fundamental to the control of migration mainly due to their ability to be 
activated by a wide variety of cell surface receptors.  
Class I PI3Kinase is sub-divided into class IA and class IB based on the structure of its 
component subunits: class IA contains 3 isoforms consisting of either a p85 or p55 regulatory 
subunit coupled to a p110α, β or δ catalytic subunit; the single isoform making up class IB 
PI3Kinase consists of a p101 regulatory subunit and p110γ catalytic subunit. Class I 
activation occurs downstream of receptor-ligand interaction on the cell surface via 
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phosphorylation of the regulatory subunit thus facilitating binding of PIP2 by the catalytic 
subunit and its subsequent phosphorylation. In the case of Class IA and Class IB PI3Kinase, 
these are activated downstream of tyrosine kinase receptors and Gαi –containing GPCRs 
[256] respectively. However, recent evidence has demonstrated significant cross-talk in the 
activation both classes through the presence of a Ras binding domain (RBD) in the p110 
subunit rendering both class IA and IB sensitive to the GTPase Ras [257]. Ras and Gβγ are 
now known to act synergistically to control PI3Kinase activation. The structure and function 
of the PI3Kinase family has been extensively reviewed in number of excellent review articles 
[255,258-261]. 
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Table 1.5 PI3Kinase Isoforms in Mammalian Cells [255,258-260] 
 
 
 
 
 Regulatory 
Subunit 
Catalytic 
Subunit 
Product Activation Cellular Processes Localization 
Class I A p85 or p55 p110 α β δ PIP3 Tyrosine Kinase Receptors 
(Integrins, FcγR); Ras-GTPase; 
Insulin Receptor A [262] 
Neutrophil Directional 
Movement [263] 
Cytoplasmic then 
recruited to the plasma 
membrane upon 
activation  B p101 or p84 p110 γ PIP3 Gβγ subunit of Gαi-proteins; Ras-
GTPase; Insulin Receptor-A [262] 
Neutrophil 
Chemokinesis [264] 
Class II  None* C2 α β γ PI(3)P 
PIP3 [265]  
TC10-GTPase [266]; Clathrin 
[267]; Insulin-Receptor-B [265]; 
Calcium [268]; Chemokines; 
Integrin Engagement** 
LPA-mediated 
migration [269] , 
endocytosis 
Associated with 
membrane structures 
e.g. Clathrin coated 
vesicles [270]  
Class III  p150 hVsp43p PI(3)P ? Intracellular trafficking 
e.g. autophagy [271] 
and phagosome 
formation [272] 
Intracellular membranes 
e.g. Golgi & 
endosomes[273] 
*Although Class II does not, at present, appear to have a regulatory subunit per se; its protein structure does contain several protein domains through which 
interaction with adaptor proteins is thought to regulate activation [274]. 
**Mechanisms for activation for Class II PI3Kinase remain poorly understood with some current mechanisms being the result of speculation based in the 
crystal structure of the protein [274] 
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Following activation, PI3Kinase catalyses the production of PIP3 which accumulates at the 
leading edge of migrating cells [275] and further recruits PH – domain containing proteins 
such as 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1), GEFs such as P-Rex1, 
Bruton’s tyrosine kinase (Btk) and PKB/Akt [276] which then activate effector proteins such 
as members of the Rho-GTPase family and the serine/threonine kinase Akt thus propagating 
the initial signal, eliciting a functional response.  
The role of PI3Kinase in controlling migration has been somewhat controversial with some 
groups reporting PI3Kinase to be an absolute requirement for migratory processes [263,277], 
while others report only limited involvement of PI3K [264,278]. There is also evidence of 
migratory processes occurring independently of PI3Kinase [211]. These discrepancies are 
likely to arise from the experimental model used as well as the type and length of stimulation. 
By considering chemokinesis (speed) as a separate parameter to chemotaxis (direction), a 
subtle but discrete role for both PI3Kinase-δ and –γ as the major PI3Kinase isoforms 
involved in migratory processes is now widely accepted. This observation may explain the 
earlier discrepancies observed regarding the involvement of PI3Kinase in migratory 
processes. PI3Kinase-γ has been shown to be the dominant PIP3 producing isoform at the 
leading edge during migration, as neutrophils from a PI3Kinase-γ deficient mouse produced 
negligible amounts of PIP3 in response to chemoattractant stimulation [279,280]. In contrast, 
PI3Kinase-δ has been shown to facilitate neutrophil spreading and polarisation across 
fibronectin-coated surfaces [281]).  
PI3Kinase signalling, and therefore PIP3 production, is regulated through the action of the 3- 
and 5- phosphatases Phosphatase and Tensin Homolog (PTEN) and Phosphatidylinositol-
3,4,5-triphosphate 5-phosphatase (SHIP1) respectively. These phosphatases are 
responsible for regulating PI3Kinase and confining PIP3 to the leading edge through de-
phosphoryation of PIP3 producing a further lipid product phosphatidylinositol- 3,4 – 
bisphosphate (PI(3,4)P2) and phosphatidylinositol – 4,5 – bisphosphate (PI(4,5)P2). In this 
manner PI3Kinase activity is antagonised maintaining cellular homeostasis. 
38 
 
1.4.2.2 Protein Kinase B (PKB)/Akt 
Akt, also known as protein kinase B (PKB), is an ~60kDa serine/threonine kinase that was 
originally identified as a retroviral oncogene [282] and most well-known for its ability to 
prolong neutrophil survival in response to pro-inflammatory cytokines [283]. Akt is abundantly 
expressed in mammalian cells as three highly homologous isoforms Akt-1 (PKBα), Akt-2 
(PKBβ) and Akt-3 (PKBγ). Akt1 and Akt2 are the most abundantly expressed isoforms with 
Akt-3 being solely expressed in the brain and testis where it has been shown to have a role 
in post-natal brain development [284,285]. Akt has been demonstrated as an essential 
component of a number of cellular processes including cellular proliferation [286], superoxide 
generation [287] and migration [288]. 
During migratory processes, Akt in known to translocate to the leading edge of migrating 
neutrophils from the cytosol by virtue of its PH domain recognising membrane localised PIP3 
produced by active PI3Kinase [289]. Current studies [290] suggest it is the Akt2 isoform that 
is recruited in this setting however, conclusive evidence of this is required before definitive 
conclusions can be drawn. Once at the membrane, Akt is phosphorylated by the action of 
two independent kinases, PDK1 and mTOR-complex 2 (mTORC2), these phosphorylate 
Threonine-308 (Thr308) and Serine-473 (Ser473) residues respectively. PDK1 is a kinase 
that has been shown to be dependent on PIP3 but unaffected by wortmannin, a broad-
spectrum PI3Kinase inhibitor, placing the action of PDK1 on Akt downstream of PI3Kinase 
[291]. For a long time the identity of the Ser473 kinase, now identified as mTORC2 (mTOR 
when in a rapamycin-insensitive complex with sin-1 and rictor) [292,293] was unclear and 
has previously been referred to as PDK2 or hydrophobic motif kinase (HM kinase). 
When phosphorylated solely at Thr308, Akt shows partial activation and in this state it is 
capable of activating mTORC1 (mTOR when complexed with raptor) through 
phosphorylation of PRAS40, a dominant negative regulator of mTORC1 [294]). Activity in this 
manner allows Akt-mediated regulation of protein synthesis and cell growth through the 
action of mTORC1. Phosphorylation of both Ser473 and Thr308 results in full-activation of 
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Akt increasing the number of Akt phosphorylation targets. These targets include caspase-9 
(phosphorylation of which prevents its protease activity [295]); Iκ-B Kinase (IκK) (affecting 
NF-κB gene transcription [296]); mTOR [297]; p47phox (mediating the respiratory burst [287]) 
and p21 Activated Kinase (PAK1) (influencing migration [298]). 
In order to maintain homeostasis, Akt signalling is antagonised through de-phosphorylation 
of Thr308 by protein phosphatase 2A (PP2A) [299], and Ser473 by PH-domain leucine-rich-
repeat-containing protein phosphatase 1 or 2 (PHLPP1/2) [300]. This is further controlled by 
de-phosphorylation of PIP3 by PTEN/SHIP1 to form PIP2. 
 
1.4.2.3 Rho-GTPases 
The Ras superfamily are a large (with approximately 150 members) conserved family of 
small (~21kDa) monomeric G-proteins consisting of 5 main groups (Ras, Rho, Rab, Ran and 
Arf) with Rho-family proteins forming the major branch. These GTPases act as molecular 
switches regulating a diverse range of cellular process by cycling between an active, 
Guanosine triphosphate (GTP) -bound and an inactive, guanosine-diphosphate (GDP) - 
bound state. This process is tightly regulated by both guanine nucleotide exchange factors 
(GEFs), which catalyse the exchange of GDP for GTP and thus activate the molecule, and 
GTPase activating proteins (GAPs), which inactivate the GTPase by exchanging GTP for 
GDP. Incorporation of prenyl groups (mainly geranylgeranyl pyrophosphates (GGP) and 
Farnesyl Pyrophosphate (FPP)) during biosynthesis allows the insertion of GTPases into the 
membrane. This supports activation through the exchange of GDP for GTP, a reaction 
catalysed by guanine nucleotide exchange factors already present in the membrane. In their 
GDP, inactive state, GTPases are sequestered in the cytoplasm where they are retained by 
GDP dissociation inhibitor (GDI) proteins by forming a high-affinity but biologically inert GDI-
GTPase complex. GDI proteins provide another checkpoint in GTPase activation by binding 
to prenyl groups and preventing their interaction with the membrane. In addition, GDI 
proteins are known to stabilize the binding of Mg2+, the dissociation of which is required for 
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nucleotide exchange. For full activation, GDP-bound GTPases must first dissociate from their 
GDI, a process that is catalysed by GDI dissociation factors (GDFs) whose identity still 
remains elusive however a single human GDF has been recently identified, PRA-1 [301]. 
Following dissociation, the GDP-bound GTPases must translocate to the membrane where, 
through interaction with GEFs, GDP is exchanged for GTP and thus activating the GTPase 
allowing interaction with effector molecules. It has been demonstrated that the interaction 
between the GDP-bound form of Rac-GTPase is modulated by inositol lipids, particularly 
PIP2 [302]. This process has been elegantly reviewed elsewhere [303]. 
In their active conformation, Rho GTPases have been shown to be key regulators of 
cytoskeletal rearrangement, stress fibre formation and cell-cycle progression and have also 
been implicated in a number of cellular functions including adhesion, migration, phagocytosis 
and ROS production, most likely owing to their ability to dynamically control remodelling of 
the cytoskeleton. Three Rho GTPases are particularly prominent in the control of migration – 
Ras homolog gene family member A (RhoA), Cell Division Control Protein 42 (Cdc42)  and 
Rac [304].  
During migration, Rac and Cdc42 are localized to the leading edge where they are involved 
in the assembly of the filamentous actin (F-actin) network through recruitment of actin 
polymers and in maintenance of the leading edge [305]. Rac- and Cdc42-GTPase are 
activated by GEFs such as P-Rex-1 [306], DOCK1/2 [307] and β-Pix localized in the 
membrane through association with PIP3. Once activated, these GTPases have been shown 
to modulate cytoskeletal rearrangement through activation of suppressor of cAR (SCAR)/ 
WASP family Verprolin-homologous protein (WAVE) family members and subsequently the 
actin nucleating complex actin-related protein 2/3 (Arp2/3) [308,309]. In addition, these 
proteins have also been shown to inhibit actin de-polymerization through phosphorylation 
and subsequent inhibition of Cofillin via LIM Kinase (LIMK) [310]. In comparison RhoA-
GTPase is found localised to the rear of the cell in the uropod where it mediates tail 
retraction and dissociation of adhesive complexes [311].  
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1.4.2.4 Reactive Oxygen Species (ROS) 
Production of ROS has been shown to occur at the leading edge of migrating neutrophils in 
an NADPH oxidase dependent manner [312]. The GTPase activating protein GIT2 links 
GPCR signalling at the surface with recruitment of NADPH oxidase [313] and subsequent 
ROS production at the leading edge. Chemoattractant-induced ROS production appears to 
function by amplifying the PIP3 signal though localized oxidation of PTEN thus suppressing 
its phosphatase activity [314-316]. Phosphorylation of Akt, itself is reduced in the presence of 
N-acetyl-L-cysteine (NAC) [317] suggesting a role for redox-mediated feedback in the 
regulation of migration. 
 
1.4.2.5 Actin Cytoskeleton 
The actin cytoskeleton is a dense network of actin fibres present within the cytoplasm that 
acts as a cellular scaffold governing cell shape, intracellular transport, cell division and, in 
motile cells, membrane protrusion and tail retraction. Protrusion in this manner is driven by 
polymerization of actin filaments just under the plasma membrane forming one of two basic 
actin structures: branched filament networks leading to sheet-like protrusions (lamellipodia) 
or un-branched actin bundles leading to finger-like protrusions (filopodia and pseudopodia) 
characteristic of the leading edge in motile cells (see Figure 1.4). The dense actin network 
present in the lamellipodia provides the scaffold upon which motility machinery can localize 
within the leading edge (reviewed extensively in [318]). 
Actin structures, once initiated, can continue extending owing to the abundance of 
monomeric actin within the cytoplasm and are only stopped through the action of capping 
protein concealing the barbed end of a growing filament [319]. However, for nucleation of 
new actin filaments, assistance is required from nucleating proteins such as the Arp2/3 
complex and the Formin family of proteins including the diaphanous-related formins (DRFs 
also known as mDia1-3). Arp2/3 is responsible for the formation of branched networks by 
nucleating actin polymerization at a 70° angle from the sides of pre-existing filaments [320], 
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while formins act to nucleate un-branched actin filaments [321] creating linear bundles 
required for membrane spikes and pseudopodia. However, these proteins do not act in 
isolation, Wiskott-Aldrich syndrome proteins (WASP) family members, PIP2 and Cdc42 are 
all required in addition to nucleating proteins to efficiently stimulate actin filament elongation 
[322].  
In order to maintain motility and the supply of monomeric actin in the cytoplasm, actin 
disassembly must also take place. This occurs through the action of cofillin by dissociating 
Arp2/3 and its associated branches from actin filaments resulting in debranching of the actin 
network [323]. This forms a cycle beginning with actin nucleation and depleting cytoplasmic 
stores of monomeric actin and ending with replenishment of those stores through actin 
filament dissociation, this cycle is known as the dendritic nucleation model [324] ensuring a 
constant supply of monomeric actin for actin nucleation and driving the leading edge forward. 
See Figure 1.5 
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Figure 1.4 Actin Structures at the Leading Edge. 
Growing actin filaments are found within the leading edge driving forward protrusion of the 
plasma membrane and generating motility. Actin filaments are found as two main 
conformations: (A) Lamellipodia, a dense actin network forming sheet-like protrusions and 
(B) Filopodia, bundles of parallel actin filaments creating finger-like protrusions. Adapted 
from [325]. 
 
Direction of Movement 
(A) Lamellipodia 
(B) Filopodia 
 
 Leading Edge 
44 
 
 
Figure 1.5 The Dendritic Nucleation Model. 
This model describes the retrograde flow of monomeric actin ensuring an adequate supply for nucleation of new fibers and the subsequent 
protrusion of the plasma membrane at the leading edge driving cell motility. Figure taken directly from [324]  
Figure 1.7  
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1.4.2.6 Other Molecules controlling migration 
Although PI3Kinase and the Rho GTPases are widely accepted as mediators of accurate 
migration, a number of other signalling pathways have been implicated in the process. 
Mitogen activated protein kinase (MAPK) family members including ERK, p38 MAPK and Jun 
N-terminus kinase (JNK) have been shown to regulate migration through interaction with 
Paxillin, a docking protein that recruits certain proteins to focal adhesion complexes including 
serine/threonine kinases and GTPases [326] and Spir, a member of the WASP family of 
proteins, both of which results in reorganisation of the actin cytoskeleton (reviewed in [327]). 
Although activated downstream of PI3Kinase [328], inhibition of ERK had no effect on 
neutrophil migration in response to IL8 [329] implying that neutrophil migration is largely 
independent of MAPK activation.  
Genetic silencing of Phospholipase-D2 (PLD2), an enzyme involved in phospholipid 
metabolism in the plasma membrane, has been shown to induce arrest of migration [330]. 
However mechanisms underlying this involvement remain largely unknown. Peng et al 
showed PLD2 to contain two Cdc42/Rac Interactive binding (CRIB) domains within its 
structure allowing direct interaction with Rac-GTPase [331] highlighting a possible 
mechanism by which PLD2 could be involved in migration. PLC has also been shown to be 
important in the regulation of migration through the translation of integrin-dependent signals 
catalysing PIP2 to produce inositol-triphosphate (IP3) and DAG, inducing the release of 
calcium from intracellular stores subsequently enhancing ROS production [332]. 
In addition, in the presence of PI3Kinase inhibitors murine neutrophils are still able to 
migrate, albeit with significantly reduced efficiency of migration. This phenomenon has been 
attributed to PKBR1, a membrane-bound isoform of Akt that is uniformly distributed 
throughout the cytoplasm but exhibits localised activation by mTORC2 upon detection of a 
chemotactic gradient [333]. Upon activation PKBR1 acts through as yet undetermined 
mechanisms to modulate both actin nucleation and disassembly (reviewed in [334]). 
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1.4.3 Pathway integration resulting in co-ordinated control of migration 
We are still to fully understand the mechanisms involved in the control of directional 
migration; until recently directional migration was thought to be under the control of a single 
linear pathway governing both motility (chemokinesis) and directionality (chemotaxis) giving 
rise to a compass like model of migration. The role of the compass needle was attributed to 
PI3Kinase due to the essential localisation of PIP3 at the leading edge [275]. However, 
inhibition of PI3K in murine neutrophils causes a reduction in the absolute number of cells 
responding but does not affect their speed or directionality [335]. This suggests there are 
additional control mechanisms acting independently of PI3K and that chemokinesis and 
chemotaxis are independently regulated.  
The idea of a complex signalling network existing not only at the leading edge but also 
throughout the cell is now widely accepted [334]. Integration of concomitant signalling 
originating at both the leading edge and uropod determine polarity leading to the spatial and 
temporal orientation of signalling molecules and laying the foundation for a function that is 
both robust and generic whilst also exhibiting exquisite sensitivity. The extent to which 
individual elements of this signalling network contribute remains unclear. The process of 
directional migration can be divided into its three components parts: polarity, motility and 
directional movement in order to understand the pathways that govern migrational control.  
 
1.4.3.1 Polarity  
Polarisation refers to the morphological changes that occur as a direct consequence of 
chemoattractant-mediated cellular activation generating a polarised phenotype with a 
flattened ‘leading edge’ at the up-gradient edge of the cell and a tail, or uropod, at the down-
gradient edge. Concomitantly, intracellular components exhibit their own, interior polarisation 
generating an internal gradient of signalling molecules causing the formation of distinct 
domains around the cell periphery.  
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The leading edge is characterised by the accumulation of F-actin [336] and the localisation of 
a number of proteins involved in cytoskeletal re-organisation and gradient sensing. These 
proteins include: PI3Kinase, particularly the p110γ isoform [337] and therefore it’s lipid 
product PIP3, the actin-nucleating protein Arp2/3 and the small GTPases Rac and Cdc42 
which play fundamental roles in both the formation of the leading edge as well as its location 
and subsequent stability [305]. Addition of a cell-permeable ester of PIP3, PIP3/AM, to human 
neutrophils induces cell polarisation with 70% of cells exhibiting a flattened morphology with 
a contracted tail. In addition, cells treated with PIP3/AM show a significant accumulation of F-
actin at the leading edge and significantly increase their speed of migration [338]. 
Conversely, the uropod is devoid of these proteins and instead contains proteins such as 
PIP2 and RhoA-GTPase (which is not detected at the leading edge). Simultaneous signalling 
originating from the leading edge and uropod have been shown to antagonize each other’s 
activity [339,340] ensuring signalling networks are compartmentalised, generating and 
subsequently maintaining a self-organising polarity in response to a chemoattractant 
gradient. An excellent example of this is the lipid product PIP3 which has been shown to 
promote the activity of Rac- and Cdc42-GTPase at the leading edge and RhoA-GTPase in 
the uropod [341]. In the case of PIP3, polarity is further maintained through the presence of 
the phosphatases PTEN and SHIP1 at the sides of the cell and in the uropod which de-
phosphorylate PIP3 to produce PI(4,5)P2 and PI(3,4)P2 respectively. Using SHIP1-/- and 
PTEN-/- knock-out mice, PTEN appears to be involved in the maintenance of the anterior-
posterior PIP3 gradient and is the main antagonist of PI3Kinase activity whilst SHIP1 is 
involved in the regulation of PIP3 production upon cell adhesion preventing the development 
of a top-down PIP3 gradient [281]. Membrane composition and integrity have also been 
shown to be essential in the maintenance of polarity; depletion of cholesterol disturbs 
membrane organisation and inhibits cell polarisation and migration by preventing the 
sustained activation of signalling molecules necessary for maintenance of the migratory 
phenotype [342]. 
48 
 
The importance of polarity, both morphologically and internally, in orchestrating migration has 
been demonstrated using neutrophils deficient in various proteins involved in the process. 
SHIP1 deficient neutrophils, which are not able to localise PIP3 to the leading edge, exhibit 
an extremely flattened and weakly polarised morphology with significantly reduced speed 
[343], inhibition of RhoA or its downstream effector Rho-associated kinase (ROCK), does not 
appear to affect motility of the cell body (therefore the leading edge) but prevents 
detachment of the uropod thereby reducing the overall speed of migration [311]. However, in 
light of this, polarity does not appear to be a response to a chemotactic gradient per se as 
neutrophils exposed to a uniform stimulus i.e. one that is constant across the length of the 
cell, still display a polarized morphology [344]. 
Overall, polarity arises from the action of a localised activator and a global inhibitor, giving 
rise to the characteristic polarised phenotype and providing the foundation for locomotion 
and gradient sensing. 
 
1.4.3.2 Motility (Chemokinesis) 
In order for a cell to become motile it must first achieve a number of parameters: forward 
propulsion at the leading edge, retraction at the rear with release of adhesive contacts and 
maintenance of membrane tension and integrity preventing cell lysis. 
Signals involved in the maintenance of polarity have been grouped into ‘frontness’ and 
‘backness’ signals which are generated at the leading edge and uropod respectively [345]. 
‘Frontness’ signalling refers to the protrusion of the leading edge driven by polymerized F-
actin, which generates the power required to force protrusions of the plasma membrane 
commonly known as pseudopods (finger like projections) and/or lamellipodia (sheet-like 
projections). ‘Backness’ signalling, on the other hand, refers to retraction and ‘de-adhesion’ 
of the uropod facilitating forward motility. Both of these pathways occur downstream of 
chemoattractant stimulation but are independently regulated. Frontness signalling is under 
the control of Gi coupled GPCRs acting through PI3Kinase, the Rho family GTPases Cdc42 
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and Rac1 and Arp2/3, which stimulates actin polymerization [346,347], see Figure 1.6. 
‘Backness’ signalling occurs downstream of G12/13 coupled GPCRs, activating RhoA and its 
downstream kinase ROCK, which mediates detachment of the uropod and contraction of 
myosin fibres [339] generating a centripetal force against which actin filaments can push in 
order to force protrusions of the membrane at the leading edge, see Figure 1.7. 
Actin polymerisation occurs at areas of dense PIP3 accumulation and is driven by the 
recruitment and activation of Arp2/3 by members of the WASP family, particularly 
SCAR/WAVE, which is itself dephosphorylated for activity by the small GTPase Rac [348]. 
The production of PIP3 in this context has been attributed to the action of the p110γ isoform 
of PI3Kinase and although this isoform appears to be dispensable for gradient sensing (see 
subsequent section), it is critical for the initiation of general motility or chemokinesis 
[264,349]. In addition, a role for Akt but not Cdc42 has also been demonstrated in generating 
motility [350]. 
In the uropod, RhoA-GTPase-/ROCK activation occurs following activation of p115Rho GEF 
by the Gα12/13 subunit of heterotrimeric G-proteins and results in the activation of the calcium 
dependent enzyme myosin light chain kinase (MLCK). This enzyme is responsible for the 
light chain phosphorylation of Myosin II initiating filament contraction and therefore retraction 
of the uropod. Neutrophils treated with either a myosin inhibitor or a MLCK inhibitor exhibit a 
dose dependent reduction in chemokinesis due to impaired uropod retraction [351]. ROCK 
has also been shown to be able to act directly on Myosin II [352] whilst MLCK can also be 
activated downstream of Ras, Mitogen Activated Protein Kinase Kinase (MEK) and ERK 
[353]. Rho-GTPase stabilizes actin within actin-myosin bundles through its action on LIMK-2 
and Cofillin [354] and enables detachment of adhesive contacts within the uropod [311]. 
The cell membrane also has a role to play in the regulation of motility. Apart from acting as a 
physical barrier, separating the interior and exterior of the cell and acting as a signalling 
platform, the membrane also generates an inward force mechanically restraining actin 
protrusions [355,356] and contributing to retractions of the uropod [357]. This allows both 
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‘frontness’ and ‘backness’ signalling to set the rate of motility: if one of these functions occurs 
at a slower rate than the other, it becomes the rate-limiting factor in speed of cell movement. 
 
1.4.3.3 Directional Sensing (Chemotaxis) 
Being able to sense the direction of a chemotactic gradient is the crux of chemotaxis, the 
process of generating polarity and chemokinesis are redundant without navigation. The exact 
mechanism of gradient sensing remains elusive, but is likely to involve integrated signalling 
from multiple pathways.  
To date the most appropriate model to accurately describe gradient sensing is proposed by 
King and Insall in 2009 [254]. Here, the Bifurcation and Bias model suggests that de novo 
synthesis of pseudopods rarely occurs and instead the splitting of existing pseudopods 
creates ‘new’ pseudopods in a receptor occupancy dependent manner; the most accurate 
pseudopods (those that sense the highest chemokine concentration) are maintained while 
others are retracted. As receptor localisation appears to remain uniform across the plasma 
membrane during migration e.g. C5a-Receptor (C5aR) [289], (although in steep gradients, a 
higher concentration of chemoattractant at the leading edge will provide greater sensitivity) 
the internal gradient of signalling molecules appears to provide the sensitivity required to 
sense direction.  
Production of ROS has been suggested as a mechanism by which cells collapse their less 
accurate pseudopods as inhibition of NADPH oxidase leads to the formation of multiple, 
sustained pseudopods within the leading edge [312]. Microtubule stability has also been 
shown to have a role in selecting and maintaining the accurate pseudopods allowing 
neutrophils to choose between protrusions to give direction [358]. In addition, murine 
neutrophils lacking the protein GIT2, the GEF that links GPCR signalling with NADPH 
oxidase recruitment, exhibit a loss in directional migration [313]. mTORC2 has also been 
shown to be involved in the generation of directional migration acting through PKBR1 [333]. 
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An essential role for PI3Kinase-δ has been observed in the control of directional migration by 
selectively amplifying the PIP3 signal in localised areas of the cell above that of the 
PI3Kinase-γ mediated PIP3 signal. However, inhibition of PI3Kinase-δ does not block the 
synthesis of F-actin or prevent adhesion to the substratum [263]. Furthermore, signalling 
pathways involved in the molecular control of migration are not unidirectional and there are 
positive feedback loops existing within the leading edge involving PI3Kinase, PIP3, multiple 
G-proteins including heterotrimeric G-proteins and small GTPases as well as NADPH 
oxidase/ROS. This governs directional migration, bringing together polarity, movement and 
direction. For example, PIP3 has been shown to be able to activate PI3Kinase [338], while 
Rac- and Cdc42-GTPase have been shown to be able to act upstream of Akt in governing 
cell motility [350]. 
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Figure 1.6 Signaling Networks at the Leading Edge of Migrating Neutrophils.  
Neutrophil migration is under the control of a dense network of signaling pathways which 
interconnect to deliver a migratory phenotype that is both robust and sensitive. Signaling at 
the leading edge originates from activation of surface receptors and results in the 
polymerization of actin filaments causing protrusion of the leading edge and forward 
motility. GPCRs; G-protein coupled receptor; R, receptor; PLCβ, phospholipase C-β; PIP
2
; 
phosphatidylinositol-2-phosphate; IP
3
, inositol-triphosphate; DAG, Diacylglycerol; PKC, 
protein kinase-C; ROS, reactive oxygen species; PIP
3
, phosphatidylinositol-(3,4,5)-
phosphate; SHIP1, phosphatidylinositol-3,4,5-triphosphate 5 phosphatase; PTEN, 
phosphatase and tensin homolog; PDK1, 3-phosphoinositide dependent kinase-1; GEFs, 
guanine nucleotide exchange factors; mTORC1, mammalian target of rapamycin complex-
2; NADPH oxidase, nicotinamide adenine dinucleotide phosphate oxidase; WASP, Wiskott-
Aldrich syndrome proteins; Arp2/3, actin-related protein-2/3; LIMK1, LIM-Kinase-1. 
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Figure 1.7 Signaling Networks within the Uropod of Migrating Neutrophils.  
Retraction of the uropod occurs due to the contraction of myosin light chain mediated 
though the activation of RhoA and myosin light chain kinase (MLCK) filaments. Uropod 
signaling originates from interaction of G-protein coupled receptors (GPCRs) coupled to the 
Gα
12/13
 subunit. GEFs, guanine nucleotide exchange factors; RhoA, RhoA-GTPase; ROCK, 
Rho-associated Kinase; LIMK2, LIM-Kinase-2; ERK, extracellular-signal-related protein 
kinase; MEK, mitogen-activated protein kinase kinase; Ras, Ras-GTPase 
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1.5 Plasma Membrane Structure 
Biological membranes, consisting mainly of phospholipids, such as phosphatidylcholine (PC), 
glycolipids such as sphingomyelin (SM) and cholesterol, provide a physical barrier 
distinguishing the cell interior from the extracellular environment. Transport across the lipid 
membrane is a tightly controlled process made possible by the presence of proteins 
embedded within the fluid lipid structure. 
 
1.5.1 Phospholipids 
Phospholipids (PLs) are a major class of membrane lipid. The most common form is 
composed of a glycerol backbone attached to a phosphorylated alcohol and two esterified 
fatty acid chains, creating an amphipathic molecule with both a hydrophilic, polar head group 
and a hydrophobic tail.  Once in the bi-layer conformation, PLs are capable of interaction with 
aqueous media found in the extracellular environment or cellular cytosol whilst 
simultaneously forming a hydrophobic barrier.  
Cellular PL biosynthesis begins with the synthesis of phosphatidate which then reacts 
successively with DAG and an alcohol (one of which must be activated by cytidine 
triphosphate [CTP]) in a multi-step process forming the complete PL. Some of the more 
common PLs found in cell membranes include PC which accounts for 50% of phospholipids 
in eukaryotic membranes [359], Phosphatidylethanolamine (PE), Phosphatidylinositol (PI), 
Phosphatidylglycerol (PG), Phosphatidylserine (PS) and SM. See Figure 1.8 for the 
chemical structure of these molecules.  
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Figure 1.8 Structure of Common Membrane Lipids. 
Chemical structure of lipid species commonly found in eukaryotic membranes. 
CH, Cholesterol; PS, Phosphatidylserine; PC, Phosphatidylcholine; PI, 
Phosphatidylinositol; PG, Phosphatidylglycerol; PE, Phosphatidylethanolamine; 
SM, Sphingomyelin. 
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The main site of phospholipid biosynthesis is the endoplasmic reticulum; however, synthesis 
also occurs within the golgi body and mitochondria [359], see Figure 1.9. Newly synthesized 
phospholipids are used to populate various cellular membranes including but not limited to, 
the plasma membrane and endosomes. As the cytosol is an aqueous solution, intracellular 
transport occurs via the endocytic pathway in the form of small membrane bound vesicles 
produced through budding of the endoplasmic reticulum and/or golgi body, or with the help of 
transport proteins [359,360]. Upon reaching the plasma membrane, PLs are distributed 
asymmetrically throughout the structure with SM and PC restricted to the exoplasmic face 
and PS and PE restricted to the cytosolic leaflet (the leaflet of the bi-layer that interacts with 
the cytoplasm) [361]. Asymmetry is achieved through the action of membrane-bound lipid 
translocases, which transport lipids across the lipid bi-layer in both an adenosine-
triphosphate (ATP) - dependent and –independent manner. Enzymes responsible for this 
movement include the P4 subfamily of P-type ATPases such as aminophospholipid 
translocase, responsible for the restriction of PC and PS to the cytosolic leaflet and 
Scramblase, a less specific translocase that has been shown to be important in the exposure 
of PS on the exoplasmic face during apoptosis [362], see Figure 1.10. 
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Figure 1.9 Differential Membrane Composition of Organelles in the Steady State. 
Membrane phospholipid (PL) composition is shown as a percentage of total PL in mammals 
(blue bars) and yeast (light blue bars) with sterol content, expressed as a molar ratio of 
cholesterol (CHO) or ergosterol (ERG) to PL, is also shown as a measure of membrane 
sterol content. Sites of synthesis are shown (central panel) for major phospholipids (blue) 
and organelle recognition and signalling pathways (red). Most lipid synthesis occurs in the 
endoplasmic reticulum (ER) and includes synthesis of Phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), Phosphatidylinositol (PI), phosphatidylserine (PS), 
phosphatidic acid (PA), Ceramide (Cer) galactosylceramide (GalCer), cholesterol and 
ergosterol. The major exceptions are Sphingomyelin (SM) and complex glycosphingolipids 
(GSLs) which are synthesized in the golgi lumen. Some synthesis of PC also occurs within 
the golgi. Lipids populating the mitochondrial membrane are synthesized within the 
organelle. R, remaining lipids; TG, triacylglycerol; PI(3,5)P
2
, CL, cardiolipin; BMP, 
bis(monoacylglycerol)phosphate); ISL, inositol sphingolipid; Sph, sphingosine; DAG, 
diacylglycerol; phosphatidylinositol-(3,5)-bisphosphate; PI(4,5)P
2
, phosphatidylinositol-(4,5)-
bisphosphate; PI(3,4,5)P
3
, phosphatidylinositol-(3,4,5)-triphosphate; PI4P, 
phosphatidylinositol-4-phosphate; S1P, sphingosine-1-phosphate. Taken directly from [359]. 
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Figure 1.10 Membrane Asymmetry in Intracellular Compartments. 
(A) Asymmetry within the plasma membrane occurs through P4-ATPase –dependent 
transport of Phosphatidylserine (PS) and Phosphatidylethanolamine (PE) to the cytosolic 
leaflet of the plasma bilayer whilst little transport of sphingomyelin (SM) and 
phosphatidylcholine (PC) exist confining these species to the outer (or exoplasmic) leaflet (B) 
Little asymmetry occurs within the endoplasmic reticulum which non-specific transport 
occurring resulting in near symmetrical distributions across the bilayer (C) Asymmetry across 
the golgi bilayer is the result of P4-ATPase transport of phosphatidylserine (PS) and 
phosphatidylethanolamine (PE) to the cytosolic face. SM is produced on the luminal leaflet 
and remains there due to the lack of transporters within the membrane structure. Taken 
directly from [359]. 
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The composition of different phospholipid species within the plasma membrane of 
neutrophils is characteristic of neutrophils. This is due to the fatty acid structure located at 
positions sn1 and sn2 of phosphatidylcholine (PC). Characteristically, neutrophils have been 
shown to be depleted in arachidonoyl-containing PC species common in other cell types 
instead containing a greater amount of the 1-alkyl-2-acyl species with the fatty acid located at 
position sn2 to be joined to the head group via an ether- rather than an ester-bond. 
The primary role of membrane phospholipids is their barrier function, but they also have a 
role in cellular metabolism, by releasing large quantities of ATP and are important signalling 
molecules involved in many signal transduction pathways. The phosholipase-A2 (PLA2) 
family of enzymes cleave the fatty acid at the sn2 position of many membrane-bound 
phospholipids producing arachidonic acid and lysophospholipids. Arachidonic acid 
metabolism leads to the production of pro-inflammatory mediators such leukotriene B4 
(LTB4), which propagate the inflammatory response and attract more cells to the site of 
infection [254]. Other phospholipids such as PS have a regulatory role in ROS production 
[363] and are also essential in the activation of other enzymes such as phospholipase-C 
(PLC) [363] which is required for the release of calcium ions from the endoplasmic reticulum, 
an important second messenger in propagating the signalling cascade. 
 
1.5.2 Glycolipids 
Glycolipids, such as sphingomyelin, are a class of membrane lipids derived from sphingosine 
that consist of a sphingosine backbone linked to a single saturated fatty acid chain and 1 or 
more carbohydrate units such as glucose or galactose. It is the presence of the sugar units 
within the molecule that gives glycolipids their characteristic structure and their asymmetrical 
distribution across the membrane favouring the luminal leaflet. Orientated in this manner, the 
carbohydrate moiety functions as a recognition molecule and provides membrane stability. 
Within the membrane, glycolipids pack together much tighter than phospholipids due to the 
presence of a fully saturated fatty acid chain which are therefore devoid of the ‘kinks’ 
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commonly seen in the fatty acid chains of phospholipids, caused by the presence of C=C 
double bonds. This reduces the mobility of the membrane in glycolipid rich areas and is 
thought to further concentrate signalling molecules. These areas are known as lipid rafts and 
will be discussed in subsequent sections.  
 
1.5.3 Membrane Cholesterol 
Cholesterol is the major sterol species found in vertebrate membranes. Although cholesterol 
falls within the lipid class of molecules, it has a very unique structure consisting of a fatty acid 
chain and a hydroxyl group separated by 4-linked hydrocarbon rings providing the bulk to the 
structure (see Figure 1.8). Cholesterol is an important precursor to a number of biologically 
important substances including bile acids, important for absorption of dietary lipids, and 
steroid hormones such as testosterone. Within the plasma membrane, cholesterol is known 
to have an important role in regulating both membrane permeability and fluidity through 
association with the acyl chains of other membrane lipids [364], particularly glycolipids. 
Cholesterol is also an integral part to other biological process such as caveolae- and clathrin-
dependent endocytosis, the process by which external material in internalized utilizing 
membrane pits coated with calveolin or clathrin respectively which then bud into the cell from 
the plasma membrane forming specialized coated vesicles within the cytoplasm [365]. 
Cholesterol biosynthesis occurs mainly in the liver however, a limited number of other 
organs, such as the brain, are capable of producing cholesterol [366]. Cholesterol 
biosynthesis begins with the conversion of 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) to Mevalonate by the enzyme HMG-CoA Reductase, the rate-limiting step in 
cholesterol biosynthesis. Mevalonate is then further metabolised in a multistep process 
resulting in the production of cholesterol and a number of prenyl groups used in the post-
translational modification of small GTPases such as Ras and Rho family members [367]. In 
addition to hepatic biosynthesis, cholesterol can also be absorbed though the intestine from 
the diet, however, increased dietary uptake will attenuate de novo cholesterol biosynthesis in 
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the liver through cholesterol-mediated inhibition of HMG-CoA Reductase. This negative 
feedback loop ensures homeostasis is maintained regulating the availability of cholesterol for 
incorporation into membranes or for further metabolism.   
Due to the amphipathic nature of the cholesterol molecule, cholesterol remains insoluble in 
the blood and must therefore be transported around the body by carrier proteins known as 
lipoproteins. Lipoproteins are classified according to the density of the protein: high-density 
lipoproteins (HDL), intermediate-density lipoproteins (IDL), low density lipoproteins (LDL) and 
very low-density lipoproteins (VLDL). These carrier proteins not only solubilise the lipid 
allowing transport but also contain cell-targeting moieties. Uptake of cholesterol occurs 
through expression of HDL and LDL receptors on the surface of target cells. 
 
1.5.4 Membrane Fluidity and Lipid Rafts 
Together, phospholipids, glycolipids and cholesterol are all important molecules in regulating 
membrane fluidity including the ability of proteins to move laterally within the bi-layer. Both 
the length of the fatty acid chain, their degree of saturation and cholesterol content contribute 
to membrane fluidity and subsequently the rate of lateral diffusion within the membrane. 
Long, saturated fatty acid chains with high level of interaction with cholesterol favours a more 
rigid membrane whereas short, unsaturated fatty acids with little interaction with cholesterol 
favours a more fluid state [368].  
Overall, membrane fluidity is not thought to be continuous throughout the entire membrane 
structure. Instead, there exist small (26-70nm) lipid-ordered zones within the more fluid, 
liquid dis-ordered structure. These liquid-ordered zones, often termed rafts, are detergent 
insoluble glycolipid and cholesterol rich areas of the membrane that are thought to be 
present in the cell membranes at all times [369]. Upon stimulation, rafts are thought to 
aggregate, increasing in size, becoming visible by light microscopy [304] and forming ‘large’ 
areas of the membrane within an otherwise fluid structure. Aggregated rafts establish a 
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platform from which signal transduction can occur, bringing molecules into the correct 
juxtaposition.  
Little work exists on the effects of age on neutrophil membrane composition and fluidity. 
Larbi et al  found the cholesterol content of lipid rafts present in the plasma membrane of T 
cells was significantly increased with age and that membrane fluidity was decreased as a 
consequence [370] however, Alvarez et al, remain the only study to date who consider the 
effects of age on neutrophil plasma membrane composition. These authors found an age 
related decrease in the cholesterol: phospholipid ratio in neutrophils, the result of a decrease 
in free cholesterol and in increase in phospholipid content in neutrophils from rat peritoneum. 
This also correlated with an observed increase in membrane fluidity [371]. However, this 
work was carried out in neutrophils isolated from rat peritoneum and therefore further 
research is required before absolute conclusions can be drawn with regard to human cells. 
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1.6 Effects of Age on Neutrophil Chemotaxis 
Age related changes in neutrophil migration have been reported since 1978, however there 
is still no consensus as to the influence of age on chemokinesis or chemotaxis.  A number of 
groups have reported no effect for age [150,372-374] while an equal number report reduced 
migratory function with increasing age [162,375-379], see Table 1.6. Of the studies 
describing no effect for age on neutrophil migration, the average age of older adults was 
commonly in the late 70s to 80s. Alonzo-Fernandez et al demonstrated migratory dynamics 
in healthy centenarians that were comparable to those observed in healthy younger adults 
(aged 25 - 35 years) [378]. It is however conceivable that no age-related changes in 
migration were observed in these studies due to the successful ageing of participants 
included in the study. Phair et al used an old cohort aged 65 to 85 years [372], therefore 
including a more diverse older cohort with respect to ageing. However the young cohort used 
in this study ranged from 27 – 43 years and although no data currently exists on the effects 
of age on migratory dynamics across the lifespan, changes may not be observed when 
young and middle aged groups are combined. In addition, Biasi et al  used the SENIEUR 
protocol to select their older adults [373], a protocol designed in 1984 by Ligthart et al [380] 
to standardize the health status on older adults being included in gerontological research by 
distinguishing extremely healthy older adults from those considered to be ‘almost healthy’ in 
order to eliminate any co-morbidities. However, this means that the older subjects included in 
this study were not representative of the general population and therefore results cannot be 
applied generally. 
A number of studies presented found neutrophil migratory dynamics to be significantly 
reduced with increasing age. This collection of studies includes both in vitro and in vivo 
studies and includes the effect of ageing in humans and rodents. There are a greater number 
of studies finding reduced migration with increasing age compared to those observing no 
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differences while also including studies utilising the SENIEUR protocol as well as assessing 
migration in cohorts with an average age skewed towards older participants. 
The majority of the studies observing both no change and significant reductions in migratory 
dynamics have done so using a modified Boyden chamber. This experimental set-up 
requires neutrophils placed in an upper chamber to migrate across a filter, which itself could 
affect migration, towards a chemotactic source placed in a lower chamber. Studies use filters 
of varying pore sizes (0.8μm-5μm) making conclusive arguments difficult to draw. In addition, 
the limitation of the Boyden chamber is principally that it assesses chemokinesis and not 
chemotaxis. Wenisch et al are the only group to have considered the effects of ageing on 
chemokinesis and chemotaxis as separate parameters [161]. In response to fMLP, 
chemokinesis appeared to be maintained while a trend toward reduced chemotaxis was 
observed in the elderly. However, this study utilised the under-agarose assay and can only 
provide rough estimations of cell movement and cannot comment on individual cell migratory 
behaviour. 
As migration relies upon a complex signalling network in order to regulate a process that is 
both robust and extremely sensitive, it is conceivable that signal transduction itself may be 
altered as a consequence of increasing age thus compromising migration.  Expression of 
triggering receptor expressed on myeloid cells-1 (TREM-1) and TLR2 and TLR4 remain 
unchanged with age [162]. However in the basal state TREM-1 has been shown to be 
present in the lipid rafts in the leading edge of neutrophils from elderly donors which cannot 
be further increased upon stimulation [381], implying dysregulated signal transduction as 
opposed to altered receptor expression as a mechanism for distorted migratory function in 
the elderly. This has been further explored by Lipschitz et al who demonstrate a significant 
reduction in the generation of a number of second messengers including IP3, DAG and PIP2 
and Ca2+ in neutrophils from the elderly [163]. In addition, neutrophils from elderly donors 
exhibit reduced actin polymerisation in response to fMLP stimulation [382]. To date, 
alterations in signalling pathways have not been causally related to aberrant migratory 
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phenotypes of the healthy elderly. However, neutrophils isolated from patients with COPD, a 
chronic inflammatory disease common in the elderly population in which neutrophils exhibit 
aberrant migration has been attributed to aberrant PI3Kinase signalling [383], suggesting that 
altered neutrophil migration may indeed be a feature of ageing and may be driven by 
dysregulated signal transduction. 
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 Table 1.6 Current Literature Examining the Effects of Increasing Chronological Age on Neutrophil Migration 
 
fMLP, f-Met-Leu-Phe; C5a, Complement Protein 5a; KC, keratinocyte chemoattractant; ZAP, zymosan activated plasma, GM-CSF, 
granulocyte/macrophage-colony stimulating factor; LPS, lipopolysaccharide, PMN, polymorphonuclear neutrophils; mo, months old 
 
* Utilized SENIEUR Protocol 
 
Details of each study are presented as completely as possible based on information available in each publication 
 Author (Year) Method Chemotactic Factor Primed Young 
n (mean; range) 
Old 
n (mean; range) 
Unchanged Phair et al (1978) Modified Boyden Chamber Insulin Generated 
Chemotactic Factor 
No 20 (27 – 43) 70 (65-88) 
 Biasi et al (1996) Method not Reported fMLP; Zymosan No * 25 (27.7 ± 2.59; 
22 - 34) 
* 25 (76.56 ± 
7.36; 69 – 100) 
 MacGregor et al (1990) Modified Boyden Chamber with 
51Cr labelling of neutrophils; 5µm 
filters 
Homologous C5a No 10 (25.5) 10 (78.9) 
 Wenisch et al (2000) Under Agarose fMLP No 11 (27 ± 5; 21 - 
36) 
11 (71 ± 7.5; 62 – 
83) 
Reduced Niwa et al (1989) Under Agarose 
Boyden; filter size not reported 
10-7M fMLP; 10-7M 
PAF; ZAP 
No 
 
30 (19 – 48)  
 Whyte et al (1993) Boyden; 5µm and 0.8µm filter fMLP; 10% ZAP No Isolated PMN aged 24 hours in culture 
 Izgüt-Uysal et al (2003) 
(Rat Model) 
Boyden 3µm filter ZAP No 20 Rats aged between 2 and 24 
months 
 Fulop et al (2004) Boyden; filter size not reported GM-CSF; LPS; fMLP Yes (90min GM-
CSF) 
Cohort details not reported 
 Alonso-Fernández et al 
(2008) 
Boyden; filter size not reported 10-8M fMLP No * 30 (28; 25 – 35) * 30 (69; 65 – 75) 
 Brubaker et al (2003) 
(BALB/c Mouse Model) 
In vivo recruitment to site of KC 
injection 
1100-1000pg KC In vivo 
inflammatory 
environment 
12 (3-4 mo) 12 (18-20 mo) 
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1.7 Potential Therapies 
1.7.1 Anti - TNFα therapy 
Potential interventions to improve aberrant neutrophil migration in the healthy elderly are 
severely lacking. Recent evidence has shown that Adalimumab, an anti-TNFα monoclonal 
antibody capable of neutralising TNFα currently used in the treatment of RA, is capable of 
restoring the migration of neutrophils isolated from the joints of RA patients to that 
comparable with healthy, disease-free patients [384]. Although this highlights the importance 
of TNFα in regulating neutrophil chemotaxis and points to a role for inflamm-ageing in driving 
defective neutrophil migration in older donors, TNFα is an essential cytokine involved in 
orchestrating the immune response and therefore neutralisation would likely increase the 
susceptibility of otherwise healthy older adults infectious diseases. 
 
1.7.2 Statin Therapy 
Statins are a class of drugs commonly prescribed to patients with hypercholesterolemia in 
order to lower serum cholesterol. This class of drugs includes 5 members, atorvastatin, 
fluvastatin, pravastatin, rosuvastatin and simvastatin, all of which act on the mevalonate 
pathway to competitively inhibit HMG-CoA reductase, preventing the conversion of HMG-
CoA to Mevalonate, a precursor to cholesterol [385].This attenuates cholesterol biosynthesis 
and is associated with a reduction in total serum as well as low-density lipoprotein 
cholesterol. In 2011, simvastatin was the most commonly prescribed drug in the UK with a 
total of 41.2 million prescription dispensed throughout the year [386]. In recent years, the 
pleiotropic effects of statins have received significant attention with statins being able to 
reduce the risk of developing a number is diseases including dementia [387], lung cancer 
[388] and cardiovascular disease [389]. Of relevance to this thesis, a number of retrospective 
cohort studies and meta-analysis have also demonstrated the ability of statins to confer a 
survival advantage in older adults with pneumonia reducing rates of morbidity and mortality 
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[390-396]. These benefits are most apparent during the early stages in infection, which 
coupled with the knowledge that statins do not confer a survival advantage to patients with 
influenza [397], would suggest that in this situation statins may be acting on the innate 
immune response and may be able to modulate neutrophil anti-microbial function.  
A number of studies have demonstrated the ability of statins to modulate neutrophil migration 
in both human and animal studies [398-401] by inhibiting the activity of RhoA-GTPase [398], 
post-translational modification of which occurs downstream of the mevalonate pathway [402]. 
Statins have also been shown to inhibit both MAPK activity and NF-κB-associated signalling 
leading to a reduction in the production of inflammatory mediators such as TNFα; IL-1β; IL-6 
and IL-8 [402]. Levels of CRP have also been shown to be sensitive to modulation by statins 
[393,403]. 
Based on current evidence, statins present a likely candidate for therapeutic intervention to 
modulate migration in the healthy elderly having been shown to affect multiple pathways 
involved in the regulation of migration a concept that therefore needs further exploration. 
 
  
 
 
 
 
 
 
 
CHAPTER 2 
 
 
METHODS 
  
70 
 
2.1 Participants 
Healthy volunteers were recruited from staff and students of the University of Birmingham 
and staff at Selly Oak and Queen Elizabeth Hospitals, alumni at the University of 
Birmingham, relatives of patients admitted into the Lung Investigation Unit, Queen Elizabeth 
Hospital and the Birmingham 1000 Elders Cohort, a research cohort of healthy older people 
aged over 60 years. To be considered “healthy” subjects were non-smokers, had no active 
symptoms or physical signs of acute or chronic disease (as assessed by attending 
physicians) and were medication free. Ethical approval was obtained and all volunteers gave 
informed consent prior to participation (REC 10/h1211/16) as per GCP guidelines.  
Initially, participants were limited to younger (mean age 28 years; range 20-35years) or older 
(mean age 70 years; range 65-91 years) volunteers, but studies were then expanded to 
include subjects across a broad age range (from age 20 – 91). 
 
2.2 Neutrophil Isolation 
Human neutrophils were isolated from the peripheral blood of healthy donors and separated 
on a Percoll density gradient (pH 8.5-9.5; Sigma Aldrich) as described previously [138]. 
Briefly, whole blood was collected into sterile vacutainers coated with Lithium heparin (BD 
Biosciences) and mixed gently to prevent coagulation. Whole blood was then mixed with 2% 
Dextran (Amersham Bioscience) in a 6:1 ratio to sediment erythrocytes. The leukocyte 
fraction was then removed and layered on to a discontinuous Percoll gradient consisting of 
56% Percoll overlaid onto 80% Percoll. Gradients were then centrifuged at 220 x g for 20 
minutes at room temperature and granulocytes were removed from the interface between 
56% and 80% Percoll. Isolated granulocytes were then washed in sterile phosphate buffered 
saline (PBS; Sigma Aldrich) and subsequently re-suspended at 2x106/ml in sterile RPMI-
1640 (with sodium bicarbonate and L-glutamine) (Sigma Aldrich). Sample purity was 
assessed using a commercial Giemsa statining kit (Reastain Quick-Diff Kit, Gentaur Europe) 
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and were routinely ≥ 95% neutrophils and neutrophil viability was above 98% as assessed by 
trypan blue exclusion. 
 
2.3 Migratory Dynamics 
Migratory parameters were assessed using an Insall Chamber [404] an improved chemotaxis 
chamber (Weber Scientific International Ltd, Teddington) as described previously [335]. 
Briefly, Bovine Albumin Fraction V (Sigma Aldrich) was added to a final concentration of 
1.125% v/v to freshly isolated neutrophils re-suspended at 5x106/ml. Neutrophils were then 
allowed to adhere to an albumin coated coverslip (22x22mm, Surgipath Medical Industries 
Inc. Europe) previously cleaned by acid washing (0.4M H2SO4) for 20 minutes at room 
temperature. Once neutrophils were adhered, the coverslip was inverted and placed onto an 
Insall chamber pre-filled with RPMI 1640. RPMI was then replaced with either fresh RPMI or 
a chemotactic stimulant (see chapter 3 for doses of stimulants used). Gradients were allowed 
to develop for up to 1 minute prior to assessment of migration.  
For investigation of the role of PI3Kinase signalling, neutrophils were pre-incubated in the 
presence of either the non-selective PI3Kinase inhibitor LY294002 (Selleck, USA 1nM); 
PI3Kinase p110α inhibitor (PIK-75, [ChemieTek; CT-PIK75] 7.8nM), PI3Kinase p110β 
inhibitor (TGX-221 [Selleck Chemicals; S1169] 10nM); PI3Kinase p110γ inhibitor (AS-
252424 [Selleck Chemicals; S2671] 33nM); PI3Kinase p110δ inhibitor (CAL-101 [Selleck 
Chemicals; S2226] 65nM). For investigation into the effects of statins on cell migration, cells 
were pre-treated Simvastatin (Sigma Aldrich; 1nM). All compounds were pre-incubated with 
neutrophils for 40 minutes prior to loading onto the Insall chamber. All incubation times 
included 20 minutes in which cells are allowed to adhere to an albumin-coated coverslip. 
Incubation times selected were based on pilot data collected by Dr. Elizabeth Sapey, prior to 
initiation of this project. 
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2.3.1 Chemo-attractant dose responses 
To determine the optimum strength of chemotactic signal which would induce the most 
efficient migration over the 12-minute period, dose response experiments were conducted in 
the presence of RPMI-1640 alone (negative control) followed by increasing doses of each 
chemo-attractant (see Table 2.1) 
Initial migration studies: stimulants selected for use in studies of migration and ageing were 
100nM Interleukin 8 (IL8 [rhCXCL8/IL8] R&D Systems); 100nM Growth Related Oncogene α 
(GROα [rhCXCL1/GROα] R&D Systems); 10nM N-Formyl-Methionyl-Leucyl-Phenylalanine 
(fMLP, Sigma Aldrich); 10nM Leukotriene B4 (LTB4, Sigma Aldrich) and 1nM complement 
protein 5a (C5a, Sigma Aldrich). 
 
2.3.2 Treatment with PI3Kinase Inhibitors 
Concentrations of LY294002, a broad-spectrum PI3Kinase inhibitor, and all isoform specific 
PI3Kinase inhibitors (PIK75, TGX-221, AS252424 and CAL-101) used during migration 
studies corresponded to IC50 values (see Table 2.2). 
 
2.3.3 Assessing migratory dynamics 
Migratory dynamics were assessed using real-time video microscopy using a Zeiss Axiovert 
200 microscope with HAL100 camera or a Leica DMI6000B with DFC360FX camera, 
capturing 36 frames over a 12 minute period with a 20 second delay between frames. 
Previous work has shown this duration of film provides similar migratory pathway data in 
comparison to longer filming times (30 minutes). A 20 second delay was optimal for studying 
migration between frames (personal communication, Dr. Elizabeth Sapey). Analysis was 
performed using vector analysis and ImageJ software (Wayne Rasband, NIH, Bethesda) on 
10 randomly assigned cells per experiment. Cells were randomly selected by dividing image 
fields into equal segments and one cell tracked from each segment. 
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Neutrophil migration was assessed measuring 4 different parameters. Firstly, the average 
speed of movement (or chemokinesis) was measured from the distance travelled between 
frames in any given direction over time and subsequently expressed as µm/minute. All 
lengths and distances were initially recorded in units of pixels and converted to μm with 
reference to the resolution of the digital image itself, and the image magnification using a 
stage graticule (Electron Microscopy Sciences, Hatfield, USA). 
 
Secondly, directional migration or chemotaxis, was measured as the average speed of 
migration in a consistent direction relative to the orientation of the chemotactic gradient, also 
expressed as µm/minute. Due to the orientation of the stage, the stable chemoattractant 
gradient was always formed in the y direction [404], therefore, only distance travelled in the y 
direction over time was included in calculations of chemotaxis. 
 
Thirdly persistence, for each frame  the orientation of the cell (as a line from tip to tail) was 
compared to the previous orientation and calculated by the cosine of the angle between 
cellular orientations in consecutive frames, expressed  with reference to the y direction and 
expressed as a score between 0 to 1. Cells that tend to move in a straight line, or cells that 
execute slow changes in direction have a high persistence value (~1); whereas cells that 
move randomly and rapidly change direction do not (~0).  
Finally chemotactic index - the accuracy of directional orientation of each cell relative to the 
chemotactic gradient throughout the duration of the film, calculated using the cosine of the 
angle between the cells direction and the orientation of the chemo-attractant gradient at each 
time from forming a vector analysis of movement. This parameter is expressed in a 
comparative scale ranging from -1 to 1 where 1 represents movement directly towards the 
chemo-attractant in all frames and -1 represents movement directly away from the chemo-
attractant source in all frames.  
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Table 2.1 Chemoattractant Dose Responses 
Doses used to determine the concentration of each 
chemoattractant capable of inducing the most efficient migration 
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Table 2.2 PI3Kinase Inhibitor Concentrations 
PI3Kinase Inhibitor concentrations used in 
migration studies 
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2.3.4 PI3Kinase Isoform selective Inhibitor cytotoxicity 
The PI3Kδ inhibitor used in this study is currently in clinical trials to be used as a 
pharmacological intervention in patients with B cell malignancies due to its ability to induce 
apoptosis in these cells [405]. We therefore assessed neutrophil viability following incubation 
with all isoform selective inhibitors used in this study to determine the effects on neutrophil 
lifespan. Following isolation, neutrophils were incubated with isoform selective inhibitors for 
40 minutes at room temperature and were then pelleted (250 x g, 4°, 5 minutes) and re-
suspended in 1x binding buffer (0.1M HEPES [pH7.4], 1.4M NaCl, 25nM CaCl2) before 
incubation with mouse anti-human Annexin-v (1:50 dilution, BD Biosciences), a marker of 
early apoptosis, for 10 minutes on ice. Sytox Blue (1:8000, Invitrogen, UK), a nuclear stain 
that is excluded from healthy cells, was then added to the cell suspension and cell viability 
measured by Flow Cytometry (CyAN, Beckman Coulter) counting 10,000 events to reduce 
sample variability. Cell viability was determined by the percentage of cells that remained both 
AnnexinV and Sytox Blue negative following 40-minute incubation with PI3K isoform 
selective inhibitors. 
 
2.4 ELISA for neutrophil elastase activity 
Neutrophil elastase (NE) activity was determined by quantifying the amounts of the elastase-
specific fibrinogen breakdown product, AαVal360, in the plasma from both young and old 
volunteers. AαVal360 quantification was determined by competition ELISA as described 
previously [406]. Briefly, rabbit anti-sera raised against the free carboxyl group of AαVal360 
was mixed with plasma samples at a 1:2500 dilution and incubated overnight at 4°C. This 
was then added into a 96-well tissue culture plate pre-coated with neutrophil elastase 
cleaved fibrinogen.  Any free AαVal360 antibody remaining in the antisera binds the degraded 
fibrinogen and is detected and quantified using a europium-conjugated anti-rabbit IgG 
secondary antibody. Individual samples were assessed in triplicate with the average result 
quoted per person to reduce intra-sample variability. 
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2.5 Neutrophil Phagocytosis (pHrodo) 
Neutrophil phagocytosis was measured using a commercially available assay and as per 
manufacturer’s instructions. Briefly, neutrophils were isolated as described in section 2.2 
and re-suspended at 1x106/ml in RPMI-1640 medium. 100ul aliquots were then incubated 
with either Staphylococcus aureus (S.aureus) or Escherichia coli (E.coli) bioparticles 
conjugated to the fluorescent dye pHrodo (Invitrogen Life Technologies, California, USA), 
which fluoresces at low pH i.e. once the particles, have been internalised into the 
phagosome. Un-opsonised particles were added at a final concentration of 0.33mg/ml for 
either 60, 45 or 30 minutes at 37°C. An equal volume of neutrophils were also stimulated 
with S.aureus or E.coli bioparticles and kept on ice for 60 minutes as a negative control. 
Following stimulation samples were washed (250 x g, 4°C, 5 minutes) in 2% cold PBS/BSA, 
transferred to cytometric tubes for analysis and quantified by flow cytometry (CyANADP, 
Beckman Coulter). Data were expressed as a phagocytic index, as described previously 
[138]: Phagocytic Index = % of phagocytosing neutrophils X mean fluorescence intensity 
(MFI). Un-opsonised particles were specifically chosen to more closely replicate the 
pulmonary environment in which non-opsonized phagocytosis predominates as the airways 
are not a particularly serum-rich environment [407]. 
 
2.6 Reactive Oxygen Species Production 
Neutrophil reactive oxygen species (ROS) production was measured in quiescent or 
stimulated neutrophils and quantified using a luminol-based assay which detects both 
extracellular and intracellular free radicals [408]. Freshly isolated neutrophils were re-
suspended at 1x106/ml in Hanks Balanced Salt Solution (HBSS: Gibco Invitrogen; 12.61mM 
CaCl2, 4.93mM MgCl2, 4.07mM MgSO4 and Phenol Red Free). 1x105 neutrophils were then 
plated out into 96-well white plates containing 25ul luminol (working concentration 100uM) 
and 75ul 1x HBSS. Neutrophil were then stimulated with 2.5μM fMLP or 1.25μM IL8 using 
25nM PMA a positive control. ROS production was measured at 1 minute intervals for 60 
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minutes using a Berthold luminometer and ROS generation calculated as area under the 
curve.  
 
2.7 Flow Cytometry 
2.7.1 Antibody Titration 
All antibodies used for flow cytometry were titrated to determine a minimum concentration 
that would saturate expression of all target molecules. Table 2.3 shows concentrations used 
for each titration, the maximum concentration used for each antibody titration was that 
suggested in the manufacturer’s instructions. Freshly isolated neutrophils or those in whole 
blood were stained for target molecules as described in subsequent sections (2.7.2 and 
2.7.3). CD63 has been described as an activatory receptor on neutrophils [409], therefore 
expression was measured in whole blood to avoid artificially high expression levels due to 
cellular activation during the isolation process. 
 
2.7.2 Neutrophil Degranulation 
Surface and internal expression of primary granule marker CD63 was measured on 
neutrophils stained in whole blood following red cell lysis. 100μl whole blood collected in 
Lithium heparin vacutainers (BD Biosciences) was washed twice (250 x g, 4°C, 5 minutes) in 
1%PBS/BSA to remove autologous plasma and re-suspended in 1% PBS/BSA. Samples 
were then incubated with relevant antibodies for 20 minutes in the dark on ice to allow 
relevant antibody binding. Post-incubation, samples were washed twice (250 x g, 4°C, 5 
minutes) in cold 1% PBS/BSA and then red cells were lysed using FACS lysing solution (BD 
Biosciences) for 10 minutes at room temperature. Samples were then washed twice (250 x g, 
4°C, 5 minutes) in cold 1% PBS/BSA and subsequently fixed and permeabilised using a 
commercially available kit according to the manufacturers instructions (Fix and Perm, 
Invitrogen-Life Technologies). During permeabilisation, relevant antibodies were added 
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simultaneously to facilitate the detection of internal epitopes and incubated for 30minutes in 
the dark on ice. Samples were then washed twice in cold 1%PBS/BSA and transferred to 
cytometric tubes for analysis. Neutrophil degranulation was assessed by flow cytometry 
(Accuri C6, BD Accuri). 
Antibodies were sourced as follows: mouse anti-human CD63-PE 1:20 dilution (Invitrogen – 
Life Technologies, clone #: CLB-gran/12 (CLB-180). Isotype control antibodies were sourced 
as follows: IgG1-PE (BioLegend, clone #: MOPC-21). 
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Table 2.3 Antibody Titrations 
Dilution of all antibodies used to determine a minimum 
concentration that would saturate expression of all target 
molecules 
Antibody Titration
Selected 
Dilution
CXCR1 1:100; 1:50; 1:25; 1:17 1:25
CXCR2 1:100; 1:50; 1:25; 1:17; 1:10 1:17
FPR1 1:50; 1:25; 1:12.5; 1:8.3 1:8.3
C5aR 1:50; 1:25; 1:12.5; 1:8.3 1:12.5
BLT1 1:50; 1:25; 1:12.5; 1:8.3 1:8.3
CD63 1:200; 1:100; 1:50; 1:20 1:20
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2.7.3 Chemokine Receptor Expression 
Surface expression of chemo-attractant receptors (CXCR1 [IL8 receptor], CXCR2 [IL8 and 
GROα receptor], FPR1 [fMLP receptor], C5aR [C5a Receptor] and BLT1 [LTB4 receptor]) 
were measured on freshly isolated peripheral blood neutrophils. Neutrophils and all reagents 
were maintained on ice to reduce receptor down-regulation and/or shedding. 2x105 
neutrophils were re-suspended in 1% PBS/BSA (Sigma Aldrich) and incubated with relevant 
FITC-labelled antibodies for 20 minutes in the dark, on ice. Post incubation, samples were 
washed (250 x g, 4°C, 5 minutes) in 1% cold PBS/BSA and transferred to cytometric tubes 
for analysis. Receptor expression was determined by flow cytometry (CyANADP, Beckman 
Coulter) counting 10,000 events to reduce sample variability. 
All antibodies were sourced from R&D systems as follows: Mouse anti-human CXCR1 
2µg/ml (clone #: 42075); mouse anti-human CXCR2 3µg/ml (clone #: 48311); mouse anti-
human FPR1 3µg/ml (clone #: 350418); mouse anti-human BLT1 3µg/ml (clone #: 
203/14F11); mouse anti-human C5aR1 2µg/ml (clone #: 347214). Isotype control antibodies 
were sourced from Dako as follows: mouse anti-human IgG2a 2µg/ml (clone #: DAK-GO5) 
and mouse anti-human IgG1 3µg/ml (clone #: DAK-GO1). 
 
2.8 Mass Spectrometry 
2.8.1 Sample Preparation 
1ml aliquots of freshly isolated neutrophils were re-suspended at 5x106/ml in RPMI-1640. 
Neutrophils from old donors were also pre-incubated ± 1nM Simvastatin for 40 minutes at 
room temperature. All samples were then centrifuged (6000rpm, 5 minutes [MSE, Micro 
Centaur]) and supernatants aspirated leaving a dry pellet. Pellets were then snap frozen in 
liquid nitrogen and stored at -80°C until use. 
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2.8.2 Lipid Extraction  
Membrane lipids were extracted from whole cell lysates with acidified chloroform and 
methanol as described previously [410]. Dimyristoyl – phosphatidycholine (DMPC, 2nmoles), 
Low-substituted Hydroxypropyl Cellulose (LHPC, 0.2nmoles), Dimyristoyl-phosphatidic acid 
(DMPA, 0.24nmoles), Dimyristoyl-phosphatidylethanolamine (DMPE, 0.8nmoles), 
Dimyristoyl-phosphatidylglycerol (DMPG, 0.4nmoles) and Dimyristoyl-phosphatidylserine 
(DMPS, 0.4nmoles) were added as internal standards with values in brackets denoting 
amounts of each standard added. Briefly, cell pellets were re-suspended in 0.8ml Dulbecco’s 
PBS (Ca2+ and Mg2+ free; Gibco) and briefly sonicated to ensure adequate dispersion of the 
pellet before addition of internal standards in the presence of butylated hydroxytoluene (BHT, 
1g/50ml). Lipids were then extracted from cell lysates with the sequential addition of 
chloroform, methanol, chloroform (1:2:1) and allowed to separate overnight at -20ºC. The 
lipid containing, chloroform-rich fraction was removed and dried under oxygen free nitrogen 
at 37°C to remove chloroform and the dry samples were stored at -20°C until use. 
 
2.8.3 Membrane Lipid Quantification 
Membrane lipid content was determined by electrospray ionisation mass spectrometry (ESI-
MS). Samples were reconstituted in 30ul of a solution containing 20% Butanol, 60% 
Methanol, 16% water and 4% concentrated aqueous ammonia (NH3(aq)) and introduced by 
direct diffusion into a triple quadropole mass spectrometer (Quattro Ultima, Micromass, 
Manchester, UK) equipped with a nanoflow electrospray ionisation interface. Phospholipid 
species were selectively detected and quantified from a variety of precursor (P) and neutral 
loss (NL) scans. Phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were 
analysed in positive ionisation from tandem MS/MS precursor scans of the 
phosphatidylcholine fragment (P184) or neutral loss of the phosphoethanolamine fragment 
(NL141+) respectively. Phosphatidylinositol (PI) and phosphatidylserine (PS) were quantified 
directly from the negative ionisation spectrum. Data were processed using Mass Lynx 
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software (Waters) and analysed using a macro developed at the University of Southampton, 
as employed in previous studies [411]. The macro enabled spectra to be smoothed, 
background subtracted and converted into centroid format and exported into individual Excel 
sample files, which were subsequently imported into the analyser programme. Correction for 
the 13C isotope was performed prior to calculation of percentage composition and 
incorporation of labelled phospholipid head groups. Only species of PC, PE, PI and PS that 
made up >2% of the total molar percentage of the respective phospholipid class are reported 
for compositional analysis. 
As free cholesterol does not ionise well using ESI-MS, it was first derivatised to cholesterol 
acetate by the action of acetyl chloride as described previously [412] using D6 cholesterol as 
an internal standard, Cholesterol species were quantified from neutral loss scans of the 
acetate fragment (NL77). 
 
2.9 SDS-Page and Western blot 
1x106 aliquots of isolated neutrophils were centrifuged at 1500xg for 2-minutes at 4°C, re-
suspended in lysis buffer (20mM 3-[N-Morpholino] propanesulfonic acid (MOPS), 50mM 
NaF, 50nM β-glycerophosphate, 10mM Na3VO4, 1% Triton X-100 [Sigma-Aldrich, UK], 1mM 
4-(2-Aminoethyl) benzensulfonyl fluoride hydrochloride (AEBSF, Sigma Aldrich), 1mM 
Dithiothreitol (DTT, Sigma Aldrich) and protease inhibitor cocktail [Sigma Aldrich]) and 
incubated on ice for 15 minutes, vortexing at 5-minute intervals. Lysates were then mixed 1:1 
with 2x SDS-sample buffer (4% Sodium Dodecyl Sulfate (SDS), 0.1M Dithiothreitol, 20% 
Glycerol, 0.0625M Tris-HCl [pH 6.8], 0.004% bromophenol blue) and boiled for 10 minutes at 
100°C. Cell lysates were then stored at -20°C until use. Prior to running the gel, defrosted 
samples were centrifuged at 3000rpm (MSE, Micro Centaur) for 2 minutes at room 
temperature.  
Cell lysates were loaded onto a 5% stacking gel and 12% resolving gel and separated by 
SDS-polyacrylamide gel electrophoresis. Lysates and pre-stained molecular weight markers 
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(GeneFlow Ltd) were run at 140 volts and subsequently transferred onto a 0.45 micron 
polyvinylidene difluoride (PVDF) membrane (Geneflow Ltd) at 450mA for 90 minutes using a 
wet blotting system (BioRad). Membranes were incubated with 5% bovine serum albumin 
made up in TBS-Tween (0.1% Tween-20 in 1xTBS [20mM Tris; 150mM NaCl]) for 1 hour at 
room temperature to prevent non-specific binding of primary antibody. Membranes were then 
probed with either 1/1000 dilution of rabbit anti-human phospho-PI3K p85 (Tyr485)/p55 
(Tyr199) (Cell Signalling Technology) or phospho-Akt (Ser473) XP (Cell Signalling 
Technology) both diluted in 5% BSA in 1xTBS-Tween overnight at 4°C with gentle agitation. 
Blots were subsequently washed 3 times in TBS-Tween for 15 minutes before incubation 
with anti-rabbit IgG secondary antibody conjugated to horse-radish peroxidase (HRP) (Dako 
Cytomation). Following incubation, blots were washed three times in 1xTBS-Tween as before 
and proteins were visualised using enhanced chemiluminescence (EZ-ECL; Geneflow Ltd) 
and autoradiography against X-ray film (Amersham Pharmacia). Equal protein loading was 
assessed by probing blots for β-actin using a mouse anti-human β-actin (Sigma Aldrich) 
primary antibody followed by anti-mouse HRP secondary antibody (Cell Signalling 
Technology) or rabbit anti-human Akt (pan) (Cell Signalling Technology) followed by anti-
rabbit HRP secondary antibody (DakoCytomation) using the same protocol. 
 
2.10 Retrospective study of hospital outcomes following admission with a 
diagnosis of community acquired pneumonia to assess whether statins impact 
upon outcomes.  
This study was a retrospective analysis of data for patients admitted to the Queen Elizabeth 
Hospital Birmingham NHS Foundation Trust, UK with a clinical and radiological diagnosis of 
community acquired pneumonia occurring between November 2009 and October 2011. 
Patients were included if they had an acute admission with a diagnosis of pneumonia in 
accordance with British Thoracic Society guidelines, namely symptoms and signs consistent 
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with an acute lower respiratory tract infection associated with new radiographic shadowing 
for which there is no other explanation, where the illness is the primary reason for hospital 
admission and is managed as pneumonia (see Figure 2.1 for selection procedure). Patients 
with other acute respiratory presentations diagnosed from medical assessment or chest 
radiography were excluded from the study. See Table 2.4 for diagnoses included and 
excluded from this study.  
Patients were classified as being on statin therapy prior to admission if they were prescribed 
a statin within 24 hours of hospital admission. 
 
2.10.1 Covariates 
Using electronic medical records, a range of clinical parameters were also collated to 
determine potential confounding effects on pneumonia outcomes. In addition to diagnosis, 
statin therapy and patient outcome, data collected included age, gender, diabetic status, 
hospital length of stay, admittance onto the intensive care unit (ICU) and ICU length of stay 
(LoS). Levels of C-reactive protein (CRP) and numbers of circulating white blood cells (WBC) 
were also recorded to monitor the inflammatory state. Biochemical data collected included, 
Haemoglobin (Hb), clotting potential (expressed as International Normalized Ratio, INR). 
Sodium (Na), Potassium (K), Urea (Ur) and Creatinine (Cr) blood levels.  
 
2.10.2 Pneumonia Outcomes and statistical analysis 
The primary outcome for this study was defined as all-cause mortality during hospital stay. 
Patients who recovered and were subsequently discharged from hospital left the study 
without the occurrence of the primary outcome and therefore constitute censored data. 
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Figure 2.1 Selection Procedure for Retrospective Cohort Study. 
Admission into the Queen Elizabeth Hospital, Birmingham UK between October 2009 and 
November 2011 were screened according to diagnosis to identify patients admitted with 
Pneumonia of unspecified of bacterial origin in their starting episode (stages 1-3). Qualifying 
patients were then split into users and non-users according to statin prescription prior to 
admission (stage 4) 
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Table 2.4 Inclusion and Exclusion Diagnoses for Retrospective Cohort Study 
Inclusion Exclusion
Pneumonia, unspecified Pneumothorax
Bacterial Pneumonia, unspecified Other spontaneous pneumothorax
Other Pneumonia, organism unspecified Traumatic Pneumothorax
Lobar Pneumonia, unspecified Traumatic Haemopneumothorax
Hypostatic Pneumonia, unspecified Pneumocystosis
Bronchopneumonia, Unspecified Pneumococcal meningitis
Pneumonitis Influenza with Pneumonia
Pneumonitis due to food and vomit Viral Pneumonia
Abscess of lung with Pneumonia Cytomegalovirus Pneumonitis
Pneumonia due to Haemophilus influenzae Septicemia due to Streptococcus pneumoniae
Pneumonia due to Escherichia coli HIV disease resulting in Pneumocystis carinii pneumonia
Pneumonia due to Klebsiella pneumoniae Abscess of lung without Pneumonia
Pneumonia due to Mycoplasma pneumoniae Hypersensitivity pneumonitis due to unspecified organic
Pneumonia due to Streptococcus pneumoniae Pneumoconiosis due to asbestos and other mineral fibres
Pneumonia due to other Streptococcus sp.
Pneumonia due to Staphylococcus sp.
Pneumonia due to Pseudomonas sp.
Varicella pneumonia
Inclusion and Exclusion diagnoses for to identify patients admitted into Queen Elizabeth 
Hospital with Pneumonia of unspecified or bacterial origin between November 2009 and 
October 2011. 
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The cohort used in this study was stratified into 2 groups - patients who were on statins upon 
admission into hospital and those who were not. The cohort was then summarised by 
comparing statin-users to non-users and continuous variables reported as means ± standard 
deviations when variables were normally distributed and as medians and interquartile ranges 
when variables were non-normally distributed. When considering categorical variables, data 
were reported as numbers with percentages in parenthesis. Normality was assessed using 
the Kologmorov-Smirnov test. Statin-users and non-users were compared using Mann-
Whitney-U test when variables were continuous and χ2-test for categorical variables.  
Logistic regression was used to calculate a predicted probability of death and evaluate the 
effects of statin therapy on the predicted survival after pneumonia. This was done using an 
uncorrected model taking into account age and statin therapy in the first instance. This model 
was then updated to correct for gender, patient diabetic status and plasma levels of CRP. 
Significance was accepted at p<0.05.  
 
2.12 Statistical Analysis 
Statistical analyses were carried out using PASW v18.0 (Chicago, IL, USA). Data were 
tested for normality using the Kolmogorov-Smirnov or Shapiro-Wilk when samples sizes 
were small. Differences between two independent or paired samples were assessed using 
either a paired or un-paired T-test and a one-way, factorial or mixed analysis of variance 
(ANOVA) was used to compare more than two groups when data sets were normally 
distributed. When data sets did not follow a normal distribution, non–parametric Mann-
Whitney-U tests were performed. Differences between categorical variables were assessed 
using χ2 test. Post-hoc analysis was performed using Bonferroni correction for multiple 
comparisons where appropriate. The effects of chronological age on migratory parameters 
were assessed by linear regression to determine the relationship. Data were subsequently 
categorized by decade and assessed using a two-way ANOVA controlling for both age and 
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gender to determine the pattern of the relationship. In all instances, graphs are presented as 
mean ± standard error of the mean (SEM) and statistical significant was accepted at p ≤ 0.05 
unless otherwise stated. Unless otherwise stated all p-values are from a 2-tailed test. 
  
 
 
 
 
 
CHAPTER 3 
 
NEUTROPHIL FUNCTIONS IN THE HEALTHY 
ELDERLY 
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3.1 Introduction 
Over the past 15 years, ageing research has uncovered numerous differences in immune 
cell function between young and old donors occurring as a consequence of natural ageing, 
termed immune-senescence. A significant proportion of this research has focussed on the 
adaptive arm of the immune response and the immune risk phenotype (IRP) which describes 
a set of parameters giving rise to an increased risk of mortality in the elderly population 
[44,413]. In comparison, our understanding of age-related alterations in innate immune 
function lags behind considerably. Ageing is associated with an increased susceptibility to 
bacterial infections [9,10,13,15] and reduced outcomes following infective events [20,21] 
which are suggestive of dysregulation of the innate immune compartment. Neutrophils are 
vital during the initial immune response to bacterial infection and therefore, these short-lived 
cells are ideal candidates for investigation into mechanisms driving immune decline 
associated with increasing age. 
The existing literature on neutrophil migration with age is contradictory with reports of both 
unchanged [150,372-374] and reduced migratory function [375-379] with age. To date, only 
one study has assessed migration in terms of both speed of migration (chemokinesis) and 
direction of migration (chemotaxis) as independent parameters, describing maintained 
chemokinesis and a trend towards reduced chemotaxis in neutrophils isolated from the 
elderly [161]. However, this study utilised the under agarose assay which can only provide 
rough estimations of cell movement and cannot comment on individual cell migratory 
behaviour. 
Altered neutrophil migration with age would clearly impact upon efficiency of pathogen 
removal, but could have consequences beyond this. There is evidence to support the 
hypothesis that neutrophils utilise proteinases to aid migration [228,239]. Neutrophil 
proteinases also facilitate cell adhesion and polarisation by interactions with integrins and 
cell signalling pathways [229]. Aberrant migration could be associated with increased 
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proteinase release, either as a consequence of cell activation by low grade systemic 
inflammation or could in fact contribute to increased systemic inflammation in older subjects 
as more proteinase would be released if the cells migratory pathways were not optimal [414]. 
If this were true, one would predict that neutrophils from older subjects may express more 
markers of primary granule degranulation on their surface, and systemically, there may be 
increased evidence of neutrophil proteinase activity, however, these data have not been 
collected in an older population. 
Studies have suggested that other anti-microbial functions of neutrophils are altered in 
elderly adults [160,161,174], however, assessment of these functions have been performed 
by separate researchers, and there are no data to compare key neutrophil functions 
(migration, phagocytosis and ROS) in the same cohort of individuals. If all functions were 
suboptimal, this may have a significant impact on the ability of cells to reach and clear 
bacterial infection.  
In this chapter it is hypothesised that neutrophils from elderly donors exhibit aberrant 
migration and that this would be associated with evidence of enhanced primary granule 
degranulation and neutrophil proteinase activity. Also where one neutrophil function was 
compromised with age, all others would be.  This hypothesis was tested by the following 
aims. 
1. To clarify the effects of increasing age on neutrophil migration by studying a cohort of 
healthy adults across the life-span; 
2. To compare markers of azurophil granule degranulation and neutrophil elastase activity in 
in vivo in young and old adults; 
3. To assess a broad range of neutrophil functions in a cohort of healthy young and old 
subjects. 
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3.2 Results 
 
3.2.1 Neutrophils respond to chemotactic stimuli in a dose dependent manner 
In order to determine the most appropriate concentration of chemokine at which to measure 
migration of neutrophils, migration of cells isolated from young donors was measured in 
response to increasing concentrations of Interleukin-8 (IL8); Growth Related Oncogene-α 
(GROα); Complement protein 5a (C5a); Leukotriene B4 (LTB4) and the bacterial peptide N-
Formyl-Methionyl-Leucyl-Phenylalanine (fMLP). All concentrations were within the range 
noted in previous studies of biological secretions in man [415]. See Table 3.1 for selected 
doses used in all subsequent migratory assays. Most chemokines tested showed a classic 
bell shaped response curve and the final concentrations for all subsequent studies were 
chosen based on the greatest chemotactic response (see Figure 3.1). 
 
3.2.2 Neutrophils from older adults show decreased migratory accuracy 
In order to assess the effects of increasing age on neutrophil migration, time-lapse video 
microscopy was used to track migration towards IL8, GROα, C5a, LTB4 and fMLP at 
concentrations as described in Table 3.1. Neutrophils were isolated from healthy elderly (age 
> 65) and young donors (age < 35). Initial analysis of migratory tracks suggested a loss of 
migratory accuracy in the elderly in response to all chemoattractants tested. Figure 3.2 A 
and B show representative images of cell tracks of neutrophils from a young and old subject 
towards IL8. Figure 3.2 C and D show composite data for 5 healthy old and young subjects 
and demonstrate clear differences in migration patterns towards the chemoattractant source 
(top of figure). Cell tracks towards GROα, C5a, LTB4 and fMLP showed similar 
characteristics (data not shown).  
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Neutrophil migratory parameters were measured in response to 0.5 – 500nM 
IL8, GROα, C5a, LTB
4
 or fMLP. The optimum dose of each chemoattractant was 
selected based on the ability to efficiently stimulate neutrophil migration in 
comparison to all other doses and used in all subsequent migratory assays.  
Chemoattractant
Dose Response 
(nM)
Optimum 
Dose (nM)
Interleukin-8 (IL8) 1; 10; 100; 250; 500 100
Growth Related Oncocgene-α (GROα) 1; 10; 100; 500 100
Complement Protein 5a (C5a) 0.5; 1; 10; 100; 250 1
Leukotriene B4 (LTB4) 0.5; 1; 10; 100; 250 10
f-Met-Leu-Phe (fMLP) 0.5; 1; 10; 100; 250 10
Table 3.1 Chemoattractant Dose Response 
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A 
C D 
E 
B 
Figure 3.1 Neutrophil Chemotactic Index in Response to Increasing 
Concentrations of IL8 GROα C5a LTB
4
 and fMLP. Neutrophil Chemotactic 
Index was measured in response to 0.5 – 500nM (A) IL8 (B) GROα (C) C5a (D) 
LTB
4
 and (E) fMLP. All data sets were normally distributed (Kolmogorov-Smirnov 
test) and statistical significance measured by repeated measures ANOVA. 
 * p<0.05 0.5nM vs. 250nM. Data are mean ± SEM (n=3). 
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Figure 3.2 Migratory Tracks of Neutrophils isolated from Young and 
Elderly donors. Images show migratory tracks on a per cell basis following 
exposure to a chemotactic gradient of 100nM IL8 (greatest at the top of the 
image). Migratory trajectories of neutrophils from (A) young and (B) old donors 
were tracked using Image J. Each track begins at the starting position of each 
respective cell and ends at the final position of the cell following 12 minutes 
recording. Neutrophil migration was further studied by arranging 5 migratory 
tracks from (C) young and (D) old donors to show their origins at x = y = 0. 
The y axis of the tracks represents the direction of the chemotactic gradient 
and the x axis denotes deviation from a straight line. All images are 
representative plots of multiple experiments.  
A B 
C D 
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3.2.3 Chemokinesis is preserved but Chemotaxis is impaired in neutrophils from older 
adults 
Neutrophil migration was then analysed using parameters of chemokinesis (non-directional 
speed of movement), chemotaxis (directional migration towards the chemoattractant source), 
directional persistence and chemotactic index. Neutrophils isolated from young and elderly 
donors demonstrated no difference in their chemokinesis (see Figure 3.3): Young vs. Old, 
mean ± SEM; IL8: 4.05 ± 0.19 vs. 4.06 ± 0.19, p=0.983; GROα: 3.73 ± 0.3 vs. 4.02 ± 0.16, 
p=0.381; C5a: 3.77 ± 0.15 vs. 3.58 ± 0.1, p=0.286; LTB4: 3.93 ± 0.26 vs. 3.6 ± 0.12, p=0.191; 
fMLP: 3.58 ± 0.2 vs. 3.96 ± 0.21, p=0.327. However, chemotaxis was significantly reduced in 
the elderly when migrating in response to all chemoattractants studied: Young vs. old, mean 
± SEM; IL8:1.41 ± 0.22 vs. 0.57 ± 0.20 p= 0.014; GROα: 0.78 ±0.19 vs. 0.09 ± 0.18 p=0.02; 
C5a: 1.24 ± 0.28 vs. 0.26 ± 0.16 p=0.01; LTB4: 0.97 ± 0.21 vs. 0.10 ± 0.18 p=0.006; fMLP: 
0.84 ± 0.11 vs. 0.29 ± 0.16 p˂0.001 (see Figure 3.3). 
Neutrophils from elderly donors also showed a significant reduction in migratory persistence, 
equating to a loss of cell orientation in respect to the chemotactic gradient, in response to 
GROα, C5a and fMLP: Young vs. old, mean ± SEM; GROα: 0.44 ± 0.03 vs. 0.24 ± 0.05 
p=0.002; C5a: 0.42 ± 0.05 vs. 0.17 ± 0.06 p=0.007; fMLP: 0.49 ± 0.05 vs. 0.27 ± 0.05 
p=0.007. Directional persistence was maintained with ageing towards IL8 and LTB4: Young 
vs. Old, mean ± SEM: IL8: 0.37 ± 0.06 vs. 0.37 ± 0.04, p=0.878; LTB4: 0.39 ± 0.06 vs. 0.27 ± 
0.05, p=0.153 (see Figure 3.4).  
Chemotactic index, an overall summary of migratory accuracy taking into account all 
parameters, was significantly reduced in neutrophils isolated from elderly donors compared 
to those isolated from young donors in response to all chemoattractants studied: Young vs. 
old, mean ± SEM; IL8: 0.27 ± 0.05 vs. 0.08 ± 0.04 p=0.011; GROα: 0.22 ± 0.05 vs. 0.04 ± 
0.04 p˂0.001; C5a: 0.26 ± 0.06 vs. 0.04 ± 0.04 p=0.008; LTB4: 0.23 ± 0.05 vs. 0.01 ± 0.04 
p=0.001; fMLP: 0.18 ± 0.04 vs. 0.04 ± 0.01 p=0.004 (Figure 3.4). 
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Figure 3.3 Neutrophil Chemokinesis and Chemotaxis in Response to IL8, 
GROα, C5a, LTB
4
 and fMLP. Chemokinesis and Chemotaxis of neutrophils 
isolated from young (black bars) and old (white bars) in response to shallow 
gradients of (A) 100nM IL8; (B) 100nM GROα; (C) 1nM C5a; (D) 10nM LTB
4
 and 
(E) 10nM fMLP. All data sets were normally distributed (Kolmogorov-Smirnov 
Test) and statistical significance measured using an independent samples T-Test. 
*p<0.05 young vs. old. Data are mean ± SEM (n=10). 
A 
C D 
E 
B 
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Figure 3.4 Neutrophil Persistence and Chemotactic Index in Response to 
IL8, GROα, C5a, LTB
4
 and fMLP. Persistence (frequency of directional change) 
and Chemotactic Index (overall summary of migration) of neutrophils isolated from 
young (black bars) and old (white bars) in response to shallow gradients of (A) 
100nM IL8; (B) 100nM GROα; (C) 1nM C5a; (D) 10nM LTB
4
 and (E) 10nM fMLP. 
All data sets were normally distributed (Kolmogorov-Smirnov Test) and statistical 
significance measured using an independent samples T-Test. *p<0.05 young vs. 
old. Data are mean ± SEM (n=10). 
A B 
C D 
E 
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3.2.4 Neutrophil migratory accuracy correlates with increasing age 
The results above demonstrated reduced migratory accuracy in the healthy elderly (aged > 
65) compared to those under the age of 35 years. It is therefore not clear whether a 
reduction in migratory accuracy is a late consequence of ageing, perhaps due to impending 
pathology, or occurs gradually during adulthood and is a biomarker of the ageing process. To 
assess migration across the life-course, migratory accuracy of neutrophils isolated from 
donors aged between 20 and 89 years old was determined. Donors were grouped according 
to decade with 10 participants in each group. See Table 3.2 for subject demographics in this 
cohort. 
Neutrophils isolated from 70 healthy donors (non-smokers with no clinical evidence of 
pathology and medication free) were migrated towards IL8 (100nM). When migratory 
parameters were plotted by age (see Figures 3.5 and 3.6) there was a significant 
relationship between increasing chronological age and chemotaxis (F(1,68)= 28.32; β = -0.542; 
p<0.001) and chemotactic index (F(1,68)= 46.42; β = -0.637; p<0.001). By applying a model of 
linear regression, these data show that ageing accounts for 28.4% (R2=0.284) of the 
observed reduction in neutrophil chemotaxis and 39.7% (R2=0.397) of the reduction in 
chemotactic index. There was no significant relationship between age and either 
chemokinesis or persistence, which was preserved across decennials.  
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  Table 3.2 Cohort Demographics 
Age (years) Gender (male)
mean ± SEM n (%)
Total 70 55 ± 2.4 35 (50)
By Decade
20-29 10 26.7 ± 0.4 5 (50)
30-39 10 34.0 ± 0.6 5 (50)
40-49 10 44.4 ± 0.8 5 (50)
50-59 10 55.0 ± 0.9 5 (50)
60-69 10 66.4 ± 0.5 5 (50)
70-79 10 75.9 ± 0.9 5 (50)
80-89 10 81.8 ± 0.6 5 (50)
n
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Figure 3.5 Relationship between Age and Neutrophil Chemokinesis and 
Chemotaxis. (A) Chemokinesis and (B) Chemotaxis of neutrophils isolated 
from donors aged between 20 and 89 years in response to shallow gradients of 
100nM IL8. All data sets were normally distributed (Kolmogorov-Smirnov test) 
and statistical significance measured by linear regression with significance 
accepted at * p<0.05.  
A 
B 
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Figure 3.6 Relationship between Age and Neutrophil Persistence and 
Chemotactic Index. (A) Persistence and (B) Chemotactic Index of neutrophils 
isolated from donors aged between 20 and 89 years in response to shallow 
gradients of 100nM IL8. All data sets are normally distributed (Kolmogorov-
Smirnov test) and statistical significance measured by linear regression with 
significance accepted at * p<0.05.  
A 
B 
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3.2.5 Loss of migratory accuracy from 60 years of age 
These data are a cross sectional sample of neutrophil function at one time point in each 
individual, and cannot be used to extrapolate what happens to an individuals neutrophil 
functions over time. However, they demonstrate a clear reduction in neutrophil migration with 
advancing age in a significant number of people. When migratory parameters were grouped 
according to decennial, there was a significant decline in chemotaxis and chemotactic index 
from the sixth decennial: Chemotaxis mean ± SEM; comparing 20-29 years to 60-60 years: 
1.78 ± 0.19 vs. 0.53 ± 0.22 p=0.006; comparing 20-29 years to 70-79 years: 1.78 ± 0.19 vs. 
0.41 ± 0.12 p=0.002; Chemotactic Index mean ± SEM; comparing 20-29 years to 60-69 
years: 0.36 ± 0.04 vs. 0.09 ± 0.04 p=0.001; comparing 20-29 years to 70-79 years: 0.36 ± 
0.04 vs. 0.05 ± 0.02 p˂0.001; comparing 20-29 years to 80-89 years: 0.36 ± 0.04 vs. 0.13 ± 
0.05 p=0.002 (see Figure 3.7). 
 
3.2.6 Neutrophils from older adults exhibit increased expression of granule specific 
markers 
To assess the extent to which neutrophils from older adults had mobilised their primary 
(Azurophil) granules, surface expression of CD63 (Granulophysin), a marker of Azurophil 
granule fusion with the plasma membrane was measured [147,416]. CD63 is also considered 
to be a marker of neutrophil activation [147] therefore, to minimise the extent to which 
neutrophils were artificially activated, expression of CD63 was measured in whole blood as 
described in chapter 2, section 2.7.2. Neutrophils from healthy older adults expressed 
significantly more CD63 on their surface compared to neutrophils isolated from young adults 
(mean ± SEM; 3218.56 ± 562.41 vs. 4364.61 ± 258.41 p= 0.044). There was no difference in 
the level of CD63 stored internally (see Figure 3.8).  
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Figure 3.7 Neutrophil Migration across the Lifespan. (A) Chemotaxis and 
(B) Chemotactic Index of neutrophils isolated from donors aged between 20 and 
89 years in response to shallow gradients of 100nM IL8. All data sets are 
normally distributed (Kolmogorov-Smirnov Test) and statistical significance 
measured by two-way ANOVA controlling for age and gender. There was no 
effect for gender on migratory parameters. *p<0.05 vs. 20yrs; # p<0.05 vs. 
30yrs; ɸ p<0.05 vs. 40yrs. Data are mean ± SEM (n=10). 
A 
B 
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Figure 3.8 Neutrophil Degranulation in cells from the Healthy Elderly. 
(A) Surface and (B) Internal expression (mean fluorescence intensity, MFI) of the primary 
granule marker CD63 on neutrophils isolated from young (filled circles) and old (open circles) 
donors. All data sets follow normal distribution (Kolmogorov-Smirnov test) and statistical 
significance assessed by independent samples T-test.    * p<0.05 young vs. old. Bar denotes 
the mean for each group. 
  
B A 
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3.2.7 Increased Neutrophil Elastase activity with age 
Neutrophil elastase cleaves fibrinogen leaving a stable by-product, termed Aα Val360, which 
can be measured in plasma.  Plasma levels of AαVal360 were measured as a footprint of 
neutrophil elastase activity in 10 healthy young and old donors. There was a significant 
increase in the concentration of AαVal360 in the plasma of old adults when compared with 
plasma from young adults (Young vs. old, mean ± SEM; 10.18 ± 0.87 vs. 25.92 ± 3.45 
p=0.002) indicating increased neutrophil elastase release and activity in the healthy elderly 
(see Figure 3.9). 
 
3.2.8 Neutrophil Phagocytosis of S.aureus but not E.coli is affected by increasing age 
Data generated so far suggest that neutrophil migration is sub-optimal in older subjects. To 
assess whether all functions were equally compromised, migration, phagocytosis and ROS 
production were assessed in a cohort of healthy old people (aged > 65) where neutrophil 
migratory function was known to be reduced (n= 8) and a cohort of healthy young adults (age 
< 35) where migratory function was known to be preserved (n=8). The phagocytic capacity of 
neutrophils isolated from both young and old donors was measured in response to 
Staphylococcus aureus (S.aureus) or Escherichia coli (E.coli). Neutrophils were co-incubated 
for 30, 45 or 60 minutes and phagocytic capacity expressed as the phagocytic index (PI) 
calculated as the percentage of neutrophils capable of phagocytosing bacteria multiplied by 
the mean fluorescence intensity (MFI). When compared to neutrophils isolated from young 
donors, the PI of neutrophils isolated from old donors in response to S.aureus showed a 
significant reduction at all time points (young vs. old, mean ±SEM; 30 minutes: 73.03 ± 9.2 
vs. 39.04 ± 11.8; p=0.019; 45 minutes: 100.6 ± 11.3 vs. 60.8 ± 15.8; p= 0.029; 60 minutes: 
139.9 ± 13.8 vs. 86.7 ± 20.7, p= 0.025). There was no difference observed in the phagocytic 
index of neutrophils from young and old donors following co-incubation with E.coli (see 
Figure 3.10). 
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Figure 3.9 Neutrophil Elastase Activity in Neutrophils Isolated from Young 
and Elderly donors. Concentration of the neutrophil-elastase specific 
fibrinogen breakdown product AαVal
360
 in plasma collected from young (filled 
circles) and elderly (open circles) donors. All data sets follow normal distribution 
(Kolmogorov-Smirnov test) and statistical significance assessed by independent 
samples T-test. *p<0.05 young vs. old. Bar denotes the mean for each group 
(n=10). 
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A B 
Figure 3.10 Neutrophil Phagocytosis of S.aureus and E.coli. Phagocytic 
Index of neutrophils isolated from young (filled circles) and old (open circles) in 
response to (A) Staphylococcus aureus or (B) Escherichia coli for 30, 45 or 60 
minutes. All data sets are normally distributed (Kolmogorov-Smirnov Test) and 
statistical significance measured by repeated measures ANOVA. *p<0.05 young 
vs. old. Data are mean ± SEM (n=8). 
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3.2.9 Neutrophil Superoxide Production is not affected by increasing age 
The production of reactive oxygen species (ROS) was measured in both quiescent and 
activated (fMLP or IL8 stimulated) neutrophils isolated from both young and old donors. PMA 
was used as a positive control. There was no significant difference in the amount of ROS 
produced either in the basal state or in response to 2.5μM fMLP, 1.25μM IL8 or 25nM PMA 
by neutrophils from either young or old donors (see Table 3.3). 
 
In summary, aberrant migration in old subjects was associated with reduced phagocytosis to 
the gram positive pathogen S.aureus, but not to the gram negative pathogen E.coli, while 
reactive oxygen species was preserved with age. 
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Neutrophils isolated from young and elderly donors and either unstimulated or 
stimulated with 2.5µM fMLP, 1.25µM IL8 or 25nM PMA in the presence of 
100µM luminol to measure the production of reactive oxygen species. There 
were no significant differences between groups. Data are mean ± SEM (n=8). 
AUC: Area under the curve. 
Unstimuated fMLP IL8 PMA
Young 46.5 ± 9.7 169.7 ± 15.4 49.7 ± 10.2 312.7 ± 28.5
Old 45.8 ± 5.4 184.2 ± 38.3 62.8 ± 7.3 337.0 ± 40.6
AUC (x1000)
Table 3.3 Neutrophil Reactive Oxygen Species Production. 
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3.3 Discussion 
Neutrophil migration is the process by which neutrophils migrate through tissue towards the 
site of infection guided by sequential chemoattractant gradients consisting of cytokines, 
lipids, complement and bacterial proteins. Upon reaching the site of infection, neutrophils 
mediate bacterial clearance and degradation utilizing a variety of anti-microbial functions. 
Within the elderly population rates of both morbidity and mortality due to bacterial infections 
are significantly increased when compared to the younger population [165,417,418]. As 
neutrophils are the first cell to be recruited to the site of infection, the aim of this chapter was 
to accurately assess the effects of increasing age on neutrophil function with a particular 
focus on neutrophil migration. A number of studies have attempted to define the effects of 
increasing chronological age on neutrophil migration [150,373,376,379], however no 
consensus has been achieved. This study is therefore the first to provide a detailed analysis 
of migratory parameters of neutrophils isolated from healthy older adults when compared to 
those isolated from younger, gender matched controls and considered some of the 
physiological consequences of the changes observed. 
Neutrophils isolated from healthy adults ≥ 60 years of age exhibited maintained 
chemokinesis but exhibit a significant reduction in chemotaxis and chemotactic index (overall 
accuracy) when migrating towards optimum concentrations of a number of physiologically 
relevant chemoattractants. Wenisch et al, the only report to date that has considered 
chemokinesis as an independent parameter to chemotaxis, reported maintained speed with a 
trend towards reduced directional migration in the elderly [161] supporting the findings 
presented here. However, due to the methodology used, direct comparisons cannot not be 
drawn. Discrepancies between work presented here and other published work reporting 
either no change or a reduction in neutrophil migration with age are also likely to be due to 
the methodology used. Most studies use a Boyden Chamber to assess migration, which 
does not allow for chemokinesis to be studied independently of chemotaxis and the results 
gained are influenced by the pore size of the filter which can vary between studies.  
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Data presented here are able to expand on the effect of age on neutrophil migration 
demonstrating a similar pattern of reduction in response to chemoattractants from different 
levels of the hierarchy e.g. intermediary chemoattractants (IL8 and LTB4) and end-point 
chemoattractants (C5a and fMLP). Cross sectional analysis of migration across the life span 
demonstrated a significant correlation between age and both chemotaxis and chemotactic 
index with maximal velocity being achieved between 20 and 30 years of age and thereafter 
exhibiting a gradual decline in function, becoming significantly compromised from 60 years 
and onwards. It is noteworthy that this initial decline in migratory parameters coincides with 
the age at which hormone changes such as the adrenopause, a gradual decline in serum 
levels of the steroid hormone dehydroepiandrosterone–sulphate (DHEAS), become 
physiologically significant by 60-70 years of age resulting serum levels being reduced to 20-
30% of those observed in younger cohorts [58]. However, DHEAS has been shown to have 
conflicting effects on neutrophil function; it enhances neutrophil superoxide generation in 
vitro through activation of Protein Kinase-Cβ (PKCβ) [419], but inhibits the migration of 
peripheral blood neutrophils although the mechanism of action remains unknown as this 
effect was shown to be independent of Akt, PKC, p38 and ERK, the classical regulators of 
migration [420]. This suggests that adrenopause is unlikely to be a driving factor behind 
reduced migratory accuracy with increasing age.  
The analysis shown here suggests that increasing chronological age can only account for 
28.4% of the reduction seen in chemotaxis and 39.7% of the reduction seen in chemotactic 
index. It is likely, therefore that other age-related changes must also influence migratory 
accuracy. Inflamm-ageing for example may affect cellular function by inducing a state in 
which neutrophils exhibit chronic low-level activation and are perhaps desensitized to 
chemokine stimulation as a result. Complement proteins present in the plasma of aged rats 
have also been shown to reduce migration of neutrophils isolated from young donors [421]. 
However, a link between these factors and an age-related reduction in neutrophil migration 
still remains to be proven and was not considered here. 
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Immune function has been shown to be an essential factor in increased longevity through the 
study of centenarian immune function. Alonso-Fernandez et al demonstrated neutrophil 
chemotaxis, phagocytosis and superoxide generation of neutrophils isolated from 
centenarians to be at a level comparable to that of a younger cohort (age 25 – 35 years) 
[378]. This suggests that those people who preserve their immune function are more likely to 
achieve extreme longevity. As shown in Figure 3.7, neutrophil chemotaxis progressively 
declines until the 8th decade after which the curve becomes more U-shaped. It may be that 
those people who have reached their 8th decade are those that exhibited a reduced level of 
immune-senescence in earlier life and are therefore the most likely to become centenarians. 
Only prospective longitudinal studies can determine how neutrophil functions decline with 
age and how this impacts on health. However, it may possible to compare an individual’s 
‘immunological age’ to that of a healthy cohort, in order to provide an indication as to how 
well their immune system is fairing against physiological changes that occur with increasing 
chronological age. 
The natural ageing process has been causally related to a decline in organ function including 
the kidneys [422], liver [423] and lungs [424]. Specifically, decline in respiratory function has 
been shown to correlate with the systemic inflammatory burden in a dose-dependent manner 
[424] and it has been hypothesised that neutrophil infiltration may be a contributing factor. 
Certainly, neutrophils contain sufficient damaging proteins to cause tissue damage if 
released extracellularly, and neutrophil proteinases have been shown to cause significant 
cell and tissue damage in vitro and animal studies. Aberrant migration in the elderly may 
further exacerbate this situation due to the internal polarisation and exocytosis of serine 
proteases such as neutrophil elastase (NE) during migratory processes [223] leaving behind 
an area of obligate tissue damage [239]. Work presented here would support this hypothesis 
as surface expression of the azurophil granule specific marker, CD63 and plasma 
concentrations of the NE-specific fibrinogen breakdown product AαVal360 were raised in the 
elderly indicating an augmented release of neutrophil elastase and evidence of its activity. 
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Coupled to aberrant migration, increased neutrophil elastase release has the potential to 
severely compromise organ function, particularly in the lungs where function relies upon the 
elastic nature of elastin, the main substrate for NE. This is demonstrated in chronic 
obstructive pulmonary disease (COPD) where plasma concentrations of AaVal360 correlate 
with disease progression and severity of emphysema [232]. 
Work presented here, although demonstrative of aberrant migration in the elderly with 
consequences for tissue integrity, included volunteers who were considered to be healthy i.e. 
medication free and having no inflammatory diseases or experiencing any infections. 
However in vivo, neutrophil migration occurs in response to infection or injury in the tissues 
with a concomitant increase in soluble inflammatory mediators favouring a pro-inflammatory 
micro-environment. It would be important to establish whether age-associated aberrant 
neutrophil migration was preserved or whether it was corrected during inflammatory insult, as 
this would have implications for the relevance of the described neutrophil phenotype in vivo. 
To investigate this, inflammation was compared during an acute episode of Streptococcus 
pneumoniae related community acquired pneumonia between young and old patients. Old 
patients (age > 65years) had significantly higher levels of inflammatory mediators and a 
greater sputum neutrophil count however, the bacterial load was also over 10 times greater 
than that observed in young patients (age < 35years) (see Table 3.4). This suggests that 
infiltrating neutrophils were either unable to efficiently phagocytose bacteria or exhibited 
delayed in arrival at the site of infection thus allowing a greater opportunity for substantial 
bacterial replication and infiltration. Neutrophil migration was also measured in these patients 
both during pneumonia infection and following recovery. Neutrophils isolated from young 
donors showed enhanced chemokinesis and chemotaxis during infection when compared to 
health, however this increase in function was absent in neutrophils isolated from old donors 
with chemotaxis exhibiting a significant reduction rather than an increase (Figure 3.11) 
(personal communication by Dr Elizabeth Sapey). These data suggest aberrant neutrophil 
functions are not corrected during heightened inflammation, are associated with worsening 
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inflammatory and infective profiles and therefore may be an important predictor of poor 
outcome and thus a target for therapeutic intervention. 
Due to the number, age range, health status and array of stimuli used, we have 
demonstrated a robust, generic migratory phenotype that is a feature of natural immune-
senescence and may be a contributing factor to increased rates of morbidity and mortality 
observed in the elderly population. 
 
In addition to migration, both phagocytosis and the production of reactive oxygen species 
(ROS) have been reported to exhibit an age related functional decline in response to specific 
stimuli [161]. The data presented here suggest that if migration is impaired, phagocytosis of 
gram positive (but not gram negative) bacteria is also reduced, without an effect on ROS 
generation. The data for ROS generation were gained utilising pro-inflammatory mediators 
and not bacteria. Niwa et al also found no difference in ROS generation to the same 
chemoattractants [375] but interestingly, Wenisch et al demonstrated a significant reduction 
in ROS response to S.aureus stimulation but not E.coli [161], again suggesting a differential 
effect between gram positive and negative stimuli. 
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Table 3.4 The Inflammatory Response during Pneumonia Infection 
Inflammatory response of 5 young and 5 elderly patients admitted into QEHB with 
pneumonia infection. All data sets were normally distributed (Kolmogorov-Smirnov 
Test) and statistical significance measured using an independent samples T-test. 
*p<0.05 young vs. old. 
IQR, Interquartile Range; IL8, Interleukin-8; LTB
4
, Leukotriene-B
4
; TNFα, Tumor 
Necrosis Factor-α; IL1β, Interleukin-1β; CRP, C-Reactive Protein; SD, Standard 
Deviation. 
*Table provided by Dr. Elizabeth Sapey 
Age < 35 Age > 65
n 5 5
Streptococcus pneumoniae  in Sputum 5 5
Bacterial Load (Sputum; cfu/ml); Median (IQR) 6x108 (3-8) 8x109 (5-10) *
Neutrophil Count/ml (Sputum); Median (IQR) 15x106 (11-25) 23x106 (14-30) *
IL8 (Sputum); nM (IQR) 33.9 (17-46) 60 (43-64) *
LTB4 (Sputum); nM (IQR) 47.3 (14-72) 74.1 (18-84) *
TNFα (Sputum); pM (IQR) 15.6 (10-28) 40.3 (24-51) *
IL1β (Sputum); pM (IQR) 17.2 (9-22) 40.1 (22-63) *
CRP (Plasma); mg/dl (IQR) 67 (21-98) 102 (52-139) *
Neutrophil Count/ml (blood); Median (IQR) 16.9x106 (12-23) 17.1x106 (11-24)
AαVal360 (Plasma); nM ± SD 2.3 ± 0.3 4.1 ± 0.4 *
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Figure 3.11 Neutrophil Migration in Response to IL8 during Pneumonia 
Infection.  
(A) Chemokinesis (speed of migration), (B) Chemotaxis (direction of migration) 
and (C) Chemotactic Index (accuracy) of neutrophils isolated from both young and 
old donors during pneumonia infection (dark grey bars) and following recovery 
(light grey bars). Migration was measured in response to shallow gradients of 
100nM IL8. All data sets were normally distributed (Kolmogorov-Smirnov Test) 
and statistical significance measured using a factorial mixed ANOVA. *p<0.05 
health vs. disease. Data are mean ± SEM (n=5). 
* Data provided by Dr. Elizabeth Sapey 
A B 
C 
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This stimuli-specific response may reflect the nature of the response required when these 
stimuli are received in vivo. For example, exposure to IL8 would normally occur during the 
initial stages of migration where ROS production would be required to facilitate migration, 
whereas exposure to S.aureus would naturally occur at the site of infection where large-scale 
ROS production would be required to eliminate pathogenic material at the site of infection. In 
order to gain a more accurate picture of ageing and ROS production, stimuli should 
encompass a number of both particulate (e.g. S.aureus) and soluble (e.g. IL8, fMLP) stimuli, 
measured in both primed and un-primed neutrophils to more accurately represent the 
inflammatory environment and should use multiple chemiluminescent substrates in order to 
detect both intra- and extra-cellular ROS [425,426] and the different radical species 
produced.  However, this is the first report where neutrophil functions have been studied in 
the same individuals where aberrant migration is coupled with poor phagocytosis of gram-
positive bacteria. These findings represent significant impairments in vital innate host 
immunity which could contribute to the poorer responses seen to acute infection in the 
elderly, together describing the decline in the anti-bacterial capacity of from elderly donors 
neutrophils, both in travelling to and at the site of infection. This also provides a potential 
mechanism by which older adults exhibit increased susceptibility gram-positive infections 
such as pneumonia [21] and bacterial sepsis [427]. 
Here it is proposed that aberrant migration in the healthy elderly results in increased 
collateral damage and delayed arrival at the site of infection, potentially allowing invading 
bacteria a greater opportunity for host infiltration. This might contribute to the increased rates 
of morbidity and mortality observed in the elderly population. The cross sectional data 
suggest that the decline in migration might progress gradually over time and that loss of 
function is due to the accumulation of changes during the ageing process rather than a single 
catastrophic event.  
Mechanisms driving this process remain unclear, however, in order to improve healthspan 
(the amount of time the average person can expect to spend in good health); a clearer 
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understanding of the mechanisms regulating neutrophil migration must be obtained. These 
data support the concept that the neutrophil is an immunotherapeutic target in both acute 
infections and chronic disease, however in order to ensure an adequate immune response 
remains, it would be important to normalise and not neutralise neutrophil function. 
  
 
 
 
 
 
CHAPTER 4 
 
 
MECHANISMS OF ALTERED NEUTROPHIL 
MIGRATION WITH AGEING 
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4.1 Introduction 
Chapter 3 demonstrated a robust aberrant migratory phenotype in neutrophils isolated from 
old donors specifically, a reduced migratory accuracy with maintained speed of migration. 
This may result in delayed arrival at the site of infection and be a major contributing factor to 
the increased rates of morbidity and mortality associated with bacterial infections in the 
elderly population.  
When a cell receives an external stimulus, it must first transmit this signal across the plasma 
membrane in order to evoke a cellular response, which in the case of cell migration would 
involve rearrangement of the actin cytoskeleton and modulation of adhesive contacts on the 
cell surface [428]. The first stage of this response is the binding of the stimulus to its 
complementary receptors on the cell surface e.g. IL8 binding to CXCR1 and/or CXCR2 
inducing ‘outside-in’ with concomitant ‘inside-out’ signalling inducing increases in integrin 
avidity on the surface [429]. This then initiates an internal signalling cascade either through 
recruitment of cellular signalling molecules to the plasma membrane or through interaction 
with the cytoskeleton inducing rearrangement, all of which results in a functional cellular 
response. As previously mentioned, signalling pathways involved in neutrophil directional 
migration are only partially understood, however signalling molecules such as 
phosphatidylinositol-3-kinase (PI3Kinase) [430], Akt/PKB [431], mammalian target of 
rapamycin (mTOR) [432] and members of the Rho-GTPase family [305] have all been 
heavily implicated in the regulation of migration. In order to identify the mechanisms driving 
aberrant neutrophil migration in the elderly and potentially intervene to improve innate 
immunity in the aged, the effects of increasing age on signalling pathways must be better 
understood.  
It was hypothesised that aberrant migration would not be caused by differential expression of 
chemoattractant receptors, as migration to a broad range of chemokines was affected by 
ageing, and would instead be driven by dysregulated cell signalling through PI3Kinase, 
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particularly the class 1 isoforms γ and δ. This hypothesis would be tested by the following 
aims: 
1. To assess chemokine receptor expression on the surface of quiescent neutrophils isolated 
from young and old adults; 
2. To measure the membrane phospholipid content of neutrophils isolated from young and 
old donors;  
3. To compare PI3Kinase and Akt activity in neutrophils isolated from young and old donors; 
4. To determine the effect of PI3Kinase inhibition on neutrophil migration using both broad-
spectrum and isoform selective inhibitors. 
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4.2 Results 
4.2.1 Effects of age on Surface Expression of Chemoattractant Receptors 
To assess any age-related defects in the proximal step of signal transduction, surface 
expression of receptors for the chemoattractants used in chapter 3 were measured on 
quiescent neutrophils isolated from healthy young (n = 20) and healthy old (n = 20) donors. 
Surface expression of CXCR1 (Young vs. old MFI ± SEM 109.8 ± 8.2 vs. 66.9 ± 9.7; 
p=0.001) and CXCR2 (Young vs. old MFI ± SEM; 68.4 ± 5.7 vs. 49.01 ± 7.8; p=0.025) was 
found to be significantly reduced on quiescent neutrophils isolated from old donors compared 
to young donors. However, there was no significant difference in surface expression of 
C5aR, BLT1 or FPR1 in neutrophils isolated from old donors (see Figure 4.1). 
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Figure 4.1 Surface Expression of Chemoattractant Receptors on Quiescent 
Neutrophils. Expression of (A) CXCR1, (B) CXCR2, (C) C5aR, (D) BLT1 and (E) 
FPR1 on the surface of quiescent peripheral blood neutrophils isolated from 
young (filled circles) and elderly (open circles) donors. Data sets were non-
normally distributed (Kolmogorov-Smirnov test), statistical significance was 
assessed via Mann-Whitney U test. Bar denotes the mean for each group (n=21). 
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4.2.2 Ageing does not alter phospholipid composition of the plasma membrane 
Alterations in the composition of phospholipids within the plasma membrane, particularly 
those with long fatty-acid chains, has been suggested as a possible mechanism by which 
age-related alterations in signal transduction may occur [162]. This may be due to reductions 
in membrane fluidity and therefore the ability of receptors to co-localize. This chapter 
therefore assessed the proportions of phosphatidylcholine (PC); phosphatidylethanolamine 
(PE), phosphatidylserine (PS) and phosphatidylinositol (PI) present in the membrane of 
quiescent neutrophils isolated from young and old donors. This work was done in 
collaboration with Professor Anthony D. Postle, Southampton Centre for Biomedical 
Research, NIHR Respiratory Biomedical Research Unit, University Hospitals Southampton, 
UK.  
 
Neutrophils isolated from old donors showed a significant reduction in the proportion of total 
PS species present in the membrane (young vs. old, mean ± SEM; 12.03 ± 0.6 vs. 9.73 ± 
0.6, p=0.009) while total proportions of total PC, PE and PI species remained unchanged 
with age (see Figure 4.2).  
 
Individual phosphatidylcholine (PC) species showed minor alterations with age: PC16:0/22:6 
and PC18:0/22:6 were significantly reduced (young vs. old, mean ± SEM; PC16:0/22:6: 0.9 ± 
0.2 vs. 0.5 ± 0.06, p=0.037; PC18:0/22:6: 0.8 ± 0.2 vs. 0.4 ± 0.05, p=0.05). There were no 
age related alterations in the proportions of individual PE, PS and PI species (Figures 4.3 - 
4.6).  
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Figure 4.2 Plasma Membrane Phospholipid Composition 
Percentage of Phosphatidylcholine (PC), Phosphatidylethanolamine (PE), 
Phosphatidylserine (PS) and Phosphatidylinositol (PI) present in the plasma 
membrane of human neutrophils isolated from young (black bars) and old (clear 
bars) donors. All data sets follow normal distribution (Kolmogorov-Smirnov test) 
and statistical significance testing by independent samples T-test. Data are mean 
± SEM (n=10). *p < 0.05 young vs. old. 
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Figure 4.3 Composition of Phosphatidylcholine species in the Plasma 
Membrane 
Percentage of Phosphatidylcholine (PC) species present in the plasma membrane 
of human neutrophils isolated from young (black bars) and old (clear bars) donors. 
All data sets follow normal distribution (Kolmogorov-Smirnov test) and statistical 
significance was assessed by independent samples T-test. Data are mean ± SEM 
(n=10). *p < 0.05 young vs. old. 
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Figure 4.4 Composition of Phosphatidylethanolamine species in the Plasma 
Membrane 
Percentage of Phosphatidylethanolamine (PE) species present in the plasma 
membrane of human neutrophils isolated from young (black bars) and old (clear 
bars) donors. All data sets follow normal distribution (Kolmogorov-Smirnov test) 
and statistical significance assessed by independent samples T-test. Data are 
mean ± SEM (n=10). 
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Figure 4.5 Composition of Phosphatidylserine species in the Plasma 
Membrane 
Percentage of Phosphatidylserine (PS) species present in the plasma membrane 
of human neutrophils isolated from young (black bars) and old (clear bars) donors. 
All data sets follow normal distribution (Kolmogorov-Smirnov test) and statistical 
significance testing by independent samples T-test. Data are mean ± SEM (n=10). 
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Figure 4.6 Composition of Phosphatidylinositol species in the Plasma 
Membrane. Percentage of Phosphatidylinositol (PI) species present in the plasma 
membrane of human neutrophils isolated from young (black bars) and old (clear 
bars) donors. All data sets follow normal distribution (Kolmogorov-Smirnov test) 
and statistical significance testing by independent samples T-test. Data are mean 
± SEM (n=10). 
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4.2.3 PI3Kinase is constitutively active in Neutrophils from older adults 
The effects of increasing chronological age were also assessed on signal transduction 
pathways known to be involved in migration. PI3Kinase is thought to be a major pathway 
involved in the control of directional migration generating an internal gradient of the inositol 
lipid PIP3, concentrated at the leading edge of migrating cells [275]. In order to assess the 
effects of age on PI3Kinase activity, neutrophil lysates from young and old donors were 
probed for the phosphorylated form of the Class IA regulatory subunit p85 in the presence or 
absence of IL8. Phosphorylation was determined via western blot using β-actin as a loading 
control and subsequently quantified by densitometry.  
Neutrophils from young adults demonstrated low-level activation in the basal state followed 
by a transient increase in p85 phosphorylation (peaking at 1 minute) in response to IL8. In 
contrast, neutrophils from older adults demonstrated constitutive, basal activation of 
PI3Kinase that was not increased further by stimulation with IL8 (see Figure 4.7). 
 
4.2.4 Dysregulated PI3Kinase activation has differential effects on Akt activity 
To determine the extent to which dysregulated PI3Kinase activity extended downstream, 
Akt/PKB activity was measured by phosphorylation of Serine473 (Ser473) in neutrophil 
lysates from both young (n = 3) and older (n = 3) adults. Akt plays a central role in multiple 
cellular responses in addition to the control of migration and can therefore be activated by 
numerous cellular signalling pathways. Neutrophils isolated from young and old donors 
showed little or no phosphorylation at Ser473 in the basal state but exhibited differential 
activation when stimulated with IL8 for 1 minute and 2 minutes which was lost by 5 minutes 
(see Figure 4.8).  
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Figure 4.7 PI3Kinase Activity with IL8 Stimulation in Neutrophils from Young 
and Old donors. Peripheral blood neutrophils isolated from (A) young and (B) old 
donors were stimulated with 100nM IL8 for the times indicated and PI3Kinase 
activation measured by the phosphorylation of the regulatory subunit p85. β-actin 
was used as a loading control. (C) Levels of phosphoPI3Kinase were quantified 
by densitometry and expressed as a ratio of phosphorylated PI3Kinase (pPI3K):β-
actin in neutrophils from both young (black bars) and old (white bars) donors. 
Images in (A) and (B) are representative of multiple independent experiments (3 
young and 4 old) which are presented in (C) as mean ± SEM.  
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Figure 4.8 Akt Activity in response to IL8 in Neutrophils from Young and Old 
donors. Peripheral blood neutrophils isolated from (A) young and (B) old donors were 
stimulated with 100nM IL8 for the times indicated and Akt activation measured by the 
phosphorylation of Ser473. Total Akt was used as a loading control. (C) Phosphorylation 
of Ser473 was quantified by densitometry and expressed as a ratio of phosphorylated Akt 
(pAkt):total Akt (tAkt) in neutrophils from both young (black bars) and old (white bars) 
donors. Images in (A) and (B) are representative of 3 independent experiments which are 
presented in (C) as mean ± SEM. Statistical significance was measured by independent t-
test. 
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4.2.5 Dysregulated PI3Kinase activity contributes to aberrant migration  
To confirm a role for constitutive PI3Kinase activity in the manifestation of aberrant migration 
in neutrophils from elderly donors, neutrophils from both young and old donors were pre-
incubated with 1μM LY294002 a broad-spectrum PI3Kinase inhibitor prior to measuring 
migratory parameters in response to IL8. 
Pre-treatment of neutrophils from young donors with LY294002 significantly reduced 
chemokinesis (untreated vs. treated, mean ± SEM; 4.9 ± 0.3 vs. 3.3 ± 0.5 μm/min; p=0.002), 
chemotaxis (untreated vs. treated, mean ± SEM; 2.0 ± 0.2 vs. 0.8 ± 0.3 μm/min; p=0.001) 
and chemotactic index (untreated vs. treated, mean ± SEM; 0.4 ± 0.03 vs. 0.1 ± 0.03 μm/min; 
p=0.008). However, when neutrophils isolated from old donors were used LY294002 had no 
effect on chemokinesis but significantly improved both chemotaxis (untreated vs. treated, 
mean ± SEM; 1.1 ± 0.2 vs. 1.7 ± 0.1 μm/min; p=0.01) and chemotactic index (untreated vs. 
treated, mean ± SEM; 0.2 ± 0.02 vs. 0.4 ± 0.02 μm/min; p-0.03) to levels observed in young 
cells (see Figure 4.9). These data support the proposal that constitutive PI3Kinase signalling 
in neutrophils from old donors is involved in the generation of an ‘old migratory’ phenotype. 
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Figure 4.9 The effect of LY294002 on Neutrophil Migration.  
Peripheral neutrophils isolated from young (black bars) and old (white bars) 
donors were incubated in the absence or presence of 1μM LY294002 and (A) 
chemokinesis, (B) chemotaxis and (C) chemotactic index were measured in 
response to 100nM IL8. All data sets were normally distributed and statistical 
significance measured by repeated measures ANOVA. * p<0.05 young vs. old; Φ 
p<0.05 young untreated vs. treated; # p<0.05 old untreated vs. treated. Data are 
mean ± SEM (n=10).  
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4.2.6 Inhibition of PI3Kinase p110 γ and δ isoforms restores migratory accuracy in 
neutrophils from older adults 
Class I PI3Kinase consists of 4 different isoforms of the p110 catalytic subunit, (α, β, γ and δ) 
all of which are expressed in human neutrophils and involved in migratory processes [255]. 
Therefore, to further elucidate the role of specific PI3Kinase isoforms in aberrant neutrophil 
migration, migratory studies were repeated in the presence or absence of inhibitors selective 
for each isoform: p110α PIK-75 (7.8nM); p110β TGX-221 (10nM); p110γ AS-252424 (33nM) 
and p110δ CAL-101 (65nM); all concentration used correspond to IC50 values to ensure 
inhibitor selectivity. 
Inhibition of p110α or p110β in neutrophils isolated from young donors resulted in a 
significant reduction in all migratory parameters: untreated vs. treated, mean ± SEM; p110α 
inhibitor: chemokinesis: 5.4 ± 0.3 vs. 4.1 ± 0.4 p=0.002; chemotaxis: 3.3 ± 0.3 vs. 1.5 ± 0.4 
p<0.001; persistence:  0.5 ± 0.06 vs. 0.35 ± 0.05 p=0.012; and chemotactic index: 0.5 ± 0.06 
vs. 0.3 ± 0.05 p=0.011; p110β inhibitor: chemokinesis: 5.4 ± 0.3 vs. 3.4 ± 0.3 p<0.001; 
chemotaxis: 3.3 ± 0.3 vs. 0.7 ± 0.2 p<0.001; persistence: 0.5 ± 0.06 vs. 0.2 ± 0.06 p=0.001; 
chemotactic index: 0.5 ± 0.06 vs. 0.1 ± 0.04 p=0.001 (see Figure 4.10). A significant 
reduction in chemokinesis was also seen in cells isolated from old donors: untreated vs. 
treated, mean ± SEM; p110α inhibitor: 4.6 ± 0.4 vs. 3.6 ± 0.5 p= 0.035; p110β inhibitor: 4.6 ± 
0.4 vs. 3.6 ± 0.4 p=0.044.  However, chemotaxis, persistence and chemotactic index were 
unaffected by inhibition of either isoform (see Figure 4.10). 
In contrast, inhibition of p110γ had no effect on chemokinesis but significantly reduced: 
chemotaxis: untreated vs. treated, mean ± SEM; 2.9 ± 0.3 vs. 1.1 ± 0.2 p=0.002; persistence: 
untreated vs. treated, mean ± SEM; 0.5 ± 0.05 vs. 0.3 ± 0.05 p=0.001; and the chemotactic 
index: untreated vs. treated, mean ± SEM; 0.5 ± 0.05 vs. 0.2 ± 0.04 p=0.001 of cells isolated 
from young adults (see Figure 4.11). However in cells isolated from older adults, inhibition 
p110γ was able to partially restore migratory accuracy by improving chemotactic index: 
untreated vs. treated, mean ± SEM; 0.2 ± 0.04 vs. 0.4 ± 0.05 p=0.01 whilst preserving 
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chemokinesis, chemotaxis and persistence (see Figure 4.11). A similar effect was seen 
upon inhibition of p110δ which restored both chemotaxis: untreated vs. treated, mean ± 
SEM; 1.2 ± 0.2 vs. 2.7 ± 0.3 p=0.001, and the chemotactic index: untreated vs. treated, 
mean ± SEM; 0.2 ± 0.04 vs. 0.6 ± 0.04 p<0.001 (see Figure 4.11) of cells isolated from older 
adults to levels comparable with those isolated from their young counterparts. In young cells, 
inhibition of p110δ resulted in a significant reduction in all migratory parameters (see Figure 
4.11). 
 
Due to the widespread reductions seen in migratory parameters following inhibition of p110 
isoforms, especially in cells isolated from young donors, the percentage of viable neutrophils 
remaining following inhibition with PI3Kinase isoform selective inhibitors (as determined by 
the percentage of cells remaining annexinV and Sytox negative following incubation) were 
measured to ensure the inhibitors used during migratory studies were not toxic.  
Following a 40-minute incubation with isoform selective PI3Kinase inhibitors, the number of 
viable cells was unchanged when compared to untreated cells (see Figure 4.12). 
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Figure 4.10 Effect of PI3Kinase p110 α and β selective inhibitors on 
Neutrophil Migration. Peripheral neutrophils isolated from young (black bars) 
and old (white bars) donors were pre-incubated in the absence or presence of 
PI3Kinase inhibitors selective for the p110α (PIK-75, 7.8nM) or p110β (TGX-221, 
10nM) catalytic subunit of class I PI3Kinase and (A) chemokinesis, (B) 
chemotaxis, (C) persistence and (D) chemotactic index measured in response to 
100nM IL8. All data sets were normally distributed (Kolmogorov-Smirnov test) and 
statistical significance measured by factorial repeated measures ANOVA. * 
p<0.05 young vs. old; ϕ p<0.05 young untreated vs. treated; # p<0.05 old 
untreated vs. treated. Data are mean ± SEM (n=10). 
A B 
C D 
140 
 
 
  
Figure 4.11 Effect of PI3Kinase p110 γ and δ selective inhibitors on 
Neutrophil Migration. Peripheral neutrophils isolated from young (black bars) 
and old (white bars) donors were pre-incubated ± PI3Kinase inhibitors selective 
for the p110γ (AS-252424, 33nM) or p110δ (CAL-101, 65nM) catalytic subunit of 
class I PI3Kinase and (A) chemokinesis, (B) chemotaxis, (C) persistence and (D) 
chemotactic index measured in response to 100nM IL8. All data sets were 
normally distributed (Kolmogorov-Smirnov test) and statistical significance 
measured by factorial repeated measures ANOVA. * p<0.05 young vs. old; ϕ 
p<0.05 young untreated vs. treated; # p<0.05 old untreated vs. treated. Data are 
mean ± SEM (n=10). 
A B 
D C 
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Fig. 4.12 Percentage Viable Cells in the Presence of PI3Kinase Isoform 
Selective Inhibitors. Percentage of viable neutrophils isolated from (A) young 
and (B) old donors following 45 minute incubation with isoform selective 
PI3Kinase inhibitors. Cell viability was determined as those that remain both 
Annexin V and Sytox negative following incubation ± PI3Kinase inhibitors. Bar 
denotes the mean for each group (n=5). 
A B 
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4.3 Discussion 
Mechanisms driving neutrophil migration are no longer thought to exist downstream of a 
single linear pathway and instead occur through the complex interaction of multiple pathways 
when in the correct spatial and temporal orientation [254]. The aim of this chapter was to 
elucidate any age-related alterations in receptor expression, membrane composition and/or 
in the PI3Kinase/Akt signalling pathway that may be involved in the generation of the ‘old-
migratory phenotype’ observed in chapter 3. The data show constitutive basal activation of 
Class I PI3Kinase, which is insensitive to further stimulation in the neutrophils of elderly 
donors but did not confirm data reported in rat neutrophils of a change in membrane fluidity 
with ageing [371]. Furthermore inhibition on PI3Kinase- and PI3Kinase-δ was able to correct 
the defects in migratory behaviour in the neutrophils from old donors. 
Detection of a chemotactic gradient through GPCRs is the first stage in responding to a 
chemotactic gradient. Surface expression of CXCR1 (IL8 Receptor A) and CXCR2 (IL8 
Receptor B which also ligates GROα, neutrophil activating peptide-2 (NAP2) and epithelial 
neutrophil activating protein-78 (ENA-78)) showed a significant reduction with increasing 
age. Neutralisation of CXCR1 has been shown to severely impair neutrophil migration [433] 
while inhibition of CXCR2 abrogates the age-associated increase in pulmonary inflammation 
following burn injury [434]. IL8 is considered to be an intermediary chemokine [211] therefore 
reduced expression of both IL8 receptors may impair migration during the early stages of 
recruitment. However, this discrepancy is unlikely to be the underlying cause of the aberrant 
migration observed here as the ‘old-migratory phenotype’ was also present when migrating 
towards C5a, fMLP and LTB4 which signal independently of CXCR1 and CXCR2. This 
suggests a generic dysregulation of signal transduction downstream of receptor-ligand 
interactions as opposed to altered receptor specific signalling or expression. 
Within the literature, few reports exist on the effects of age on neutrophil membrane 
composition and fluidity. Alvarez et al reported an age-related increase in the phospholipid 
143 
 
content of rat peritoneal neutrophils [371] while Ponnappan et al showed that increasing age 
did not affect the fatty acid composition of membrane phospholipids in human lymphocytes 
[435].To date these reports remain the only published work investigating the effects of ageing 
on membrane lipid composition. Here small but statistically significant changes in both the 
proportion of membrane phospholipid species and in individual phospholipid species were 
detected in neutrophils from old donors. The discrepancies with published work are likely due 
to the intrinsic differences between rat and human neutrophils or could also arise from the 
fact that here peripheral blood neutrophils were assessed, whereas Alvarez et al used 
peritoneal cells which would be activated. However, the changes observed in phospholipid 
species are small in magnitude and are therefore unlikely to underlie any changes in 
membrane fluidity and subsequently aberrant migration with ageing. The significant 
reductions in phosphatidylserine (PS), a phospholipid essential in the recognition apoptotic 
neutrophils, may impact on the resolution of inflammation through reduced clearance of 
apoptotic neutrophils, though this has not been tested here. 
All chemoattractants utilized in this study signal through GPCRs with a common downstream 
event being the activation of class I PI3Kinase isoforms [436]. Work presented here 
demonstrated a constitutive activation of PI3Kinse in the basal state of neutrophils isolated 
from healthy elderly donors which could not be further activated following stimulation with 
IL8. PI3Kinase signalling is a significant contributor to the regulation of migratory processes 
acting as both an initiator and amplifier of the PIP3 response during inflammation. Inflamm-
ageing may be a contributing factor to the sustained PI3Kinase activity observed with ageing, 
with heightened inflammatory mediators, such as IL8 itself [437], leading to basal activation 
and desensitisation of immune cells. Indeed exposure to chemokines can result in 
internalisation of their receptor [211], which could explain the reduced CXCR1 and 2 seen in 
neutrophils from old donors.  
Interestingly, inhibition of PI3Kinase-γ reduces mortality in a murine model of bacterial 
sepsis, partly by reducing the systemic inflammatory response syndrome (SIRS) [438]. This 
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thesis is the first study to demonstrate dysregulated PI3Kinase during natural ageing [439]. 
Although not directly related, mutations in the gene encoding PI3Kinase are a common 
feature in a number of cancers including glioblastomas (27% of cases), gastric (25%), breast 
(8%) and lung (4%) cancers which are causally related to aberrant migration, a requirement 
for invasive migration and metastasis [440]. 
Increased basal PI3Kinase activity did not directly translate into a downstream signal, at least 
not through Akt phosphorylation which was not raised in the basal state. At early time points 
after stimulation with IL8 Akt phosphorylation was significantly higher in the elderly than in 
the young however; this was not sustained over time. There are a number of possible 
reasons for this, firstly, phosphorylation of the p85 subunit may not represent a concomitant 
increase in the levels of membrane localised PIP3, the p85 regulatory subunit controls the 
activity of class IA isoforms (α, β and δ) while PI3Kinase-γ, which is under the control of a 
p101 regulatory subunit, constitutes the dominant PIP3 producing isoform at the leading edge 
[279,280]. However the ability of inhibitors of both PI3Kinase  and δ to correct the aged 
migratory phenotype do not support this proposal.  
Secondly, sustained, dysregulated PI3Kinase activity may not be sufficient to induce 
sustained up regulation of Akt activity. Additional levels of regulation exist for both PIP3 and 
Akt independent of PI3Kinase in the form of PTEN and SHIP1 for PIP3 [281] and PP2A [299] 
and PHLPP1/2 [300] for Akt. This possibility was not investigated here but the differential 
activity of either PIP3 or Akt regulators in neutrophils from old vs. young donors should be 
included in future research. In the literature, there are a number of animal models 
demonstrating the importance of PI3Kinase and PIP3 phosphatases in the control of 
directional migration. Dictyostelium discoideum lacking PTEN demonstrate preserved 
chemokinesis but reduced chemotaxis [441]; knockout of PTEN in Zebrafish results in 
reduced accuracy of migration, a phenotype that is amenable to correction by LY294002, a 
broad-spectrum PI3Kinase inhibitor [442] and finally, by using a green fluorescent protein 
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(GFP) construct specific for the PH domain of Akt, in the absence of SHIP1, Akt exhibits 
limited translocation to the leading edge of migrating murine neutrophils [343]. These models 
suggest that the balance between PI3Kinase and PTEN/SHIP1 activity in the regulation of 
PIP3 production and localisation is essential in the co-ordination of chemotaxis and could be 
altered with ageing. This is supported by data presented here demonstrating a causal 
relationship between PI3Kinase activity and the generation of the ‘old migratory’ phenotype 
through inhibition of PI3Kinase using LY294002. 
Thirdly, it is possible that the constitutive activation of PI3Kinase presented here does not 
result in irregular PIP3 production per se (potentially due to compensation by PI3Kinase-γ 
and/or PTEN/SHIP1), and instead this activity results in inappropriate localisation of PIP3. 
Here directional migration was partly restored through inhibition of PI3Kinase-γ while 
inhibition of PI3Kinase-δ was able to recover migratory parameters in old donor neutrophils 
to levels comparable with the young. It is well documented within the literature the 
importance of these isoforms in the regulation of chemokinesis and chemotaxis 
[256,264,278]. Here it is proposed that 50% inhibition of these isoforms (the concentration 
used was in the IC50 range) during migratory processes is sufficient to normalize PIP3 
production reducing the background ‘noise’, allowing greater amplification of the PIP3 signal 
upon activation of PI3Kinase-δ and better orientating the cell along the chemotactic gradient. 
This is supported by work carried out by Boulven et al who reported a biphasic PIP3 
response when stimulated with fMLP and attributed the early peak to the action of 
PI3Kinase-γ and the later peak to an unidentified Class IA PI3Kinase isoform [278]. The data 
shown here would support the notion that the other Class IA isoform involved is in fact 
PI3Kinase-δ.  
Restoring neutrophil migration through inhibition of PI3Kinase-γ and –δ isoforms will reduce 
both collateral damage caused by aberrant migration and pathological inflammation thus 
improving clinical outcomes during infection. Aberrant signalling as a consequence of 
increasing age may be a function of inflamm-ageing but restoring these pathways may 
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prevent the concurrent amplification of inflammation thus restoring immune homeostasis and 
rebuilding neutrophil functions. 
  
 
 
 
 
 
 
CHAPTER 5 
 
SIMVASTATIN AND NEUTROPHIL MIGRATION  
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5.1 Introduction 
So far the data in this thesis have established an ‘old-migratory phenotype’ exhibiting 
reduced migratory accuracy with maintained speed of migration in neutrophils from old 
healthy donors. This phenotype is causally related to constitutive PI3Kinase signalling and 
can be corrected by inhibition of either PI3Kinase-γ or –δ isoforms highlighting a mechanism 
by which therapeutic intervention may be possible.  
Development of new drugs, from conception to clinical use, can take up to 20 years however 
in this study, it was decided to look for treatments which had the potential to impact upon 
immune-senescence in the short term. The influence of statins, specifically simvastatin, on 
neutrophil migration in the healthy elderly was selected as this drug is widely prescribed to 
treat high serum cholesterol. Importantly, a number of studies have also shown multiple 
members of the statin family to have pleiotropic effects independent of their cholesterol 
lowering abilities, particularly in conferring a survival advantage in older adults with 
pneumonia [390-396]. In addition, the inhibition of HMG-CoA Reductase by statins also leads 
to reduced prenylation of small GTPases such as Rho and Rac, inhibiting their function 
[398,443,444]. As Rac lies downstream of PI3Kinase it was possible that inhibiting this 
pathway with statins would have the same effect as a PI3Kinase inhibitor.  
 
Considering these data, it was hypothesised that statins would be able to correct the 
migratory deficit in older adults and thus increase innate immunity. This hypothesis was 
tested by the following aims: 
1. To evaluate the effects of statins on pneumonia outcomes in a retrospective cohort study; 
2. To assess the effects of simvastatin in vitro on the migration of neutrophils isolated from 
young and old donors; 
3. To identify a mechanism by which statins may act to influence neutrophil migratory 
dynamics in the healthy elderly.  
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5.2 Results 
5.2.1 Statin Therapy prior to admission to hospital improves Pneumonia outcomes 
To confirm published work on the effects of statin therapy on pneumonia outcomes, patients 
admitted into the Queen Elizabeth Hospital between November 2009 and October 2011 with 
pneumonia of a bacterial or unspecified origin as their starting episode, were grouped 
according to statin therapy and outcomes assessed based on their age, gender, 
inflammatory- and diabetic - status with the clinical endpoint being death.  
Of the 2068 patients admitted into QEHB with pneumonia, 634 were taking a statin upon 
admission and 1434 were not. Clinical data relating to white blood cell (WBC) count, 
Haemoglobin, C-reactive Protein (CRP), Haemoglobin (Hb), Creatinine (Cr) and Diabetic 
status was also collated from the hospital database and stratified according to statin therapy.  
Patients taking statins prior to admission into hospital had a significantly longer hospital stay 
than non-users (statin user vs. statin free, mean ± SD; 13.5 ± 15.2 vs. 8.7 ± 12.7 days, 
p<0.001), but were also more likely to survive (statin user vs. statin free, %; 83.1 vs. 75.5, 
p<0.001). Patients taking statins prior to admission were also significantly older (statin user 
vs. statin free, mean ± SD, 75.66 ± 11.7 vs. 69.2 ± 20.1, p<0.001), more likely to be admitted 
onto ITU during their hospital stay (statin user vs. statin free, %; 10.6 vs. 7.1, p=0.008) and 
more likely to be diabetic (statin user vs. statin free, %; 36.4 vs. 12.1, p<0.001). In addition, 
those on statin therapy prior to admission had higher levels of circulating potassium, urea 
and creatinine but lower levels of haemoglobin and sodium than those not on a statin. 
Although differences between these two groups are statistically significant they are not 
considered to be clinically significant and are therefore unlikely to impact on patient outcome. 
There was no difference in CRP or numbers of circulating WBC between the two groups (see 
Table 5.1).  
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Characteristics of patients admitted into the Queen Elizabeth hospital with pneumonia of 
unspecified or bacterial origin in their starting episode. ICU, Intensive Care Unit; IQR, 
Interquartile Range; CRP, C-reactive Protein; WBC, White Blood Cell Count; INR, 
International Normalized Ratio. Mann-Whitney U-test was conducted for continuous variables 
and χ
2
-test for categorical variables 
  
Table 5.1 Cohort characteristics split according to Statin treatment   
Statin User Statin Free n (%) p value
n (%) 634 (30.7) 1434 (69.3) 2068
Age, mean ± SD (years) 75.66 ± 11.7 69.2 ± 20.1 <0.001
Male 356 (56.2) 691 (48.2) 1047 (50.6) 0.001
Female 278 (43.8) 743 (51.8) 1021 (49.3)
Survived 527 (83.1) 1083 (75.5) 1610 (77.9) <0.001
Died 107 (16.9) 351 (24.5) 458 (22.2)
Yes 231 (36.4) 173 (12.1) 404 (19.6) <0.001
No 403 (63.6) 1259 (87.9) 1662 (80.4)
Hospital Length of Stay, mean ± SD (days) 13.5 ± 15.2 8.7 ± 12.7 <0.001
Yes 67 (10.6) 102 (7.1) 169 (8.1) 0.008
No 567 (89.4) 1332 (92.9) 1899 (91.8)
8.6 ± 10.3 7.7 ± 8.86 0.483
93 (34 - 211) 102 (43-215.25) 1801 0.188
11.9 (10.7-13.3) 12.6 (11.1-14) 1572 <0.001
12.8 (9.3-16.5) 12.6 (8.9-16.9) 1573 0.709
1.1 (1-1.3) 1.1 (1-1.3) 1270 0.907
138 (134-141) 139 (136-142) 1505 <0.001
4.2 (3.8-4.7) 4.1 (3.7-4.6) 1510 0.005
8.5 (6.1-12.3) 7.3 (4.9-11.3) 1683 <0.001
102 (70-176) 83 (61-134) 715 <0.001
Gender, n (%)
Diabetic, n (%)
Patient Outcome, n (%)
Admittance onto ICU, n (%)
ICU Length of Stay, mean ± SD (days)
Potassium, median (IQR)
Urea, median (IQR)
Creatinine, median (IQR)
CRP, median (IQR)
Haemoglobin, median (IQR)
WBC, median (IQR)
INR, median (IQR)
Sodium, median (IQR)
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Utilizing logistic regression, it was possible to assess the predicted probability of death 
(PPoD) from pneumonia, controlling for age and gender, demonstrating a significant positive 
relationship between age and PPoD (see Figure 5.1). The unadjusted Odds Ratio (OR) for 
death from pneumonia was 1.045, meaning for every 1 year increment in age, the probability 
of death increases by 4.5% (p<0.001). However when on a statin prior to admission, the OR 
is reduced to 0.525 (p<0.001) (model 1). There was also a significant effect for gender on 
this model while diabetic status had no effect on PPoD (p=0.946) (model 2; see Table 5.2). 
This model was then further expanded to take into account the inflammatory burden, 
represented by plasma CRP levels (model 3). Taking CRP into account (in addition to age, 
statin therapy and gender), the OR increased by 0.7 to 1.744 (p<0.001). In this model, 
gender no longer had a significant effect on the PPoD. This is represented graphically in 
Figure 5.2 where PPoD is shown as a function of plasma CRP levels in patients aged 79 
years, an age bracket chosen to give the greatest spread of data between the groups. 
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Figure 5.1 Relationship between Predicted Probability of death from Pneumonia and 
Increasing Chronological Age. The relationship between predicted probability of death 
from Pneumonia and increasing chronological age stratified according to statin usage prior to 
admission (not taking a statin, black lines; taking a statin, grey lines) and gender (male, 
circles; female, triangles). Relationships were assessed by linear regression controlling for 
age, statin therapy, gender and diabetic status. 
 
  
 
 
 
p<0.005 
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Table 5.2 Relationship between Predicted Probability of Death from Pneumonia 
and Increasing Chronological Age  
Values were obtained from logistic regression models. Model 1 was adjusted for 
Statin Therapy; Model 2 was adjusted for Statin Therapy, Gender and Diabetic 
status; Model 3 was adjusted for Statin Therapy, Gender and C-reactive Protein 
(CRP), diabetes was removed from this model as it has no significant effect in 
model 2. 
S.E, Standard Error; OR, Odds Ratio 
Lower Upper
Model 1 Age .044 .004 <0.001 1.045 1.037 1.053
Statin User -.645 .126 <0.001 .525 .410 .671
Model 2 Age .045 .004 <0.001 1.046 1.038 1.054
Statin User -.652 .130 <0.001 .521 .404 .672
Gender .222 .112 .047 1.248 1.003 1.554
Diabetes -.055 .146 .707 .946 .710 1.261
Model 3 Age .052 .005 <0.001 1.053 1.044 1.063
Statin User -.679 .137 <0.001 .507 .388 .644
Gender .145 .123 .240 1.156 .908 1.472
CRP .556 .126 <0.001 1.744 1.450 2.233
β S.E p OR
95% CI for OR
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Figure 5.2 Relationship between Predicted Probability of death from Pneumonia and 
C-reactive Protein at 79 years old. The relationship between predicted probability of death 
from Pneumonia and increasing levels of C-reactive protein (CRP) at 79 years old stratified 
according to statin therapy prior to admission (not taking a statin, black lines; taking a statin, 
grey lines) and gender (male, circles; female, triangles). Relationships were assessed by 
linear regression controlling for CRP, age, statin therapy and gender. *p<0.05 statin free vs. 
statin given 
  
 
 
p<0.005 
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5.2.2 Simvastatin restores directional migration of neutrophils from older adults 
To begin establishing a causative relationship between statin therapy and pneumonia 
outcomes, migratory parameters were measured on freshly isolated peripheral blood 
neutrophils from both young and old donors in the presence or absence of 1nM simvastatin, 
a plasma concentration equivalent to clinical clinically prescribed doses. Migratory studies 
were repeated using the Insall chamber, imaged using real-time video microscopy and cell 
tracked using ImageJ in response to 100nM IL8 and 10nM fMLP. 
Neutrophils isolated from, young (n=10) and elderly (n=10) donors demonstrated maintained 
chemokinesis and persistence in response to IL8 and fMLP as reported in chapter 3. Both 
chemotaxis and chemotactic index were significantly reduced in neutrophils isolated from 
elderly donors when compared to those isolated from young donors (young vs. old, mean ± 
SEM; IL8: chemotaxis 1.7 ± 0.2 vs. 0.4 ± 0.2 p<0.001; chemotactic index 0.4 ± 0.04 vs. 0.1 ± 
0.04 p<0.001; fMLP: chemotaxis 1.7 ± 0.2 vs. 0.9 ± 0.2 p=0.008; chemotactic index: 0.4 ± 
0.04 vs. 0.1 ± 0.03 p<0.001). Pre-incubation with 1nM simvastatin had no effect on migratory 
parameters of neutrophils isolated from young donors but significantly improved both the 
chemotaxis and chemotactic index of neutrophils isolated from old donors in response to 
both IL8 and fMLP (old untreated vs. treated, mean ± SEM; IL8: chemotaxis 0.4 ± 0.2 vs. 2.2 
± 0.1 p<0.001; chemotactic index: 0.09 ± 0.03 vs. 0.5 ± 0.04 p<0.001; fMLP: chemotaxis 0.9 
± 0.2 vs. 1.8 ± 0.2 p=0.005; chemotactic index 0.1 ± 0.03 vs. 0.4 ± 0.03 p=0.001 ) restoring 
these parameters to levels comparable to neutrophils isolated from young donors (see 
Figures 5.3 and 5.4). 
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Figure 5.3 Effect of Simvastatin on Neutrophil Migration toward IL8. 
Peripheral neutrophils isolated from young (black bars) and old (white bars) were 
pre-incubated for 40 minutes with 1nM Simvastatin and (A) chemokinesis (B) 
chemotaxis (C) persistence and (D) chemotactic index measured in response to 
100nM IL8. All data sets were normally distributed (Kolmogorov-Smirnov test) and 
statistical significance measured by factorial repeated measures ANOVA. *p<0.05 
young vs. old; # p<0.05 old untreated vs. treated. Data are mean ± SEM (n=10). 
A B 
C D 
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Figure 5.4 Effect of Simvastatin on Neutrophil Migration toward fMLP. 
Peripheral neutrophils isolated from young (black bars) and old (white bars) were 
pre-incubated for 40 minutes with 1nM Simvastatin and (A) chemokinesis (B) 
chemotaxis (C) persistence and (D) chemotactic index measured in response to 
10nM fMLP. All data sets were normally distributed (Kolmogorov-Smirnov test) 
and statistical significance measured by factorial repeated measures ANOVA. 
*p<0.05 young vs. old; ϕ p<0.05 young untreated vs. treated; # p<0.05 old 
untreated vs. treated. Data are mean ± SEM (n=10). 
A B 
C D 
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5.2.3 Simvastatin does not alter phospholipid composition of the plasma membrane  
In order to ascertain a potential mechanism by which simvastatin was able to modulate 
neutrophil migration, the membrane phospholipid composition of neutrophils isolated from old 
donors pre-incubated for 40 minutes with 1nM simvastatin prior to lipid extraction was 
assessed. Compared to neutrophil isolated from older adults not pre-treated with simvastatin, 
there was no significant difference in the proportion of total PC, PE, PS and PI species in the 
plasma membrane (see Figure 5.5). Comparing individual phospholipid species, there were 
also no significant differences in the composition of PC, PS or PI species however, the 
proportion of PE 18:0p/18:2 in the membrane of neutrophils from older adults pre-treated 
with simvastatin was significantly reduced (old untreated vs. old treated, mean ± SEM; 8.43 ± 
0.43 vs. 7.36 ± 0.68, p=0.05) (see Figures 5.6 to 5.9). This work was done in collaboration 
with Professor Anthony D. Postle, Southampton Centre for Biomedical Research. 
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Figure 5.5 Effect of Simvastatin on Plasma Membrane Phospholipid 
Composition.  
Percentage of Phosphatidylcholine (PC), Phosphatidylethanolamine (PE), 
Phosphatidylserine (PS) and Phosphatidylinositol (PI) present in the plasma 
membrane of human neutrophils isolated from old donors and pre-treated with 
(hashed bars) and without (clear bars)  1nM Simvastatin for 40 minutes prior to 
measurement. All data sets were normally distributed (Kolmogorov-Smirnov test) 
and statistical significance assessed by independent samples T-test. Data are 
mean ± SEM (n=10).  
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Figure 5.6 Effect of Simvastatin on Composition of Phosphatidylcholine 
Species  
Percentage of Phosphatidylcholine (PC) species present in the plasma 
membrane of were measured in human neutrophils isolated from old donors 
(clear bars) a proportion of which were treated with 1nM Simvastatin for 40 
minutes prior to measurement (hashed bars). All data sets were normally 
distributed (Kolmogorov-Smirnov test) and statistical significance assessed by 
independent samples T-test. Data are mean ± SEM (n=10). 
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Figure 5.7 Effect of Simvastatin on Composition of Phosphatidylethanolamine 
Species.  
Percentage of Phosphatidylethanolamine (PE) species present in the plasma 
membrane of were measured in human neutrophils isolated from old donors (clear 
bars) a proportion of which were treated with 1nM Simvastatin for 40 minutes prior 
to measurement (hashed bars). All data sets were normally distributed 
(Kolmogorov-Smirnov test) and statistical significance assessed by independent 
samples T-test. Data are mean ± SEM (n=10). *p<0.05 untreated vs. treated.  
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Figure 5.8 Effect of Simvastatin on Composition of Phosphatidylserine 
Species.  
Percentage of Phosphatidylserine (PS) species present in the plasma membrane 
of were measured in human neutrophils isolated from old donors (clear bars) a 
proportion of which were treated with 1nM Simvastatin for 40 minutes prior to 
measurement (hashed bars). All data sets were normally distributed (Kolmogorov-
Smirnov test) and statistical significance assessed by independent samples T-
test. Data are mean ± SEM (n=10). 
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Figure 5.9 Effect of Simvastatin on Composition of Phosphatidylinositol 
Species. 
Percentage of Phosphatidylinositol (PI) species present in the plasma membrane 
of were measured in human neutrophils isolated from old donors (clear bars) a 
proportion of which were treated with 1nM Simvastatin for 40 minutes prior to 
measurement (hashed bars). All data sets were normally distributed (Kolmogorov-
Smirnov test) and statistical significance assessed by independent samples T-
test. Data are mean ± SEM (n=10). 
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5.2.4 Membrane Cholesterol:PC Ratio is not altered by increasing age or Simvastatin 
treatment 
Cholesterol is the major sterol species found within membranes and is known to play a 
significant role in influencing membrane fluidity through interactions with the fatty acid tails of 
membrane phospholipids thereby preventing lateral movement and inducing a more rigid 
membrane structure [368]. Serum cholesterol is known to increase with age however, little is 
known about the effects of age on membrane cholesterol content. Although it was felt 
unlikely that pre-incubation with 1nM simvastatin for 40 minutes would significantly alter 
membrane composition, statin therapy has been shown to modulate cholesterol levels of 
synaptosomal plasma membranes within the brains of patients with Alzheimer’s disease 
ultimately altering membrane micro-domains and affecting membrane fluidity [445]. This 
possibility was therefore examined. 
Neutrophils isolated from old donors showed a significant increase in membrane content of 
both cholesterol and PC when compared to young donors (young vs. old, mean ± SEM; 
cholesterol: 1.1 ± 0.2 vs. 1.8 ± 0.2 p=0.019; PC: 5.2 ± 0.5 vs. 7.8 ± 0.9, p=0.012) resulting in 
an unchanged cholesterol: PC ratio. Pre-incubation of neutrophils from old donors with 1nM 
simvastatin had no effect on either membrane cholesterol or PC content nor on the ratio of 
cholesterol:PC (see Figure 5.10). 
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Figure 5.10 Composition of free Cholesterol and Phosphatidylcholine 
species in the Plasma Membrane. Proportion of (A) Cholesterol and (B) 
Phosphatidylcholine (PC) and (C) ratio of cholesterol: PC species present in the 
plasma membrane of human neutrophils isolated from young (black bars) and old 
(clear bars) donors. Neutrophils isolated from old donors were also pre-incubated 
with 1nM Simvastatin for 40 minutes (hashed bars) prior to measurement. All data 
sets follow normal distribution (Kolmogorov-Smirnov test). Data are mean ± SEM 
(n=10). *p < 0.05 old vs. young. 
A B 
C 
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5.3 Discussion 
Statins have been shown to have pleiotropic effects beyond their ability to lower serum 
cholesterol conferring a survival advantage to patients with pneumonia [390-396]. However 
their specific mechanisms of action remain elusive although effects on the innate immune 
system have been indirectly implicated. The aim of this chapter was to investigate the effects 
of simvastatin on the migratory dynamics of neutrophils isolated from young and old donors 
and identify any potential mechanisms by which this may occur. The data confirm previously 
published work documenting the ability of statins to confer a survival advantage during 
infection [390-396] and demonstrate for the first time how migration in the elderly but not the 
young is sensitive to modulation by simvastatin. 
Statins have been shown to modulate the function of small GTPases known to be essential 
in mediating a number of neutrophil anti-microbial functions including phagocytosis, ROS 
production and migration due to their capacity to dynamically re-model the cytoskeleton 
[446]. In the case of migration, addition of C3 exo-enzyme, a specific inhibitor for Rho 
proteins, significantly impairs the ability of THP-1 monocytes to migrate towards monocyte 
chemoattractant protein-1 (MCP1) [401]. Statins are able to mediate this effect on small 
GTPases by preventing their isoprenylation [401,447] through inhibition of the enzyme 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting step in the 
mevalonate pathway. In the absence of a prenyl group (either farnesyl pyrophosphate (FPP) 
or geranylgeranyl pyrophosphate (GGP)), small GTPases cannot be inserted into the 
membrane thereby preventing interaction with activatory molecules and inducing functional 
inactivity [447]. 
In recent years, the pleiotropic effect of statins have received significant attention with statins 
being suggested to reduce the risk of a number of diseases including dementia [387], lung 
cancer [388] and cardiovascular disease [389]. Stains have also been recently recognized as 
having anti-inflammatory properties through modulation of cytokine secretion [448] and 
prevention of endothelial dysfunction [449]. Although the observation is well documented, the 
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mechanism by which statins confer a survival advantage during pneumonia infection remains 
unclear. It was hypothesised that this may be due to the improvement of neutrophil function, 
strengthening defences previously weakened by natural ageing. 
A number of previous studies have demonstrated the ability of statins to reduce neutrophil 
migratory efficiency in both human and animal studies [398-400], however these authors 
used statin concentrations 1,000 – 10,000 times that which would be considered 
therapeutically relevant. Data presented here indicate the ability of simvastatin, when used at 
therapeutic concentrations, to act directly on neutrophils in such a way as to reverse the age-
associated decline in neutrophil migratory accuracy.  
Statins are most well known for their ability to lower serum cholesterol which itself is known 
to increase with during ageing [450], however little is known on the effects of statins on 
membrane composition and therefore their ability to alter membrane fluidity. To date, no 
reports exist on the ability of statins to modulate neutrophil membrane phospholipid 
composition. Here the data show no change in the proportion of phospholipids in the 
membrane following pre-incubation of neutrophils from older adults with 1nM simvastatin with 
the exception of PE 18:0p/18:2. However the observed reduction on this single species is 
unlikely to constitute the mechanism by which statins modulate improvements in neutrophil 
migration especially as this phospholipid would not be considered to have a particularly long 
fatty acid chain and therefore its ability to alter membrane fluidity would be severely limited. 
The data also show a significant increase in the amount of cholesterol present in lipid 
extracts from neutrophils isolated from older adults. However the amount of 
phosphatidylcholine (PC), the most abundant phospholipid in eukaryote membranes [359], 
also showed a significant increase with age resulting in a cholesterol:PC ratio that was not 
affected by ageing. Pre-incubation of neutrophils from older adults with 1nM simvastatin prior 
to lipid extraction did not appear to have any effect on membrane composition and is 
therefore not a contributing factor to the ability of simvastatin to modulate neutrophil 
migration in the elderly.  
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It is proposed that restoring neutrophil migration through the action of simvastatin may have 
the potential to impact upon immune senescence in the short term reducing both pathological 
inflammation and the rates of morbidity and mortality from bacterial infections observed in the 
elderly population. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
CHAPTER 6 
 
 
CAN SIMVASTATIN IMPROVE NEUTROPHIL 
FUNCTIONS IN THE HEALTHY ELDERLY?  
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6.1 Introduction 
The data so far have demonstrated a robust aberrant migratory phenotype in the healthy 
elderly which was restored in in vitro studies through inhibition of class I PI3Kinase isoforms, 
specifically PI3Kinase γ and δ, or through inhibition of the mevalonate pathway by treatment 
with simvastatin. Inhibition of either of these pathways may be particularly effective at 
improving innate immunity and thus reducing the rates of morbidity and mortality associated 
with infection. PI3Kinase-δ isoform inhibitors have been used in clinical trials of patients 
chronic lymphoid leukaemia for lymphoid malignancies with some suggestion of efficacy 
[451], however these trials have reported a number a grade 3 (severe) adverse events 
including pneumonia and neutropenia [452] which may limit clinical use, particularly in the 
elderly population. In contrast, Statins, a class of drugs widely prescribed to treat 
hypercholesterolemia, are safe in most patients and relatively well tolerated. This makes 
them an attractive intervention to improve neutrophil function in the elderly. 
Existing population-based retrospective studies already suggest statin therapy may improve 
innate immune function in vivo as well as in vitro as reduced rates of morbidity and mortality 
from bacterial pneumonia have been observed in elderly patients when on statin therapy 
prior to admission into hospital [393,395,396]. However, in vivo pleiotropic effects of statins, 
specifically on neutrophil anti-microbial functions with advancing age, are yet to be 
elucidated.  
Based on data presented in chapter 5, it was hypothesised that in vivo simvastatin therapy in 
older adults would restore neutrophil anti-microbial functions to levels comparable to the 
young. This hypothesis was tested by carrying out a double-blind placebo controlled trial 
investigating the effects of 80mg/day Simvastatin on neutrophil anti-microbial functions. The 
primary outcome was neutrophil chemotaxis in response to IL8 and fMLP. Secondary 
outcomes were other neutrophil migratory parameters (chemokinesis, persistence and 
chemotactic index, percentage cells adhering, migrating and time to initiation of migration), 
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neutrophil phagocytosis of S.aureus and E.coli bioparticles, reactive oxygen species 
production in response to IL8 and fMLP, patient safety and drug tolerability. 
 
Work presented in this chapter was completed in partnership with Dr. Jaimin Patel, under the 
clinical supervision of Dr Elizabeth Sapey and Dr David Thickett, University Hospital 
Birmingham, Birmingham, UK  
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6.2 Methods 
In order to assess the effect of statin treatment on neutrophil function in vivo, a randomised 
double blind, placebo-controlled, crossover study was used to assess whether a daily dose 
of 80mg Simvastatin taken orally for two weeks was sufficient to correct any age-related 
defects in neutrophil functions namely migration, phagocytosis and superoxide production.  
 
6.2.1 Study Design 
Power analysis suggested that a sample size of 20 was adequate. 22 healthy older (age > 
60) volunteers were recruited into the study to allow for non-completion and were 
randomised to receive either a matched placebo or 80mg Simvastatin daily for 2 weeks in a 
cross–over, double-blinded, placebo controlled trial.  This followed a two week wash out 
period (chosen to allow a new population of blood neutrophils to be released) and then 
subjects received the alternative treatment, again in a double blinded fashion. Simvastatin 
and placebo were both manufactured by Bilcare Ltd to GMP standards and the trial received 
ethical approval, Medicines and Healthcare Products Regulatory Agency (MHRA) approval 
and was sponsored by the University of Birmingham in accordance with national regulations 
for Clinical Trials of an investigational medicinal product [453]. Neither medical nor laboratory 
staff involved in the trial were aware of the identity of the drug being taken until all analysis 
was competed and the trial database unblinded. All assays were performed by a single 
analyst. 
Subjects were recruited from the 1000 Elders Cohort, a research cohort of healthy older 
people and written informed consent was obtained (REC 11/SC/0356). Subjects attended the 
Wellcome Trust Clinical Research Facility (WTCRF) for 4 visits over a 6-8 week period.  
Visit 1: Subject eligibility for the study was assessed by fulfilment of all inclusion criteria and 
none of the exclusion criteria (see Table 6.1). In order to assess liver function (LTFs), thyroid 
function (TFTs), creatine kinase (CK), urea and electrolyte levels (U&Es), and baseline 
cholesterol a peripheral blood sample was collected from each participant. Results were 
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reviewed by the trial physicians (Sapey and Thickett) to ensure all criteria were met and 
there were no contraindications to inclusion. 
Visit 2: Inclusion and exclusion criteria were reassessed and patients were randomised to 
receive either placebo or simvastatin. A 35ml peripheral blood sample was collected from 
each subject to measure neutrophil function (migration, phagocytosis and superoxide 
production) immediately prior to simvastatin/placebo administration.  
Visit 3: Following completion of the first 2 weeks of therapy, subjects returned to the WTCRF 
where a 35ml blood sample was collected to allow measurement of neutrophil function 
(migration, phagocytosis and superoxide production) and assessment of relevant health 
parameters (clinical review, LFTs, TFTs, U&Es, CK and full blood count) following 
simvastatin or placebo administration to ensure there were no adverse effects of the 
treatment. Cholesterol levels were assessed but were not made available to trial personnel. 
Subjects were then prescribed the alternative treatment (80mg Simvastatin or placebo) and 
asked to begin taking these tablets in 14 days time to allow a 2 week wash out period.  
Visit 4: After completion of the second treatment, subjects returned to the WTCRF where 
their health status and cholesterol levels were assessed as before, and a 35ml blood sample 
was collected to measure neutrophil function following the second set of treatment. Subjects 
were asked to return all medication packaging and a treatment diary to prove compliance. 
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Table 6.1 Inclusion and Exclusion Criteria for Statin Clinical Trial 
MRC, Medical Research Council; FEV, Forced Expiratory Volume; FVC, Forced 
Vital Capacity; TLC, Total Lung Capacity; KCO, Gas Transfer Coefficient; COPD, 
Chronic Obstructive Pulmonary Disease; TB, Tuberculosis 
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6.2.2 Measurement of Neutrophil Function 
Neutrophil migration was measured as described in section 2.3 in response to 100nM IL8 
and 10nM fMLP; phagocytosis was measured as described in section 2.5 and superoxide 
production was measured as described in section 2.6. 
Additional migratory parameters were determined as described below: 
Neutrophil adherence (%): the number of adherent cells present within the field of view 
divided by the total number of cells in the field x100. 
Proportion of migrating cells (%): the number of migrating cells present within the field of 
view divided by the number of adhered cells in the field x 100 
Time to first movement (seconds): average time taken to migrate 5µm (half the average body 
length of a polarised cell) and presented in 20s intervals due to time delay between frames. 
 
6.2.3 Rational for choice of drug and dose 
The in vitro data collected had suggested a positive effect on neutrophil migration with 
simvastatin, but other classes of statins have not been tested. It was therefore decided to 
utilise simvastatin. Although there is a large amount of data suggesting statins may be 
beneficial in animal models of infection and acute lung injury, only a single study has 
compared 2 doses of simvastatin (5 or 20 mg/kg given intraperitoneally 24 hours before and 
concomitantly with the injury to induce lung injury) and only the higher dose was effective in 
attenuating lung injury [454]. In a double-blind placebo-controlled study, Steiner et al 
exposed healthy volunteers to low dose intravenous endotoxin, which produces a detectable 
systemic inflammatory and pro-coagulant response without adverse effect [455]. Simvastatin 
80mg for 4 days before endotoxin challenge inhibited these processes [455]. No other clinical 
studies have been published demonstrating that a lower dose is effective. Furthermore, in a 
study where 2265 patients following an acute coronary syndrome were randomised to 
receive 80 mg simvastatin, myopathy (CK >10 times the upper limit of normal associated 
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with muscle symptoms) occurred in only 0.4% and rhabdomyolysis (CK > 10000 units/L with 
or without muscle symptoms) in 0.13% after 24 months treatment [456]. 
14 days therapy had been selected based on two factors. Firstly, 80mg Simvastatin once 
daily achieves steady-state plasma concentrations, as demonstrated by a study of healthy 
volunteers (with no reported adverse events in this healthy group) [457]. Secondly, 14 days 
will allow all circulating neutrophils to be exposed to the simvastatin, based on studies of 
average neutrophil maturation and lifespan of approximately 11 days [124]. 
In light of these data, it was proposed that Simvastatin 80mg was the only choice where both 
in vitro studies and clinical data supported efficacy while maintaining an acceptable safety 
profile. 
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6.3 Results 
To assess the in vivo effects of simvastatin on neutrophil function, 20 healthy volunteers 
aged over 60 years (range 60-94 years) were recruited to the study and given either placebo 
or 80mg/day simvastatin for two weeks after which neutrophils were isolated from whole 
blood. The trial was unblinded following all data analysis in an “intention to treat” manner. 
Demographics and health status at enrolment of all patients who completed the trial are 
shown in Table 6.2. During the study, there were no serious adverse events (SAE). Adverse 
events (AE) consisted of 1 subject who developed a migraine whilst on placebo (although 
this patient reported a medical history of migraines) and 2 subjects who developed 
generalised aches whilst on the statin however none of these patients felt these side-effects 
were severe enough to withdraw from the trial, with all patients successfully completing the 
study protocol. 1 additional patient presented with a raised Creatine Kinase (CK) after taking 
the statin however, this was asymptomatic and did not result in this patient withdrawing from 
the trial. Upon consulting their GP, their CK levels had returned to baseline two weeks after 
completing the study protocol. 1 patient developed a chest infection whilst taking the placebo 
and subsequently withdrew from the trial before taking the statin, with one further patient 
withdrawing from the trial due to reports of negative side-effects of simvastatin appearing in 
the media during the course of the trial.  19 out of the 20 patients included in the study took 
the full statin course, with only 1 patient failing to take 1 tablet during the middle of the statin 
course.  
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Table 5.2 Subject Characteristics upon Enrolment  
Demographics and health status of study participants at visit 1. Participant health status 
was determined on the basis of lung function and biochemical blood tests and assessed 
by medical staff at the QE hospital. Upon determination of health status, qualifying 
participants were then enrolled into the trail and subsequent visits arranged. PYH, Pack 
year history; FEV1, Forced Expiratory Volume; FVC, Forced Vital Capacity; pp, 
percentage predicted; BMI, Body Mass Index; IQR, Interquartile Range; eGFR, estimated 
Glomerular Filtration Rate; TSH, Thyroid Stimulating Hormone.  
n completed (total) 20 (23)
Age, mean (range), years 71.9 (60-94)
Gender, n (%)
Male 9 (43)
Female 12 (57)
Smoker
Never 13
Ex, n (PYH) 6 (21.5)
Current, n (PYH) 2 (21.5)
FEV1 , mean ± SD (L) 2.67 ± 0.7
FEV1pp, mean ± SD (L) 115.5 ± 19.1
FVC, mean ± SD (L) 3.573 ± 0.8
FVCpp, mean ± SD (L) 123.25 ± 21.9
Ratio , mean ± SD 74.7 ± 9.1
BMI, mean ± SD 26.04 ± 3.7
Heart Rate, median (IQR) bpm 67 (64.5-72.0)
Blood Pressure, median (IQR) mmHg
Systolic 142 (132-149)
Diastolic 82 (74-90.5)
Oxygen Sats, median (IQR) % 97 (96-98)
Urea, median (IQR) mmol/L 5.3 (4.4-6.5)
Creatinine, median (IQR) μmol/L 79 (69.5-80.5)
eGFR, median (IQR) ml/min/1.73m2 78 (66-85.5)
Bilirubin, median (IQR) μmol/L 8 (7-10)
Alkaline Phosphatase, median (IQR) IU/L 70 (60-78.5)
Alanine Transferase, median (IQR) IU/L 17 (15-22)
TSH,  median (IQR) mU/L 1.9 (1.1-3.7)
FreeT4, median (IQR) pmol/L 15 (14.1-16.8)
Creatine Kinase, median (IQR) IU/L 80 (59.5-134.5)
Health Status at 
Enrollment
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6.3.1 80mg/day Statin Therapy does not affect the health status of older adults 
Throughout the trial, the health status of each volunteer was monitored to ensure there were 
no adverse side effects related to statin administration. There was no significant change in 
parameters used to quantify health status following prescription of 80mg/day simvastatin 
compared to placebo. See Table 6.3. 
 
6.3.2 Statin administration reduced serum cholesterol 
To ensure tablets taken during this trial had therapeutic value, serum cholesterol was 
measured at baseline and after taking both placebo and statin as a marker of compliance. 
Serum cholesterol values remained unchanged following placebo but were significantly 
reduced following statin administration (baseline vs. placebo, median (IQR); 5.7 (5.2-6.4) vs. 
5.8 (5.1-6.1) mmol/L p=0.1; baseline vs. statin, median (IQR); 5.7 (5.2-6.4) vs. 3.8 (3.6-4.4) 
mmol/L p<0.001). See Figure 6.1. 
180 
 
 
 
B v P B v S P v S
Heart Rate, median (IQR) bpm 67 (64.5-72.0) 73 (65-78) 72 (65.3-79.8) 0.023 0.025 1.000
Blood Pressure, median (IQR) mmHg
Systolic 142 (132-149) 136 (122-145) 139.5 (127.8-144.8) 0.155 1.000 0.758
Diastolic 82 (74-90.5) 81 (73.5-85) 77 (68-82) 0.757 0.214 1.000
Oxygen Sats, median (IQR) % 97 (96-98) 97 (97-98) 97.5 (96-98) 0.254 0.429 1.000
Urea, median (IQR) mmol/L 5.3 (4.4-6.5) 5.7 (5.1-6.2) 5.6 (4.9-6.8) 1.000 0.902 1.000
Creatinine, median (IQR) μmol/L 79 (69.5-80.5) 74.5 (64-81.3) 74.5 (68.5-80) 1.000 1.000 0.668
eGFR, median (IQR) ml/min/1.73m2 78 (66-85.5) 80.5 (68-89) 79 (66.3-86.8) 0.845 1.000 0.614
Bilirubin, median (IQR) μmol/L 8 (7-10) 7 (6.5-10) 7 (2.3-10.8) 1.000 1.000 1.000
Alkaline Phosphatase, median (IQR) IU/L 70 (60-78.5) 74 (58.5-83.50 69.5 (56.8-79.5) 0.427 1.000 0.314
Alanine Transferase, median (IQR) IU/L 17 (15-22) 17 (13-21) 17 (15-21.5) 1.000 1.000 0.942
TSH,  median (IQR) mU/L 1.9 (1.1-3.7) 1.9 (0.9-5.3) 1.81 (1.1-6.2) 0.889 1.000 1.000
FreeT4, median (IQR) pmol/L 15 (14.1-16.8) 15.5 (12.9-17.2) 15.9 (13-16.5) 1.000 1.000 1.000
Creatine Kinase, median (IQR) IU/L 80 (59.5-134.5) 78 (56.5-104) 74.5 (64.8-115.25) 1.000 0.928 0.909
Baseline Placebo Statin
p value
Participant health status was determined on the basis of biochemical blood tests and assessed and monitored though out the trial 
by medical staff at the QE hospital. Upon determination of health status, qualifying participants were then enrolled into the trail and 
subsequent visits arranged. IQR, Interquartile Range, eGFR, estimated Glomerular Filtration Rate, TSH, Thyroid Stimulating 
Hormone.  
Table 6.3 Health status of Study Participants throughout the Trial Protocol 
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Figure 6.1 Serum Cholesterol levels Throughout Trial Protocol 
Serum Cholesterol was measured at baseline and following prescription of both 
placebo and simvastatin to confirm compliance with trial protocol. Data sets were 
normally distributed and significance assessed by repeated measured ANOVA. 
*p<0.05 baseline vs. simvastatin; φ p<0.05 placebo vs. simvastatin, Data sets are 
from 20 independent experiments with bar showing the mean for each group. 
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6.3.3 In vivo statin therapy restores neutrophil migration in the healthy elderly 
Neutrophil migration was measured in response to 100nM IL8 and 10nM fMLP at baseline 
and following prescription of placebo or 80mg/day simvastatin for two weeks. Statistical 
significance was measured using the Wilcoxon Signed-Rank test and p values manually 
adjusted for Bonferroni correction and therefore significance was accepted at p ≤ 0.017 with 
the exception of neutrophil persistence which was normally distributed and therefore 
assessed using a repeated measured ANOVA with significance accepted at p < 0.05. 
Following a two week prescription of 80mg/day of simvastatin, chemokinesis was reduced in 
the basal state (in the presence of buffer alone) compared to baseline (mean ± SEM; 2.92 ± 
0.1 vs. 2.6 ± 0.1, p = 0.16) but not when compared to placebo (placebo vs. simvastatin, 
mean ± SEM; 2.78 ± 0.15 vs. 2.6 ± 0.12, p = 0.184). In the presence of IL8, chemokinesis 
following simvastatin treatment was unaffected when compared to both baseline and placebo 
values (baseline vs. simvastatin, mean ± SEM; IL8: 4.05 ± 0.13 vs. 3.94 ± 0.17 p = 0.297; 
placebo vs. simvastatin, mean ± SEM; 4.06 ± 0.13 vs. 3.94 ± 0.17, p = 0.221). Chemokinesis 
towards fMLP was also unaffected by simvastatin therapy when compared to baseline 
(baseline vs. statin, mean ± SEM; 4.12 ± 0.12 vs. 3.71 ± 0.18, p = 0.025) or placebo (4.06 ± 
0.15 vs. 3.71 ± 0.18, p = 0.091) (see Figure 6.2). 
Chemotaxis was unaffected by simvastatin treatment in the basal state (mean ± SEM; 
baseline vs. simvastatin, 0.19 ± 0.07 vs. 0.21 ± 0.07, p = 0.174; placebo vs. simvastatin, 4.06 
± 0.13 vs. 3.93 ± 0.17, p = 0.184). There was a trend towards increased chemotaxis with 
statin therapy when migrating towards IL8 (baseline vs. simvastatin, mean ± SEM; 0.96 ± 
0.13 – 1.28 ± 0.16, p = 0.020; placebo vs. baseline, mean ± SEM; 0.86 ± 0.17 vs. 1.28 ± 
0.16, p = 0.022). Migration towards fMLP was significantly increased when compared to both 
baseline and placebo values (baseline vs. simvastatin, mean ± SEM; 0.766 ± 0.15 vs. 1.09 ± 
0.09, p = 0.013; placebo vs. simvastatin, mean ± SEM, 0.55 ± 0.13 vs. 1.09 ± 0.09, p = 
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0.001). There was no significant difference in chemotaxis following placebo treatment 
compared to baseline (see Figure 6.3).  
184 
 
 
  
Figure 6.2 Effect of Simvastatin on Neutrophil Chemokinesis in response to 
IL8 or fMLP. Migration of neutrophils isolated from old donors at baseline (black 
bars) and after prescription of placebo (hashed bars) or 80mg/day simvastatin 
(white bars) for two weeks. Chemokinesis was measured in response to 100nM 
IL8 or 10nM fMLP. Data sets were non-normally distributed and statistical 
significance assessed by Wilcoxon-Signed Rank Test with significance accepted 
at p<0.017 to adjust for Bonferroni correction.  Data are mean ± SEM (n=20). 
*p<0.017 compared to baseline; #p<0.017 compared to placebo 
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Figure 6.3 Effect of Simvastatin on Neutrophil Chemotaxis in response to 
IL8 or fMLP. 
Migration of neutrophils isolated from old donors at baseline (black bars) and after 
prescription of placebo (hashed bars) or 80mg/day simvastatin (white bars) for two 
weeks. Chemotaxis was measured in response to 100nM IL8 or 10nM fMLP. Data 
sets were non-normally distributed and statistical significance assessed by 
Wilcoxon-Signed Rank Test with significance accepted at p<0.017 to adjust for 
Bonferroni correction.  Data are mean ± SEM (n=20). *p<0.017 compared to 
baseline; #p<0.017 compared to placebo 
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Persistence, a measure of cell orientation toward the chemotactic gradient, was unaffected in 
the basal state following simvastatin treatment (baseline vs. simvastatin, mean ± SEM; 0.24 
± 0.03 vs. 0.25 ± 0.02, p = 1.000; placebo vs. statin, mean ± SEM, 0.17 ± 0.02 vs. 0.25 ± 
0.02, p = 0.213). In response to a gradient of IL8, persistence was significantly increased 
following simvastatin treatment when compared to baseline (baseline vs. simvastatin, mean 
± SEM; 0.26 ± 0.03 vs. 0.41 ± 0.04) but not when compared to placebo (placebo vs. 
simvastatin, mean ± SEM; 0.31 ± 0.03 vs. 0.41 ± 0.04, p = 0.106). Persistence toward fMLP 
was unaffected by statin therapy when compared to baseline (baseline vs. simvastatin, mean 
± SEM; 0.25 ± 0.03 vs. 0.30 ± 0.03 p = 0.983). Following placebo treatment, persistence was 
unaffected in the basal state and when migrating towards IL8 but was significantly increased 
when compared to baseline and following simvastatin therapy when migrating toward fMLP 
(baseline vs. placebo, mean ± SEM; 0.25 ± 0.03 vs. 0.4 ± 0.02, p = 0.001; placebo vs. 
simvastatin, mean ± SEM; 0.4 ± 0.02 vs. 0.29 ± 0.03, p = 0.044) (see Figure 6.4). 
 
In the basal state, the chemotactic index (CI), an overall measure of migratory accuracy, was 
unaffected by simvastatin therapy. When migrating towards IL8, CI was significantly 
increased when compared to placebo (placebo vs. simvastatin, mean ± SEM, 0.16 ± 0.03 vs. 
0.24 ± 0.03, p = 0.007) but not when compared to baseline (baseline vs. simvastatin, mean ± 
SEM; 0.15 ± 0.02 vs. 0.23 ± 0.03, p = 0.091). In response to fMLP, CI was significantly 
increased following simvastatin treatment when compared to both baseline and placebo 
(baseline vs. simvastatin, mean ± SEM; 0.12 ± 0.02 vs. 0.20 ± 0.03, p = 0.015; placebo vs. 
simvastatin, mean ± SEM; 0.09 ± 0.03 vs. 0.20 ± 0.03, p = 0.001). There was no significant 
difference following placebo treatment compared to baseline (see Figure 6.5).  
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Figure 6.4 Effect of Simvastatin on Neutrophil Persistence in Response to 
IL8 or fMLP. Migration of neutrophils isolated from old donors at baseline (black 
bars) and after prescription of placebo (hashed bars) or 80mg/day simvastatin 
(white bars) for two weeks. Persistence was measured in response to 100nM IL8 
or 10nM fMLP. Data was normally distributed and significance assessed by 
repeated-measured ANOVA with significance accepted at p<0.05. Data are mean 
± SEM (n=20). *p<0.017 compared to baseline; Φ p<0.017 compared to statin 
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Figure 6.5 Effect of Simvastatin on Neutrophil Chemotactic Index in 
response to IL8 or fMLP. Migration of neutrophils isolated from old donors at 
baseline (black bars) and after prescription of placebo (hashed bars) or 80mg/day 
simvastatin (white bars) for two weeks. Chemotactic index was measured in 
response to 100nM IL8 or 10nM fMLP. Data sets were non-normally distributed 
and statistical significance assessed by Wilcoxon-Signed Rank Test with 
significance accepted at p<0.017 to adjust for Bonferroni correction. Data are 
mean ± SEM (n=20). *p<0.017 compared to baseline; #p<0.017 compared to 
placebo 
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Additional parameters pertaining to neutrophil migration were also collated, namely 
percentage of cell adhered to the coverslip (% adherent), the percentage of those adherent 
cells that initiated migration (% migration) and the time to first movement defined as the 
average time taken to migrate five micrometres (chosen to represent half the average body 
length of a polarised cell). 
In the basal state, the proportion of adherent cells was significantly reduced following 
placebo treatment compared to baseline (baseline vs. placebo, mean ± SEM, 79.15 ± 1.57 
vs. 73.35 ± 1.88, p <0.001) and further reduced following simvastatin therapy (baseline vs. 
simvastatin, mean ± SEM, 79.15 ± 1.57 vs. 67.25 ± 2.81, p < 0.001; placebo vs. simvastatin 
73.35 ± 1.88 vs. 67.25 ± 2.81, p = 0.017). In the presence of IL8, % adherent cells was 
significantly reduced following simvastatin therapy when compared to both baseline and 
following placebo therapy (baseline vs. placebo, mean ± SEM; 90.85 ± 1.06 vs. 73.4 ± 1.79, 
p < 0.001; placebo vs. simvastatin, mean ± SEM, 89.1 ± 1.36 vs. 73.4 ± 1.79, p < 0.001). In 
response to fMLP, % adherent cells was unchanged when compared to baseline (baseline 
vs. simvastatin, mean ± SEM, 85.63 ± 2.27 vs. 82.8 ± 1.70, p = 0.097) while there was a 
trend towards reduced adherence following statin therapy compared to placebo (placebo vs. 
simvastatin, mean ± SEM, 87.45 ± 1.7 vs. 82.8 ± 1.70, p = 0.029). There was no effect on % 
adherence following placebo treatment when exposed to either IL8 or fMLP (see Figure 6.6). 
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Figure 6.6 Effect of Simvastatin on Neutrophil Adherence when Migrating 
towards IL8 and fMLP. Migration of neutrophils isolated from old donors at 
baseline (black bars) and after prescription of placebo (hashed bars) or 80mg/day 
simvastatin (white bars) for two weeks. Adherence was measured in response to 
100nM IL8 or 10nM fMLP. Data sets were non-normally distributed and statistical 
significance assessed by Wilcoxon-Signed Rank Test with significance accepted 
at p<0.017 to adjust for Bonferroni correction. Data are mean ± SEM (n=20). 
*p<0.017 compared to baseline; #p<0.017 compared to placebo 
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The proportion of cells migrating (% migration) was unaffected by simvastatin in the basal 
state when compared to baseline or placebo (baseline vs. simvastatin, mean ± SEM, 26.9 ± 
1.34 vs. 23.65 ± 1.60, p = 0.105; placebo vs. simvastatin, mean ± SEM, 22.3 ± 1.85 vs. 23.65 
± 1.60, p = 1.000). When migrating towards IL8, the proportion of migrating neutrophils was 
significantly increased following simvastatin therapy compared to baseline (baseline vs. 
simvastatin, mean ± SEM, 48.35 ± 1.57 vs. 65.6 ± 4.48, p = 0.002) but not compared to 
placebo (placebo vs. simvastatin, mean ± SEM; 74.45 ± 3.94 vs. 65.6 ± 4.48, p = 0.882). In 
response to fMLP, the proportion of migrating cells was significantly increased following 
simvastatin therapy when compared to both baseline and placebo (baseline vs. simvastatin, 
mean ± SEM; 56.7 ± 1.82 vs. 47.33 ± 1.68, p < 0.001; placebo vs. simvastatin, mean ± 
SEM,; 56.35 ± 1.52 vs. 47.33 ± 1.68, p = 0.002). Following placebo treatment, the proportion 
of migrating cells was significantly increased in response to IL8 compared to baseline 
(baseline vs. placebo, mean ± SEM; 48.35 ± 1.56 vs. 74.45 ± 3.94, p < 0.001) but unaffected 
in the basal state or when migrating towards fMLP (see Figure 6.7). 
In the basal state, the time to first movement was unaffected by simvastatin treatment when 
compared to both baseline and following placebo (baseline vs. simvastatin, mean ± SEM, 
114 ± 4.83 vs. 121 ± 3.40, p = 0.086; placebo vs. simvastatin, mean ± SEM, 122 ± 4.32 vs. 
121 ± 3.40, p = 448). When migrating towards IL8 and fMLP, this was significantly increased 
following simvastatin therapy when compared to both baseline and placebo (baseline vs. 
simvastatin, mean ± SEM; IL8: 95 ± 3.51 vs. 113 ± 3.33, p = 0.003; fMLP: 87.37 ± 2.74 vs. 
110 ± 4.35, p < 0.001; placebo vs. simvastatin, mean ± SEM; IL8: 92 ± 2.25 vs. 113. ± 3.33, 
p < 0.001; fMLP: 89 ± 2.70 vs. 110 ± 4.35, p = 0.003). There was no effect on the time to first 
movement following placebo treatment when exposed to either IL8 or fMLP or in the basal 
state (see Figure 6.8). 
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Figure 6.7 Effect of Simvastatin on Percentage of Migrating Neutrophil in 
response to IL8 and fMLP. Migration of neutrophils isolated from old donors at 
baseline (black bars) and after prescription of placebo (hashed bars) or 80mg/day 
simvastatin (white bars) for two weeks. Proportion of migrating neutrophils was 
measured in response to 100nM IL8 or 10nM fMLP. Data was normally distributed 
and significance assessed by repeated-measured ANOVA with significance 
accepted at p<0.05. Data are mean ± SEM (n=20). *p<0.017 compared to 
baseline; #p<0.017 compared to placebo 
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B 
Figure 6.8 Effect of Simvastatin on Neutrophil Time to First Movement in 
response to IL8 and fMLP. Migration of neutrophils isolated from old donors at 
baseline (black bars) and after prescription of placebo (hashed bars) or 80mg/day 
simvastatin (white bars) for two weeks. Initiation Time was measured in response 
to 100nM IL8 or 10nM fMLP Data sets were non-normally distributed and 
statistical significance assessed by Wilcoxon-Signed Rank Test with significance 
accepted at p<0.017 to adjust for Bonferroni correction. Data are mean ± SEM 
(n=20). *p<0.017 compared to baseline; #p<0.017 compared to placebo 
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6.3.4 In vivo statin therapy has no effect on neutrophil phagocytosis in the healthy 
elderly 
Neutrophil phagocytosis was measured in response to S.aureus and E.coli bioparticles at 
baseline and following prescription of placebo or simvastatin and the phagocytic index (PI) 
calculated. Changes in Phagocytic Index (mean ± SEM) between treatment groups are 
presented in Figure 6.9.  
There was no significant difference following statin prescription compared to baseline at any 
time point nor was there any difference between baseline and placebo at any time point. 
There was a significant effect for placebo treatment at 30 minutes when compared to statin 
treatment (placebo vs. statin, mean ± SEM, 54.09 ± 9.04 vs. 31.56 ± 6.39, p=0.046); this 
effect was lost at later time points.  
Upon co-incubation with E.coli bioparticles for 30-minutes, there was a significant increase in 
the phagocytic capacity of neutrophils isolated following placebo prescription when compared 
to baseline (Baseline vs. placebo, mean ± SEM; 19.2 ± 4.3 vs. 33.21 ± 4.5, p=0.042). There 
was no difference observed in the phagocytic capacity of neutrophils in response to E.coli 
bioparticles at any subsequent time points or following prescription of 80mg/day simvastatin 
(see Figure 6.9). 
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Figure 6.9 Effect of Simvastatin on Neutrophil Phagocytosis of S.aureus and 
E.coli. 
Phagocytic Index of neutrophils isolated from old donors at baseline (black circles) 
and after prescription of placebo (black triangles) or 80mg/day simvastatin (black 
diamonds) for two weeks. Phagocytosis was measured in response to (A) 
Staphylococcus aureus and (B) Escherichia coli for 30, 45 or 60 minutes. All data 
sets are normally distributed and statistical significance measured by repeated 
measured ANOVA with significance accepted at p<0.05. Φp<0.05 Placebo vs. 
Statin; *p<0.05 Baseline vs. Placebo. Data are mean ± SEM (n=20). PI: 
Phagocytic Index. 
A 
B 
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6.3.5 In vivo statin therapy has no effect on ROS production in the healthy elderly  
Production of reactive oxygen species (ROS) was measured by neutrophils isolated from 
healthy elderly donors at baseline and following placebo or simvastatin therapy using PMA 
as a positive control. There was a significant increase in the amount of ROS produced in 
response to 2.5μM fMLP and 25nM PMA but not 1.25nM IL8 when compared to unstimulated 
neutrophils (unstimulated vs. stimulated, mean ± SEM; fMLP: 47.75 ± 6.84 – 191.168 ± 
41.43, p= 0.009; PMA: 47.75 ± 6.84 – 342.84 ± 51.75, p < 0.001). There was however, no 
significant difference in the amount of ROS generated by neutrophils isolated from donors 
following prescription of placebo or simvastatin for two weeks compared to baseline or 
placebo (see Figure 6.10).  
In summary, a daily dose of 80mg Simvastatin for two weeks, improved neutrophil 
chemotaxis, reduced neutrophil adherence to albumin, reduced the percentage of cells that 
migrate but increased the time taken to initiate movement. In addition, 80mg/day Simvastatin 
did impact upon phagocytosis or ROS production. 
  
197 
 
 
  
Figure 6.10 Effect of Simvastatin on Neutrophil ROS Production in 
Response to fMLP, PMA and IL8. 
Production of Reactive Oxygen species (ROS) by neutrophils isolated from old 
donors at baseline (black bars) and after prescription of placebo (hashed bars) or 
80mg/day simvastatin (white bars) for two weeks. ROS production was measured 
in response to 2.5μM fMLP, 25nM PMA or 1.25μM IL8 in the presence of 100μM 
luminol. Data are mean ± SEM (n=20). AUC: area under the curve. 
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6.4 Discussion 
Statins are a family of drugs widely prescribed in the general population to lower serum 
cholesterol. Simvastatin, the most commonly prescribed member of this family, is relatively 
well tolerated, safe to prescribe and inexpensive to manufacture as it is off patent. The 
previous chapter demonstrated the in vitro ability of simvastatin to restore aberrant neutrophil 
migration in neutrophils from the healthy elderly to levels comparable to that seen in young 
donors. This medication was therefore used in a clinical trial as a potential intervention to 
overcome immune-senescence in the healthy elderly population. The data demonstrate for 
the first time the ability of simvastatin to improve neutrophil migration but not ROS production 
in response to both intermediate (IL8) and end-point (fMLP) chemoattractants, or 
unopsonised phagocytosis of S.aureus or E.coli bioparticles in a small cohort of older adults.  
Little work exists on the in vivo effects of simvastatin of neutrophil function in the healthy 
elderly with this report forming the most complete assessment to date. The primary endpoint 
of this trial was the improvement of neutrophil chemotaxis in response to IL8 and fMLP. A 
number of secondary endpoints were also modified by simvastatin including neutrophil 
chemokinesis, persistence and chemotactic index along with percentage adherence, 
percentage cells migrating and time to first movement. Other secondary end-points were not 
improved including phagocytosis and ROS production. Overall, prescription of simvastatin 
improved migratory dynamics without negatively impacting on other neutrophil functions and 
would therefore appear to be a safe intervention with which to improve neutrophil migration in 
older adults.  
The only other clinical trial to date investigating the effects statins on neutrophil migration 
found migration to be reduced following a two week prescription of 40mg atorvastatin [458], 
while data presented here describe a beneficial effect of simvastatin on neutrophil migration 
in the healthy elderly. Comparisons between these two studies should however be drawn 
with caution for a number of reasons: firstly, different statins were used. It is currently unclear 
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whether actions on cell behaviour are a class effect or limited to certain statins. Secondly the 
statins used were at different doses. Although within the clinical range, the concentration of 
simvastatin used in this thesis was 80mg/day whereas atorvastatin was used at 40mg/day, 
the mid-range dose. Mita et al have suggested differential effects across the statin family: in 
an open-label prospective crossover trial, pravastatin was found to have a more favourable 
effect on pancreatic β-cell function compared to Atorvastatin in patients with type-2 diabetes 
[459]. This suggests that different statins have the ability to differentially regulate cell function 
perhaps owing to their different chemical structures and doses used. Secondly, studies 
performed by Kinsella et al measured neutrophil function in 15 male healthy volunteers who 
ranged from 25 – 60 years [458], therefore utilizing a different cohort in both age and gender 
compared to studies presented here. Thirdly, discrepancies in methodology may explain the 
differences observed; Kinsella et al quantified neutrophil migration in response to 10nM fMLP 
using a modified Boyden chamber assay in which neutrophils migrated across a human 
pulmonary artery endothelial cell (HPAEC) monolayer grown on a transwell filter, as 
compared to albumin coated glass coverslips used in our studies. The former method does 
not allow for chemokinesis to be measured independently of chemotaxis as defined in this 
study and in our studies it was only the latter that was improved by simvastatin.  
Mechanisms underlying the ability of simvastatin to modulate neutrophil migration remain 
unknown, however modulation of adhesive contacts may provide some explanation. Cellular 
adhesion to the substratum constitutes a major component of forward movement by 
providing traction and driving cellular motility during migratory processes. Here it was 
demonstrated that there was a reduced percentage of adherent cells following simvastatin 
therapy, both in the basal state and in response to IL8. Weitz-Schmidt et al  reported a novel 
binding site within the structure of the β2 integrin LFA1 to which simvastatin and lovastatin 
have been shown to bind subsequently preventing integrin activation [460]. In the model 
used in this study, neutrophils migrate across albumin-coated surfaces (a surrogate for 
ICAM-1) utilizing β2 integrins for traction, a process which is therefore susceptible to 
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modulation by simvastatin and lovastatin through allosteric binding to β2 integrins. Whether 
or how this could contribute to improved directional migration is unclear.  
The time to first movement was also significantly increased while the % of migrating cells 
was reduced in response to IL8 and fMLP following statin therapy. This suggests that in the 
presence of statins, as well as improving migratory accuracy (evidenced by increased 
chemotaxis and chemotactic index), statins are also able to improve the efficiency with which 
neutrophils from old donors respond i.e. fewer cells respond to a chemotactic gradient but of 
those that do, migration occurs more accurately. This may be a result of simvastatin reducing 
baseline activation (demonstrated as a reduced chemokinesis in the basal state) allowing 
greater amplification of activatory signals upon meeting an inflammatory stimulus i.e. a 
chemokine gradient. Within the context of infection and inflammation, this may correct the 
hypothesised “delayed arrival” at the site of infection driven by poor accuracy, and also 
reduce the increased ‘bystander’ tissue damage postulated to occur in the elderly, by 
reducing “wandering” and ultimately improving patient outcomes.  
In some instances, data presented in this study also shows a significant effect following 
prescription of placebo for two weeks. Reasons underlying this are unclear however it may 
stem from the experimental design used as 50% of participants received the placebo after 
previously taking simvastatin for two weeks. Although a two week wash-out period was 
deemed to be sufficient time to allow for complete renewal on neutrophils within the bone 
marrow, it is plausible that some neutrophils exposed to the statin during treatment 1 still 
remained and were contributing to migratory dynamics when measured following placebo 
prescription. Based on data collected here, we are unable to conclusively test this hypothesis 
due to the small number of subjects randomised to the group which received the statin first. 
  
 
 
 
 
 
CHAPTER 7 
 
 
DISCUSSION 
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7.1 Ageing and neutrophil migration 
We are currently living through a demographic shift in the population, with the proportion of 
those aged over 65 years soon to outnumber those aged under 16 years for the first time in 
history [2]. However, although we, as a population, are living longer, we are not living 
healthier with increments in health-span lagging significantly behind increments in lifespan 
[5]. This severely compromises the quality of life of older adults with an increased incidence 
of infectious diseases and chronic inflammatory conditions [9,10,15,26], both associated with 
poorer clinical outcomes and ultimately increasing burdens on the provision of hospital and 
community based healthcare. 
Natural ageing is accompanied by wide spread immune senescence evident within both the 
adaptive and innate compartments of the immune response (reviewed in [137,414]). 
Adaptive immune senescence is widely documented encompassing observations of a 
reduced vaccine response [63-65], including a lesser ability to produce a protective antibody 
titer [66], an inverted CD4+:CD8+ T cell ratio [33] and a reduced output of naïve T cells from 
the thymus (reviewed in [461]).  
In comparison, our knowledge of innate immune senescence is not as well advanced in 
particular with reference to neutrophil senescence. The effects of age on neutrophil 
migration, the process by which these cells migrate out of the blood toward to site of 
infection, was first investigated in 1978 [372] however in the intervening 35 years, no clear 
picture has emerged. Here a body of data describe a robust ‘old-migratory’ phenotype in 
healthy older adults, characterised by a maintained speed of migration but with reduced 
directional speed and overall accuracy of migration [439]. This phenotype was characteristic 
of neutrophils from older adults over the age of 60 years, was present in response to a 
number of physiological chemoattractants encompassing multiple stages of the inflammatory 
response and is therefore not stimuli specific. Related data suggested this defect does not 
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“correct” during infective episodes, data presented here (and provided by Dr. Elizabeth 
Sapey) showed worsening migration towards IL8 during pneumonia infection in older adults. 
 
7.2 Reduced Neutrophil chemotaxis and health 
The age-related reduction in chemotactic accuracy could have implications both when older 
people are uninfected and during acute infective events. Poor migratory accuracy could limit 
an effective response to invading bacteria, but may also be associated with increased 
bystander tissue damage. While there remains debate as to whether neutrophils need to 
utilise neutrophil elastase to migrate [462,463], there is clear evidence to suggest elastase is 
released upon migration [223,239,464]. There is also evidence to support an area of obligate 
tissue damage directly next to neutrophils following neutrophil elastase release [239]. The 
‘old-migratory’ phenotype presented here may lead to increased “wandering” during 
interstitial migration, if this were the case, and elastase were released  throughout the 
extended migratory period, then increased tissue damage would occur as a result of the 
circuitous route of migration. 
While this thesis has no direct evidence to support this proposal, the data provide indirect 
evidence which is in keeping with this hypothesis. Neutrophils from healthy elderly donors 
with no clinical symptoms or signs of acute or chronic infection exhibited increased 
expression of CD63, an azurophil specific granule specific marker on their surface with 
concomitant increases in the concentrations of the neutrophil elastase-specific fibrinogen 
breakdown product AαVal360 in the plasma. CD63 was measured on neutrophils using a 
protocol to minimize experimental activation, and the increased expression is consistent with 
mobilisation of primary granules to the cell surface and degranulation in the basal state in the 
elderly. AαVal360 is a well-validated systemic footprint of elastase activity [406] and since 
there is no evidence of there being more circulating neutrophils with old age [130] and the 
propensity for apoptosis of neutrophils from the elderly is increased in the basal state (as 
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measured in this study) [465] we propose that this equates to more elastase being released 
per cell, although this would need to be confirmed. Altered neutrophil migration may also 
have implications in health, as transient movements into tissue as the cells circulate will 
generate tissue damage and an inflammatory response. Therefore the reduced chemotactic 
accuracy could contribute to inflamm-ageing. 
Alternatively, inflamm-ageing may be a driver of neutrophil senescence and not a 
consequence. Although adults included in this study were considered healthy, a typical 
“western” lifestyle with low physical activity, a calorie-rich but nutrient-poor diet and endemic 
obesity may impact on results. In 2011, 25.9% of women and 23.6% of men in England were 
considered to be obese (a body mass index > 30kg/m2) and 35.8% of women and 35.5% of 
men in the United States [466]. Obesity has been reported to be associated with increased 
systemic inflammation (Inflamm-ageing), particularly TNFα and IL6 [467,468] secreted by an 
abnormal accumulation of macrophages present within white adipose tissue, the magnitude 
of which is proportional to adipocyte size and body index [468]. Inflamm-ageing may affect 
cellular function by inducing a state in which immune cells, in this case neutrophils, are 
exposed to chronic low level activation reducing their ability to respond to activatory signals 
during infection, thereby compromising function. There are few studies of neutrophil function 
with age in populations where obesity is less endemic. In Japan, where only 2.3% of men 
and 3.4% of women were considered to be obese in 2000 [466] and the proportions of 
centenarians equates to 53/100,000 of the population [469], neutrophil immune-senescence 
has not been associated with BMI (although none of the participants in the relevant study 
were obese), but instead correlated with stressful life events [470]. Psychological stress has 
also been associated with systemic inflammation and subsequent immune-senescence 
[471], once again supporting the hypothesis that inflammation drives immune dysfunction, 
perhaps including the ‘old-migratory’ phenotype. It would be informative to repeat these 
studies in elderly adults from communities with extended longevity and less ‘negative’ 
lifestyle practices (such as traditional Japanese diet consisting mainly of fish and protein 
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[472] and low psychological stress to try and determine if alterations in neutrophil behaviour 
are an intrinsic, unalterable process of ageing of whether environmental factors are key. 
In addition, this thesis only tested neutrophil functions in a cohort of healthy older adults on a 
single occasion. Although there was a negative relationship between neutrophil directional 
migration and accuracy of migration with increasing age, we can only hypothesise that 
neutrophil function declines within an individual over time due to the cross-sectional nature of 
the study. It would be of value to prospectively and longitudinally measure neutrophil function 
in healthy older adults to see if a decline in migratory dynamics occurs as they age.   
 
7.3 Potential technical study limitations 
The chosen migratory assay has enabled us to adequately differentiate between 
chemokinesis and chemotaxis revealing differences that up until now have remained largely 
elusive. However, there are limitations associated with our methods. Firstly any protocol 
utilised to isolate neutrophils will result in a degree of neutrophil activation, although Percoll 
(as used in this thesis) has been shown to induce minimum neutrophil activation [473]. There 
is a clear difference between migratory dynamics of “older” and “younger” cells which were 
prepared using the same technique, reducing the possibility of cellular activation as a driving 
factor behind the ‘old-migratory’ phenotype. Secondly, the study used an albumin coated 
surface to overcome hydrostatic forces of glass alone, which in itself may impact on results. 
Albumin is a surrogate for ICAM-1 [474] an adhesion marker highly expressed on the 
endothelium facilitating extravasation from the blood stream and also on fibroblasts present 
within the interstitium upon initiation of inflammation [475-477]. ICAM-1 is recognised by 
LFA-1/Mac-1 expressed on the neutrophil surface however, neutrophils lacking CD18 are still 
capable of migration (albeit with a 50% reduction in efficiency [478]) implying migration can 
occur independently of CD18 ligation with ICAM-1. Neutrophils are also thought to utilise 
VCAM-1 (which is bound by VLA-4, [478]) to provide traction during migratory processes. It 
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would therefore be of value to repeat initial migration studies using different surfaces to 
determine a role for ICAM-1 and/or CD18 in the development of the ‘old-migratory’ 
phenotype as observed here. Thirdly, this assay utilises shallow gradients and migratory 
measurements are taken in 2D. This is not physiological and does not replicate the 
complexity inherent within a neutrophils journey from the blood to areas of infected or 
inflamed tissue. A more physiological in vitro model would be to establish a 3D system where 
cells transmigrate through endothelium, into a collagen based gel (forming the interstitum). 
 
 
7.4 Mechanisms of reduced chemotaxis with age 
Following the initial observation of reduced chemotaxis in old donor cells, this thesis went on 
to investigate potential mechanisms which may underlie this migratory defect. 
Phosphatidylinositol-3-kinase (PI3Kinase) and its lipid product phosphatidylinositol - 3,4,5 - 
triphosphate (PIP3) are important components of the signalling network present within the 
leading edge of migrating cells. PI3Kinase-dependent PIP3 production is confined to the 
leading edge [346] where it initiates a signalling cascade resulting in the localised assembly 
of F-actin protrusions driving the forward motility of the plasma membrane [315] through 
recruitment and activation of a number of downstream effectors including small-GTPases, 
WASP family members and actin nucleating proteins (reviewed in [479]).  
The data presented here demonstrated constitutive, basal activation of PI3Kinase in 
neutrophils isolated from old donors while, in those isolated from young donors this activity 
was transient. The antibody utilised has the advantage of measuring PI3Kinase regulatory 
subunit phosphorylation, and thus is a surrogate of kinase activity.  However, it only 
measures Class IA activity (p85) and therefore it is not possible to comment on Class IB 
activity; studies of the p110 subunit would be needed in order to clarify this.  In addition, 
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increased PI3Kinase activity might not have influenced migration, and alternative elements 
involved in directional migration could be the key effectors.  
To explore this and try to confirm the importance of dysregulated PI3Kinase, the study 
utilised isoform selective inhibitors and repeated the migratory assays.  PI3Kinase-γ is the 
main isoform responsible for PIP3 production at the leading edge in response to GPCR 
stimulation, while PI3Kinase-δ is responsible for the localised production in response to 
tyrosine kinase receptor stimulation [256]. The data demonstrated PI3Kinase-γ and –δ to be 
the most relevant isoforms in the generation of the ‘old-migratory’ phenotype with inhibition of 
these isoforms able to restore migratory parameters of neutrophils isolated from old donors 
to levels comparable to those observed in neutrophils isolated from young donors [439]. 
Crucially inhibition of the phosphatase SHIP which regulates PI3Kinase phosphorylation and 
activity, further reduces neutrophil chemotactic accuracy in “old” cells (personal 
communication, Dr. Elizabeth Sapey), further supporting the suggestion that aberrant 
migration is driven by constitutive activation of the PI3Kinase pathway. 
  
The mechanisms driving up-regulation of PI3Kinase activity remain to be determined. 
Activation of PI3Kinase was measured through phosphorylation of the p85 regulatory subunit 
which is responsible for the regulation of PI3Kinase-α, -β and -δ isoforms, while PI3Kinase-γ 
is under the control of a p101 regulatory subunit [480]. The ability of PI3Kinase-γ selective 
inhibitors to restore migratory dynamics as well as the δ isoform inhibitor would suggest this 
isoform is also dysregulated as a consequence of natural ageing.  Dysregulation of class IA 
PI3Kinase could suggest dysregulated integrin signalling with increasing age as these 
isoforms are activated downstream of tyrosine kinase receptors including members of the 
integrin family [481]. However, inhibition of SHP-1, a tyrosine kinase specific protein 
phosphatase, does not alter the migratory phenotype of older adults (Dr. Adam Usher, 
personal communication). Class IB PI3Kinase is under the control of the Gβγ subunit of 
GPCRs [280], the activity of which may be influenced by an increased pro-inflammatory 
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micro-environment (a result of inflamm-ageing) leading to sustained GPCR activation and 
subsequent aberrant signal transduction (see Figure 7.1). The apparent combined 
dysregulation of PI3Kinase-γ and –δ isoforms may have a number of explanations. Firstly, in 
the model used here, both PI3Kinase-γ and –δ isoforms are activated due to the adhesive 
nature of the assay (via integrins) and exposure to pro-inflammatory chemokine gradients 
respectively. Secondly, there is emerging evidence of redundancy within the class 1A and 1B 
isoforms, with different isoforms sharing activity streams previously considered to be 
separate [482,483]. Finally, although inhibitors used in this thesis are selective for the 
different isoforms of PI3Kinase, it is unclear whether they are also isoform specific. 
Measuring migratory dynamics and PI3Kinase activity of young neutrophils pre-incubated 
with plasma or serum from elderly donors may reveal environmental factors influencing 
PI3Kinase activity (and by extension the migratory phenotype). This would also determine if 
the phenotype observed here is a consequence of intrinsic age-related alterations or is 
modulated thought environmental factors.  
  
Figure 7.1 Proposed Age-Related Alterations in Leading Edge Signalling. 
Homeostatic signalling pathways within the leading edge of neutrophils isolated from young donors (A) lead to compartmentalized PIP3 at the leading edge (B), however, within the elderly 
(C), inflamm-ageing (chronic pro-inflammatory micro-environment) leads to sustained stimulation of GPCRs resulting in basal PI3K activity and enhanced PIP3 production which is no 
longer compartmentalised  within the leading edge (D) thus affecting the spatial and temporal localization of down-stream signalling molecules ultimately compromising actin nucleation.  
Part (B) and (D) adapted from [281].  
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7.5 Correcting the age-related decline in chemotaxis 
If increased PI3Kinase activity were to be a consequence of the altered micro-environment 
i.e. inflamm-ageing, interventions aimed at reducing systemic inflammation could be effective 
in improving neutrophil migration. For example increasing physical activity may be effective 
as exercise is known to reduce inflammation [484,485], reducing BMI could also help as 
adipose tissue is a major source of inflammatory cytokines [486]. Interestingly, by stratifying 
200 older adults according to their levels of physical activity, the migratory dynamics of those 
who were in the lowest decile for physical activity were significantly lower than those who 
were the most physically active (David Bartlett, personal communication). This suggests 
modulation of physical activity may improve migratory outcomes, although lifestyle 
interventions are notoriously difficult to implement with poor levels of compliance. 
 
The alternative to this is pharmacological intervention, however drug development can take 
anywhere up to 20 years from conception to treatment therefore the use of PI3Kinase 
inhibitors may take many years to implement. Such drugs may also be expensive and not 
suitable for long term use. In contrast the data reported here showed the beneficial effects of 
simvastatin on neutrophil migratory function. In recent years statins have received a great 
deal of attention due to their pleiotropic, anti-inflammatory properties that occur outside of 
their ability to lower serum cholesterol for example, in a number of retrospective cohort 
studies and meta-analyses, statins have been show to confer a survival advantage to 
bacterial pneumonia patients when taking a statin prior to admission [390-396]. Work 
published by other groups have previously demonstrated the ability of statins to modulate 
neutrophil migration in younger cohorts [398] however, work presented here is the first in 
which statins have been shown to restore migration in a cohort made up exclusively of older 
adults (age ≥ 60 years). Mechanisms driving this phenomenon have been previously 
attributed to the inactivation of GTPases by inhibiting their isoprenylation and subsequent 
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insertion into the membrane [398]. This study did not test this mechanism but did not support 
changes in either the phospholipid composition or cholesterol content of the plasma 
membrane as contributory factors to statin-mediated modulation of migratory dynamics. 
Stains are a class of drugs relatively well tolerated within the population that are widely 
prescribed to treat hypercholesterolemia or reduce cardiovascular risk. The ability of 
simvastatin to restore neutrophil migration in the healthy elderly was shown here both in vitro 
and in vivo. Restoration of neutrophil migration in the elderly by simvastatin, potentially 
through inhibition of RhoA [398], downstream of PI3Kinase-γ and –δ isoforms could imply 
broader dysregulation of signalling pathways involved in the control of migration (see Figure 
7.1A), or even other neutrophil functions which rely upon small GTPases. Upstream of 
PI3Kinase is the small GTPase Ras to which all isoforms containing a p110 catalytic subunit 
(i.e. all class I isoforms) are sensitive and the action of which is essential for full activation of 
both p110γ and p110δ isoforms [256,487,488]. Statins would also inhibit Ras function and 
this could explain their beneficial effect on migration. In addition, the small GTPases, RhoA, 
Rac and Cdc42 which are classically thought to exist downstream of PI3Kinase, are also 
capable of positive feedback onto PI3Kinase activity (see Figure 7.1A). As the inhibitory 
activity of statins is generic to all isoprenylated proteins, simvastatin may be able to 
simultaneously affect both Rho-family-GTPases and PI3Kinase/Akt signalling. One surprising 
aspect of the results in this context was that other neutrophil functions affected by ageing, 
specifically phagocytosis, were not improved by the stain intervention. As phagocytosis also 
involves small GTPases [489,490] it was anticipated that this would also be improved. 
However, the decline in phagocytosis with age appears to be due largely to reduced CD16 
expression [138] and thus affecting signalling events may not overcome this issue. 
Determination of small GTPase activity before and after statin treatment of neutrophils from 
old donors would significantly enhance our understanding of the mechanism driving the 
pleiotropic effects of statins and the age-related defect in migration. Such studies were 
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attempted during the latter stages of the thesis, but significant variability was found in the 
data making firm conclusions difficult to draw. 
In addition to the inhibition of small-GTPases, there are a number of additional potential 
mechanisms through which statins may act. Endothelial dysfunction is a common feature of 
natural ageing [491], a process in which there is a systemic imbalance between vasodilating 
agents, such as nitric oxide, and vasoconstricting agents, such as endothelin -1, thus 
favouring the vasoconstricting state [449]. This results in a pro-inflammatory environment 
characterised by reduced nitric oxide (NO) generation, up-regulation of adhesion molecules 
such as V-CAM1 and ICAM-1 and generation of chemokine molecules such as MCP-1 [491]. 
Statins have been shown to inhibit this process restoring the balance between 
vasoconstriction and vasodilation essential for proper endothelial function. Here the ability of 
statins to activate a signalling pathway in the endothelium involving PI3Kinase, Akt and 
endothelial nitric oxide synthase (eNOS) [492] was key to their mode of action and results in 
increased nitric oxide (NO) production. In a murine model of endothelial activation induced by 
thrombin, intraperitoneal injection of rosuvastatin prior to thrombin injection resulted in 
increased release of NO from the vasculature and a 70% reduction in endothelial expression 
of P-selectin thus reducing leukocyte adherence and transmigration [493]. In the healthy 
elderly, where inflamm-ageing, the systemic sub-clinical elevation of pro-inflammatory 
cytokines is common, statins may act to limit inappropriate activation of the endothelium by 
IL6 and/or TNFα indirectly preventing inappropriate extravasation of leukocytes including 
monocytes and neutrophils. Thus statins may be having quite different effects on endothelial 
and neutrophil PI3Kinase activity. 
The anti-inflammatory effects of statins have also been shown to result from reductions in the 
circulating levels of pro-inflammatory mediators: statin therapy correlates with reductions in 
CRP in a number of clinical trials [403,494], while monocyte expression of TNFα and IL-1β in 
previously hyperlipidaemic patients following an 8-week course of 20mg/day of simvastatin 
has been shown to be significantly reduced [495]. Interestingly, CRP has also been shown to 
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decrease eNOS activity [496,497] heightened levels of which, as part of the inflamm-ageing 
phenotype, may further exacerbate endothelial dysfunction in the elderly. 
Work presented in this thesis invites the proposition that simvastatin has therapeutic potential 
in reducing rates of morbidity and mortality from bacterial diseases in the elderly population, 
possibly by modulating neutrophil migration. Throughout this thesis, only the effects of a 
single statin (at a single dose) were considered. Although undoubtedly critical to mounting an 
effective immune response, neutrophils do not act in isolation. The effects of statins on T cell 
function have been well studied with reports documenting suppression of the acute 
inflammatory response by favouring a Th2 mediated response, potentially protecting against 
Th1 driven diseases such as rheumatoid arthritis [498,499]. Additional reports also document 
the opposing actions of simvastatin and atorvastatin on expression of HLA-DR and the 
immune response to bacterial super-antigens [500].  
Lipophilic statins (including simvastatin, atorvastatin, lovastatin and fluvastatin) have also 
been shown to compromise natural killer (NK) cell degranulation and cytotoxicity through 
inhibition of conjugate formation between NK and target cells by inhibiting LFA-1 [501]. 
Further exploration of the most effective statin at mediating restoration of neutrophil 
migratory parameters, may lead to an intervention able to reduce the rates of morbidity and 
mortality from bacterial infections in the elderly. However such studies must also establish a 
therapeutic regime that does not compromise other immune functions, that could for example 
reduce NK cell function and increase susceptibility to viral infections to which older adults are 
already susceptible [9]. 
 
7.6 Future Work 
This thesis has provided a detailed description of neutrophil immune-senescence with a 
specific focus on neutrophil migratory dynamics, identified mechanisms possibly driving this 
aberrant migration and highlighted a potential therapeutic intervention to restore neutrophil 
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migration in the healthy elderly. However, many studies are still required in order to 
completely understand mechanisms driving migratory senescence, and to efficiently 
intervene to improve immunity in older adults.  
1. Migratory dynamics should be characterised when cells are migrating across 
components of the extracellular matrix such as fibronectin, collagen, hyaluronic acid 
and/or laminin as well as through 3D gels/matrices to determine if the migratory 
phenotype is applicable to interstitial migration. 
2. Migratory dynamics should be characterised in response to inflammatory biological 
secretions, such as sputum from patient with bacterial infections, containing a complex 
milieu of chemotactic mediators to better characterise migratory defects during clinical 
inflammation. 
3. Expression of chemoattractant receptors should be examined to include expression on 
activated cells as well as receptor placement with respect to the chemotactic gradient, 
localisation to lipid rafts and membrane fluidity to determine if receptor localisation 
contributes to migratory defects.  
4. Expression of adhesion receptors on the surface of quiescent and activated neutrophils 
to examine a role for altered adhesive contacts in migratory dynamics. 
5. To assess the effects of ageing on the activity of class 1B PI3Kinase isoforms; on 
molecules governing PI3Kinase activity (SHIP1 and PTEN) and on the intensity and 
cellular localisation of the lipid product PIP3 in migrating neutrophils from old donors. 
This would generate a more complete picture of the role PI3Kinase plays in generation 
of the ‘old-migratory’ phenotype.  
6. To examine the effects of ageing on other pathways known to be involved in the 
regulation of migration including mTOR and small GTPase family members.  
7. To determine the effects of age on the interaction between small-GTPases, actin 
nucleating proteins and the actin cytoskeleton and the effects this may have on 
pseudopod formation, sustainability and retraction on during directional sensing. 
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8. It would also be pertinent to determine the mechanism by which simvastatin is able to 
modulate neutrophil migration and to examine in more detail the effects of other statins 
on neutrophil functions including phagocytosis and ROS production. 
9. Pre-incubating neutrophils isolated from young and old donors with plasma or serum 
from old or young donors prior to measuring migratory dynamics would determine if the 
defect observed in this work is cell intrinsic or a product of the inflammatory 
microenvironment. 
 
 
In conclusion, work presented here describes a generic, robust migratory phenotype 
characterised by a maintained speed of migration but with reduced migratory accuracy. This 
phenotype appears to be driven by dysregulated PI3Kinase activity and is amenable to 
correction through inhibition of PI3Kinase-γ and -δ isoforms and treatment with Simvastatin. 
Aberrant migration as described here may cause increased collateral damage to otherwise 
healthy tissue and manifest as delayed arrival to the site of infection and raised systemic 
inflammation, ultimately compromising host defences and contributing to the increased rates 
of morbidity and mortality observed in the elderly population. 
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